nih-gov/www.ncbi.nlm.nih.gov/omim/230800

5772 lines
564 KiB
Text

<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en-us" xml:lang="en-us" >
<head>
<!--
################################# CRAWLER WARNING #################################
- The terms of service and the robots.txt file disallows crawling of this site,
please see https://omim.org/help/agreement for more information.
- A number of data files are available for download at https://omim.org/downloads.
- We have an API which you can learn about at https://omim.org/help/api and register
for at https://omim.org/api, this provides access to the data in JSON & XML formats.
- You should feel free to contact us at https://omim.org/contact to figure out the best
approach to getting the data you need for your work.
- WE WILL AUTOMATICALLY BLOCK YOUR IP ADDRESS IF YOU CRAWL THIS SITE.
- WE WILL ALSO AUTOMATICALLY BLOCK SUB-DOMAINS AND ADDRESS RANGES IMPLICATED IN
DISTRIBUTED CRAWLS OF THIS SITE.
################################# CRAWLER WARNING #################################
-->
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
<meta http-equiv="cache-control" content="no-cache" />
<meta http-equiv="pragma" content="no-cache" />
<meta name="robots" content="index, follow" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta name="title" content="Online Mendelian Inheritance in Man (OMIM)" />
<meta name="description" content="Online Mendelian Inheritance in Man (OMIM) is a comprehensive, authoritative
compendium of human genes and genetic phenotypes that is freely available and updated daily. The full-text,
referenced overviews in OMIM contain information on all known mendelian disorders and over 15,000 genes.
OMIM focuses on the relationship between phenotype and genotype. It is updated daily, and the entries
contain copious links to other genetics resources." />
<meta name="keywords" content="Mendelian Inheritance in Man, OMIM, Mendelian diseases, Mendelian disorders, genetic diseases,
genetic disorders, genetic disorders in humans, genetic phenotypes, phenotype and genotype, disease models, alleles,
genes, dna, genetics, dna testing, gene testing, clinical synopsis, medical genetics" />
<meta name="theme-color" content="#333333" />
<link rel="icon" href="/static/omim/favicon.png" />
<link rel="apple-touch-icon" href="/static/omim/favicon.png" />
<link rel="manifest" href="/static/omim/manifest.json" />
<script id='mimBrowserCapability'>
function _0x5069(){const _0x4b1387=['91sZIeLc','mimBrowserCapability','15627zshTnf','710004yxXedd','34LxqNYj','match','disconnect','1755955rnzTod','observe','1206216ZRfBWB','575728fqgsYy','webdriver','documentElement','close','open','3086704utbakv','7984143PpiTpt'];_0x5069=function(){return _0x4b1387;};return _0x5069();}function _0xe429(_0x472ead,_0x43eb70){const _0x506916=_0x5069();return _0xe429=function(_0xe42949,_0x1aaefc){_0xe42949=_0xe42949-0x1a9;let _0xe6add8=_0x506916[_0xe42949];return _0xe6add8;},_0xe429(_0x472ead,_0x43eb70);}(function(_0x337daa,_0x401915){const _0x293f03=_0xe429,_0x5811dd=_0x337daa();while(!![]){try{const _0x3dc3a3=parseInt(_0x293f03(0x1b4))/0x1*(-parseInt(_0x293f03(0x1b6))/0x2)+parseInt(_0x293f03(0x1b5))/0x3+parseInt(_0x293f03(0x1b0))/0x4+-parseInt(_0x293f03(0x1b9))/0x5+parseInt(_0x293f03(0x1aa))/0x6+-parseInt(_0x293f03(0x1b2))/0x7*(parseInt(_0x293f03(0x1ab))/0x8)+parseInt(_0x293f03(0x1b1))/0x9;if(_0x3dc3a3===_0x401915)break;else _0x5811dd['push'](_0x5811dd['shift']());}catch(_0x4dd27b){_0x5811dd['push'](_0x5811dd['shift']());}}}(_0x5069,0x84d63),(function(){const _0x9e4c5f=_0xe429,_0x363a26=new MutationObserver(function(){const _0x458b09=_0xe429;if(document!==null){let _0x2f0621=![];navigator[_0x458b09(0x1ac)]!==![]&&(_0x2f0621=!![]);for(const _0x427dda in window){_0x427dda[_0x458b09(0x1b7)](/cdc_[a-z0-9]/ig)&&(_0x2f0621=!![]);}_0x2f0621===!![]?document[_0x458b09(0x1af)]()[_0x458b09(0x1ae)]():(_0x363a26[_0x458b09(0x1b8)](),document['getElementById'](_0x458b09(0x1b3))['remove']());}});_0x363a26[_0x9e4c5f(0x1a9)](document[_0x9e4c5f(0x1ad)],{'childList':!![]});}()));
</script>
<link rel='preconnect' href='https://cdn.jsdelivr.net' />
<link rel='preconnect' href='https://cdnjs.cloudflare.com' />
<link rel="preconnect" href="https://www.googletagmanager.com" />
<script src="https://cdn.jsdelivr.net/npm/jquery@3.7.1/dist/jquery.min.js" integrity="sha256-/JqT3SQfawRcv/BIHPThkBvs0OEvtFFmqPF/lYI/Cxo=" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/jquery-migrate@3.5.2/dist/jquery-migrate.js" integrity="sha256-ThFcNr/v1xKVt5cmolJIauUHvtXFOwwqiTP7IbgP8EU=" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/bootstrap@3.4.1/dist/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@3.4.1/dist/css/bootstrap.min.css" integrity="sha256-bZLfwXAP04zRMK2BjiO8iu9pf4FbLqX6zitd+tIvLhE=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@3.4.1/dist/css/bootstrap-theme.min.css" integrity="sha256-8uHMIn1ru0GS5KO+zf7Zccf8Uw12IA5DrdEcmMuWLFM=" crossorigin="anonymous">
<script src="https://cdn.jsdelivr.net/npm/moment@2.29.4/min/moment.min.js" integrity="sha256-80OqMZoXo/w3LuatWvSCub9qKYyyJlK0qnUCYEghBx8=" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/eonasdan-bootstrap-datetimepicker@4.17.49/build/js/bootstrap-datetimepicker.min.js" integrity="sha256-dYxUtecag9x4IaB2vUNM34sEso6rWTgEche5J6ahwEQ=" crossorigin="anonymous"></script>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/eonasdan-bootstrap-datetimepicker@4.17.49/build/css/bootstrap-datetimepicker.min.css" integrity="sha256-9FNpuXEYWYfrusiXLO73oIURKAOVzqzkn69cVqgKMRY=" crossorigin="anonymous">
<script src="https://cdn.jsdelivr.net/npm/qtip2@3.0.3/dist/jquery.qtip.min.js" integrity="sha256-a+PRq3NbyK3G08Boio9X6+yFiHpTSIrbE7uzZvqmDac=" crossorigin="anonymous"></script>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/qtip2@3.0.3/dist/jquery.qtip.min.css" integrity="sha256-JvdVmxv7Q0LsN1EJo2zc1rACwzatOzkyx11YI4aP9PY=" crossorigin="anonymous">
<script src="https://cdn.jsdelivr.net/npm/devbridge-autocomplete@1.4.11/dist/jquery.autocomplete.min.js" integrity="sha256-BNpu3uLkB3SwY3a2H3Ue7WU69QFdSRlJVBrDTnVKjiA=" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/jquery-validation@1.21.0/dist/jquery.validate.min.js" integrity="sha256-umbTaFxP31Fv6O1itpLS/3+v5fOAWDLOUzlmvOGaKV4=" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/js-cookie@3.0.5/dist/js.cookie.min.js" integrity="sha256-WCzAhd2P6gRJF9Hv3oOOd+hFJi/QJbv+Azn4CGB8gfY=" crossorigin="anonymous"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/ScrollToFixed/1.0.8/jquery-scrolltofixed-min.js" integrity="sha512-ohXbv1eFvjIHMXG/jY057oHdBZ/jhthP1U3jES/nYyFdc9g6xBpjDjKIacGoPG6hY//xVQeqpWx8tNjexXWdqA==" crossorigin="anonymous"></script>
<script async src="https://www.googletagmanager.com/gtag/js?id=G-HMPSQC23JJ"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){window.dataLayer.push(arguments);}
gtag("js", new Date());
gtag("config", "G-HMPSQC23JJ");
</script>
<script src="/static/omim/js/site.js?version=Zmk5Y1" integrity="sha256-fi9cXywxCO5p0mU1OSWcMp0DTQB4s8ncFR8j+IO840s="></script>
<link rel="stylesheet" href="/static/omim/css/site.css?version=VGE4MF" integrity="sha256-Ta80Qpm3w1S8kmnN0ornbsZxdfA32R42R4ncsbos0YU=" />
<script src="/static/omim/js/entry/entry.js?version=anMvRU" integrity="sha256-js/EBOBZzGDctUqr1VhnNPzEiA7w3HM5JbFmOj2CW84="></script>
<div id="mimBootstrapDeviceSize">
<div class="visible-xs" data-mim-bootstrap-device-size="xs"></div>
<div class="visible-sm" data-mim-bootstrap-device-size="sm"></div>
<div class="visible-md" data-mim-bootstrap-device-size="md"></div>
<div class="visible-lg" data-mim-bootstrap-device-size="lg"></div>
</div>
<title>
Entry
- #230800 - GAUCHER DISEASE, TYPE I; GD1
- OMIM
</title>
</head>
<body>
<div id="mimBody">
<div id="mimHeader" class="hidden-print">
<nav class="navbar navbar-inverse navbar-fixed-top mim-navbar-background">
<div class="container-fluid">
<!-- Brand and toggle get grouped for better mobile display -->
<div class="navbar-header">
<button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#mimNavbarCollapse" aria-expanded="false">
<span class="sr-only"> Toggle navigation </span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>
<a class="navbar-brand" href="/"><img alt="OMIM" src="/static/omim/icons/OMIM_davinciman.001.png" height="30" width="30"></a>
</div>
<div id="mimNavbarCollapse" class="collapse navbar-collapse">
<ul class="nav navbar-nav">
<li>
<a href="/help/about"><span class="mim-navbar-menu-font"> About </span></a>
</li>
<li class="dropdown">
<a href="#" id="mimStatisticsDropdown" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false"><span class="mim-navbar-menu-font"> Statistics <span class="caret"></span></span></a>
<ul class="dropdown-menu" role="menu" aria-labelledby="statisticsDropdown">
<li>
<a href="/statistics/update"> Update List </a>
</li>
<li>
<a href="/statistics/entry"> Entry Statistics </a>
</li>
<li>
<a href="/statistics/geneMap"> Phenotype-Gene Statistics </a>
</li>
<li>
<a href="/statistics/paceGraph"> Pace of Gene Discovery Graph </a>
</li>
</ul>
</li>
<li class="dropdown">
<a href="#" id="mimDownloadsDropdown" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false"><span class="mim-navbar-menu-font"> Downloads <span class="caret"></span></span></a>
<ul class="dropdown-menu" role="menu" aria-labelledby="downloadsDropdown">
<li>
<a href="/downloads/"> Register for Downloads </a>
</li>
<li>
<a href="/api"> Register for API Access </a>
</li>
</ul>
</li>
<li>
<a href="/contact?mimNumber=230800"><span class="mim-navbar-menu-font"> Contact Us </span></a>
</li>
<li>
<a href="/mimmatch/">
<span class="mim-navbar-menu-font">
<span class="mim-tip-bottom" qtip_title="<strong>MIMmatch</strong>" qtip_text="MIMmatch is a way to follow OMIM entries that interest you and to find other researchers who may share interest in the same entries. <br /><br />A bonus to all MIMmatch users is the option to sign up for updates on new gene-phenotype relationships.">
MIMmatch
</span>
</span>
</a>
</li>
<li class="dropdown">
<a href="#" id="mimDonateDropdown" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false"><span class="mim-navbar-menu-font"> Donate <span class="caret"></span></span></a>
<ul class="dropdown-menu" role="menu" aria-labelledby="donateDropdown">
<li>
<a href="https://secure.jhu.edu/form/OMIM" target="_blank" onclick="gtag('event', 'mim_donation', {'destination': 'secure.jhu.edu'})"> Donate! </a>
</li>
<li>
<a href="/donors"> Donors </a>
</li>
</ul>
</li>
<li class="dropdown">
<a href="#" id="mimHelpDropdown" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false"><span class="mim-navbar-menu-font"> Help <span class="caret"></span></span></a>
<ul class="dropdown-menu" role="menu" aria-labelledby="helpDropdown">
<li>
<a href="/help/faq"> Frequently Asked Questions (FAQs) </a>
</li>
<li role="separator" class="divider"></li>
<li>
<a href="/help/search"> Search Help </a>
</li>
<li>
<a href="/help/linking"> Linking Help </a>
</li>
<li>
<a href="/help/api"> API Help </a>
</li>
<li role="separator" class="divider"></li>
<li>
<a href="/help/external"> External Links </a>
</li>
<li role="separator" class="divider"></li>
<li>
<a href="/help/agreement"> Use Agreement </a>
</li>
<li>
<a href="/help/copyright"> Copyright </a>
</li>
</ul>
</li>
<li>
<a href="#" id="mimShowTips" class="mim-tip-hint" title="Click to reveal all tips on the page. You can also hover over individual elements to reveal the tip."><span class="mim-navbar-menu-font"><span class="glyphicon glyphicon-question-sign" aria-hidden="true"></span></span></a>
</li>
</ul>
</div>
</div>
</nav>
</div>
<div id="mimSearch" class="hidden-print">
<div class="container">
<form method="get" action="/search" id="mimEntrySearchForm" name="entrySearchForm" class="form-horizontal">
<input type="hidden" id="mimSearchIndex" name="index" value="entry" />
<input type="hidden" id="mimSearchStart" name="start" value="1" />
<input type="hidden" id="mimSearchLimit" name="limit" value="10" />
<input type="hidden" id="mimSearchSort" name="sort" value="score desc, prefix_sort desc" />
<div class="row">
<div class="col-lg-8 col-md-8 col-sm-8 col-xs-8">
<div class="form-group">
<div class="input-group">
<input type="search" id="mimEntrySearch" name="search" class="form-control" value="" placeholder="Search OMIM..." maxlength="5000" autocomplete="off" autocorrect="off" autocapitalize="none" spellcheck="false" autofocus />
<div class="input-group-btn">
<button type="submit" id="mimEntrySearchSubmit" class="btn btn-default" style="width: 5em;"><span class="glyphicon glyphicon-search"></span></button>
<button type="button" class="btn btn-default dropdown-toggle" data-toggle="dropdown"> Options <span class="caret"></span></button>
<ul class="dropdown-menu dropdown-menu-right">
<li class="dropdown-header">
Advanced Search
</li>
<li style="margin-left: 0.5em;">
<a href="/search/advanced/entry"> OMIM </a>
</li>
<li style="margin-left: 0.5em;">
<a href="/search/advanced/clinicalSynopsis"> Clinical Synopses </a>
</li>
<li style="margin-left: 0.5em;">
<a href="/search/advanced/geneMap"> Gene Map </a>
</li>
<li role="separator" class="divider"></li>
<li>
<a href="/history"> Search History </a>
</li>
</ul>
</div>
</div>
<div class="autocomplete" id="mimEntrySearchAutocomplete"></div>
</div>
</div>
<div class="col-lg-4 col-md-4 col-sm-4 col-xs-4">
<span class="small">
</span>
</div>
</div>
</form>
<div class="row">
<p />
</div>
</div>
</div>
<!-- <div id="mimSearch"> -->
<div id="mimContent">
<div class="container hidden-print">
<div class="row">
<div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
<div id="mimAlertBanner">
</div>
</div>
</div>
<div class="row">
<div class="col-lg-2 col-md-2 col-sm-2 hidden-sm hidden-xs">
<div id="mimFloatingTocMenu" class="small" role="navigation">
<p>
<span class="h4">#230800</span>
<br />
<strong>Table of Contents</strong>
</p>
<nav>
<ul id="mimFloatingTocMenuItems" class="nav nav-pills nav-stacked mim-floating-toc-padding">
<li role="presentation">
<a href="#title"><strong>Title</strong></a>
</li>
<li role="presentation">
<a href="#phenotypeMap"><strong>Phenotype-Gene Relationships</strong></a>
</li>
<li role="presentation">
<a href="/clinicalSynopsis/230800"><strong>Clinical Synopsis</strong></a>
</li>
<li role="presentation">
<a href="#text"><strong>Text</strong></a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#description">Description</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#clinicalFeatures">Clinical Features</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#biochemicalFeatures">Biochemical Features</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#otherFeatures">Other Features</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#pathogenesis">Pathogenesis</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#inheritance">Inheritance</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#diagnosis">Diagnosis</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#clinicalManagement">Clinical Management</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#molecularGenetics">Molecular Genetics</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#populationGenetics">Population Genetics</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#history">History</a>
</li>
<li role="presentation" style="margin-left: 1em">
<a href="#animalModel">Animal Model</a>
</li>
<li role="presentation">
<a href="#seeAlso"><strong>See Also</strong></a>
</li>
<li role="presentation">
<a href="#references"><strong>References</strong></a>
</li>
<li role="presentation">
<a href="#contributors"><strong>Contributors</strong></a>
</li>
<li role="presentation">
<a href="#creationDate"><strong>Creation Date</strong></a>
</li>
<li role="presentation">
<a href="#editHistory"><strong>Edit History</strong></a>
</li>
</ul>
</nav>
</div>
</div>
<div class="col-lg-2 col-lg-push-8 col-md-2 col-md-push-8 col-sm-2 col-sm-push-8 col-xs-12">
<div id="mimFloatingLinksMenu">
<div class="panel panel-primary" style="margin-bottom: 0px; border-radius: 4px 4px 0px 0px">
<div class="panel-heading mim-panel-heading" role="tab" id="mimExternalLinks">
<h4 class="panel-title">
<a href="#mimExternalLinksFold" id="mimExternalLinksToggle" class="mimTriangleToggle" role="button" data-toggle="collapse">
<div style="display: table-row">
<div id="mimExternalLinksToggleTriangle" class="small" style="color: white; display: table-cell;">&#9660;</div>
&nbsp;
<div style="display: table-cell;">External Links</div>
</div>
</a>
</h4>
</div>
</div>
<div id="mimExternalLinksFold" class="collapse in">
<div class="panel-group" id="mimExternalLinksAccordion" role="tablist" aria-multiselectable="true">
<div class="panel panel-default" style="margin-top: 0px; border-radius: 0px">
<div class="panel-heading mim-panel-heading" role="tab" id="mimClinicalResources">
<span class="panel-title">
<span class="small">
<a href="#mimClinicalResourcesLinksFold" id="mimClinicalResourcesLinksToggle" class=" mimSingletonTriangleToggle" role="button" data-toggle="collapse" data-parent="#mimExternalLinksAccordion">
<div style="display: table-row">
<div id="mimClinicalResourcesLinksToggleTriangle" class="small mimSingletonTriangle" style="color: #337CB5; display: table-cell;">&#9660;</div>
&nbsp;
<div style="display: table-cell;">Clinical Resources</div>
</div>
</a>
</span>
</span>
</div>
<div id="mimClinicalResourcesLinksFold" class="panel-collapse collapse in mimLinksFold" role="tabpanel" aria-labelledby="clinicalResources">
<div class="panel-body small mim-panel-body">
<div><a href="https://clinicaltrials.gov/search?cond=GAUCHER DISEASE, TYPE I" class="mim-tip-hint" title="A registry of federally and privately supported clinical trials conducted in the United States and around the world." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'Clinical Trials', 'domain': 'clinicaltrials.gov'})">Clinical Trials</a></div>
<div><a href="#mimEuroGentestFold" id="mimEuroGentestToggle" data-toggle="collapse" class="mim-tip-hint mimTriangleToggle" title="A list of European laboratories that offer genetic testing."><span id="mimEuroGentestToggleTriangle" class="small" style="margin-left: -0.8em;">&#9658;</span>EuroGentest</div>
<div id="mimEuroGentestFold" class="collapse">
<div style="margin-left: 0.5em;"><a href="https://www.orpha.net/consor/cgi-bin/ClinicalLabs_Search_Simple.php?lng=EN&LnkId=644&Typ=Pat" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'EuroGentest', 'domain': 'orpha.net'})">Gaucher disease&nbsp;</a></div><div style="margin-left: 0.5em;"><a href="https://www.orpha.net/consor/cgi-bin/ClinicalLabs_Search_Simple.php?lng=EN&LnkId=11102&Typ=Pat" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'EuroGentest', 'domain': 'orpha.net'})">Gaucher disease type 1&nbsp;</a></div>
</div>
<div><a href="https://www.ncbi.nlm.nih.gov/books/NBK1269/" class="mim-tip-hint" title="Expert-authored, peer-reviewed descriptions of inherited disorders including the uses of genetic testing in diagnosis, management, and genetic counseling." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'Gene Reviews', 'domain': 'ncbi.nlm.nih.gov'})">Gene Reviews</a></div>
<div><a href="https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=230800[mim]" class="mim-tip-hint" title="Genetic Testing Registry." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'GTR', 'domain': 'ncbi.nlm.nih.gov'})">GTR</a></div>
<div><a href="https://www.acmg.net/PDFLibrary/Gaucher.pdf" class="mim-tip-hint" title="Information and resources for newborn screening and genetics." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'Newborn Screening', 'domain': 'www.acmg.net'})">Newborn Screening</a></div>
<div><a href="#mimOrphanetFold" id="mimOrphanetToggle" data-toggle="collapse" class="mim-tip-hint mimTriangleToggle" title="European reference portal for information on rare diseases and orphan drugs."><span id="mimOrphanetToggleTriangle" class="small" style="margin-left: -0.8em;">&#9658;</span>Orphanet</div>
<div id="mimOrphanetFold" class="collapse">
<div style="margin-left: 0.5em;"><a href="https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=355" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'OrphaNet', 'domain': 'orpha.net'})">Gaucher disease</a></div><div style="margin-left: 0.5em;"><a href="https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=77259" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'OrphaNet', 'domain': 'orpha.net'})">Gaucher disease type 1</a></div>
</div>
<div><a href="https://www.possumcore.com/nuxeo/nxdoc/default/a0ddfaa3-623f-4f15-a799-7beb68bf961b/view_documents?source=omim" class="mim-tip-hint" title="A dysmorphology database of multiple malformations; metabolic, teratogenic, chromosomal, and skeletal syndromes; and their images." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'POSSUM', 'domain': 'possum.net.au'})">POSSUM</a></div>
</div>
</div>
</div>
<div class="panel panel-default" style="margin-top: 0px; border-radius: 0px">
<div class="panel-heading mim-panel-heading" role="tab" id="mimAnimalModels">
<span class="panel-title">
<span class="small">
<a href="#mimAnimalModelsLinksFold" id="mimAnimalModelsLinksToggle" class="collapsed mimSingletonTriangleToggle" role="button" data-toggle="collapse" data-parent="#mimExternalLinksAccordion">
<div style="display: table-row">
<div id="mimAnimalModelsLinksToggleTriangle" class="small mimSingletonTriangle" style="color: #337CB5; display: table-cell;">&#9658;</div>
&nbsp;
<div style="display: table-cell;">Animal Models</div>
</div>
</a>
</span>
</span>
</div>
<div id="mimAnimalModelsLinksFold" class="panel-collapse collapse mimLinksFold" role="tabpanel">
<div class="panel-body small mim-panel-body">
<div><a href="https://www.alliancegenome.org/disease/DOID:0110957" class="mim-tip-hint" title="Search Across Species; explore model organism and human comparative genomics." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'Alliance Genome', 'domain': 'alliancegenome.org'})">Alliance Genome</a></div>
<div><a href="http://www.informatics.jax.org/disease/230800" class="mim-tip-hint" title="Phenotypes, alleles, and disease models from Mouse Genome Informatics." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'MGI Mouse Phenotype', 'domain': 'informatics.jax.org'})">MGI Mouse Phenotype</a></div>
<div><a href="https://omia.org/OMIA000405/" class="mim-tip-hint" title="Online Mendelian Inheritance in Animals (OMIA) is a database of genes, inherited disorders and traits in 191 animal species (other than human and mouse.)" target="_blank">OMIA</a></div>
<div><a href="https://wormbase.org/resources/disease/DOID:0110957" class="mim-tip-hint" title="Database of the biology and genome of Caenorhabditis elegans and related nematodes." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'Wormbase Disease Ontology', 'domain': 'wormbase.org'})">Wormbase Disease Ontology</a></div>
</div>
</div>
</div>
<div class="panel panel-default" style="margin-top: 0px; border-radius: 0px">
<div class="panel-heading mim-panel-heading" role="tab" id="mimCellLines">
<span class="panel-title">
<span class="small">
<a href="#mimCellLinesLinksFold" id="mimCellLinesLinksToggle" class="collapsed mimSingletonTriangleToggle" role="button" data-toggle="collapse" data-parent="#mimExternalLinksAccordion">
<div style="display: table-row">
<div id="mimCellLinesLinksToggleTriangle" class="small mimSingletonTriangle" style="color: #337CB5; display: table-cell;">&#9658;</div>
&nbsp;
<div style="display: table-cell;">Cell Lines</div>
</div>
</a>
</span>
</span>
</div>
<div id="mimCellLinesLinksFold" class="panel-collapse collapse mimLinksFold" role="tabpanel">
<div class="panel-body small mim-panel-body">
<div><a href="https://catalog.coriell.org/Search?q=OmimNum:230800" class="definition" title="Coriell Cell Repositories; cell cultures and DNA derived from cell cultures." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'CCR', 'domain': 'ccr.coriell.org'})">Coriell</a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<span>
<span class="mim-tip-bottom" qtip_title="<strong>Looking for this gene or this phenotype in other resources?</strong>" qtip_text="Select a related resource from the dropdown menu and click for a targeted link to information directly relevant.">
&nbsp;
</span>
</span>
</div>
<div class="col-lg-8 col-lg-pull-2 col-md-8 col-md-pull-2 col-sm-8 col-sm-pull-2 col-xs-12">
<div>
<a id="title" class="mim-anchor"></a>
<div>
<a id="number" class="mim-anchor"></a>
<div class="text-right">
<a href="#" class="mim-tip-icd" qtip_title="<strong>ICD+</strong>" qtip_text="
<strong>SNOMEDCT:</strong> 62201009<br />
<strong>ORPHA:</strong> 355, 77259<br />
<strong>DO:</strong> 0110957<br />
">ICD+</a>
</div>
<div>
<span class="h3">
<span class="mim-font mim-tip-hint" title="Phenotype description, molecular basis known">
<span class="text-danger"><strong>#</strong></span>
230800
</span>
</span>
</div>
</div>
<div>
<a id="preferredTitle" class="mim-anchor"></a>
<h3>
<span class="mim-font">
GAUCHER DISEASE, TYPE I; GD1
</span>
</h3>
</div>
<div>
<br />
</div>
<div>
<a id="alternativeTitles" class="mim-anchor"></a>
<div>
<p>
<span class="mim-font">
<em>Alternative titles; symbols</em>
</span>
</p>
</div>
<div>
<h4>
<span class="mim-font">
GD I<br />
GAUCHER DISEASE, NONCEREBRAL JUVENILE<br />
GLUCOCEREBROSIDASE DEFICIENCY<br />
ACID BETA-GLUCOSIDASE DEFICIENCY<br />
GBA DEFICIENCY
</span>
</h4>
</div>
</div>
<div>
<br />
</div>
</div>
<div>
<a id="phenotypeMap" class="mim-anchor"></a>
<h4>
<span class="mim-font">
<strong>Phenotype-Gene Relationships</strong>
</span>
</h4>
<div>
<table class="table table-bordered table-condensed table-hover small mim-table-padding">
<thead>
<tr class="active">
<th>
Location
</th>
<th>
Phenotype
</th>
<th>
Phenotype <br /> MIM number
</th>
<th>
Inheritance
</th>
<th>
Phenotype <br /> mapping key
</th>
<th>
Gene/Locus
</th>
<th>
Gene/Locus <br /> MIM number
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<span class="mim-font">
<a href="/geneMap/1/1217?start=-3&limit=10&highlight=1217">
1q22
</a>
</span>
</td>
<td>
<span class="mim-font">
Gaucher disease, type I
</span>
</td>
<td>
<span class="mim-font">
<a href="/entry/230800"> 230800 </a>
</span>
</td>
<td>
<span class="mim-font">
<abbr class="mim-tip-hint" title="Autosomal recessive">AR</abbr>
</span>
</td>
<td>
<span class="mim-font">
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
</span>
</td>
<td>
<span class="mim-font">
GBA1
</span>
</td>
<td>
<span class="mim-font">
<a href="/entry/606463"> 606463 </a>
</span>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div>
<div class="btn-group ">
<a href="/clinicalSynopsis/230800" class="btn btn-warning" role="button"> Clinical Synopsis </a>
<button type="button" id="mimPhenotypicSeriesToggle" class="btn btn-warning dropdown-toggle mimSingletonFoldToggle" data-toggle="collapse" href="#mimClinicalSynopsisFold" onclick="ga('send', 'event', 'Unfurl', 'ClinicalSynopsis', 'omim.org')">
<span class="caret"></span>
<span class="sr-only">Toggle Dropdown</span>
</button>
</div>
&nbsp;
<div class="btn-group">
<button type="button" class="btn btn-success dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
PheneGene Graphics <span class="caret"></span>
</button>
<ul class="dropdown-menu" style="width: 17em;">
<li><a href="/graph/linear/230800" target="_blank" onclick="gtag('event', 'mim_graph', {'destination': 'Linear'})"> Linear </a></li>
<li><a href="/graph/radial/230800" target="_blank" onclick="gtag('event', 'mim_graph', {'destination': 'Radial'})"> Radial </a></li>
</ul>
</div>
<span class="glyphicon glyphicon-question-sign mim-tip-hint" title="OMIM PheneGene graphics depict relationships between phenotypes, groups of related phenotypes (Phenotypic Series), and genes.<br /><a href='/static/omim/pdf/OMIM_Graphics.pdf' target='_blank'>A quick reference overview and guide (PDF)</a>"></span>
<div>
<p />
</div>
<div id="mimClinicalSynopsisFold" class="well well-sm collapse mimSingletonToggleFold">
<div class="small" style="margin: 5px">
<div>
<div>
<span class="h5 mim-font">
<strong> INHERITANCE </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<span class="mim-font">
- Autosomal recessive <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/258211005" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">258211005</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0441748&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0441748</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0000007" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0000007</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0000007" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0000007</a>]</span><br />
</span>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> HEAD & NECK </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<div>
<span class="h5 mim-font">
<em> Eyes </em>
</span>
</div>
<div style="margin-left: 2em;">
<span class="mim-font">
- Brown accumulation of Gaucher cells at corneoscleral limbus <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856519&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856519</a>]</span><br /> -
White deposits in corneal epithelium, anterior chamber angle, ciliary body, and pupillary margin <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856520&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856520</a>]</span><br /> -
Perimacular grayness <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856521&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856521</a>]</span><br /> -
Macular atrophy <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/238828009" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">238828009</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1288283&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1288283</a>, <a href="https://bioportal.bioontology.org/search?q=C0423421&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0423421</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0032026" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0032026</a>, <a href="https://hpo.jax.org/app/browse/term/HP:0007401" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0007401</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0007401" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0007401</a>]</span><br /> -
Increased retinal vascular permeability <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856522&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856522</a>]</span><br />
</span>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<em> Nose </em>
</span>
</div>
<div style="margin-left: 2em;">
<span class="mim-font">
- Epistaxis <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/249366005" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">249366005</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/R04.0" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">R04.0</a>]</span> <span class="mim-feature-ids hidden">[ICD9CM: <a href="https://purl.bioontology.org/ontology/ICD9CM/784.7" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">784.7</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0014591&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0014591</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0000421" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0000421</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0000421" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0000421</a>]</span><br />
</span>
</div>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> CARDIOVASCULAR </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<div>
<span class="h5 mim-font">
<em> Vascular </em>
</span>
</div>
<div style="margin-left: 2em;">
<span class="mim-font">
- Increased retinal vascular permeability <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856522&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856522</a>]</span><br /> -
Pulmonary hypertension <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/70995007" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">70995007</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/I27.20" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">I27.20</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0020542&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0020542</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002092" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002092</a>]</span><br />
</span>
</div>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> RESPIRATORY </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<div>
<span class="h5 mim-font">
<em> Lung </em>
</span>
</div>
<div style="margin-left: 2em;">
<span class="mim-font">
- Pulmonary infiltrates, diffuse (less than 5% of patients) <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0748143&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0748143</a>]</span><br /> -
Interstitial lung disease <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/233703007" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">233703007</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/J84.9" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">J84.9</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C5441745&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C5441745</a>, <a href="https://bioportal.bioontology.org/search?q=C0206062&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0206062</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0006530" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0006530</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0006530" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0006530</a>]</span><br /> -
Restrictive impairment <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856532&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856532</a>]</span><br /> -
Dyspnea <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/267036007" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">267036007</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/230145002" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">230145002</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/R06.02" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">R06.02</a>, <a href="https://purl.bioontology.org/ontology/ICD10CM/R06.0" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">R06.0</a>, <a href="https://purl.bioontology.org/ontology/ICD10CM/R06.00" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">R06.00</a>]</span> <span class="mim-feature-ids hidden">[ICD9CM: <a href="https://purl.bioontology.org/ontology/ICD9CM/786.05" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">786.05</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0013404&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0013404</a>, <a href="https://bioportal.bioontology.org/search?q=C2024878&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C2024878</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002094" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002094</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002094" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002094</a>]</span><br />
</span>
</div>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> ABDOMEN </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<div>
<span class="h5 mim-font">
<em> Liver </em>
</span>
</div>
<div style="margin-left: 2em;">
<span class="mim-font">
- Hepatomegaly <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/80515008" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">80515008</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/R16.0" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">R16.0</a>]</span> <span class="mim-feature-ids hidden">[ICD9CM: <a href="https://purl.bioontology.org/ontology/ICD9CM/789.1" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">789.1</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0019209&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0019209</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002240" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002240</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002240" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002240</a>]</span><br />
</span>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<em> Spleen </em>
</span>
</div>
<div style="margin-left: 2em;">
<span class="mim-font">
- Splenomegaly <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/16294009" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">16294009</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/R16.1" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">R16.1</a>]</span> <span class="mim-feature-ids hidden">[ICD9CM: <a href="https://purl.bioontology.org/ontology/ICD9CM/789.2" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">789.2</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0038002&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0038002</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001744" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001744</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001744" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001744</a>]</span><br />
</span>
</div>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> SKELETAL </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<span class="mim-font">
- Osteolytic lesions <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/203522001" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">203522001</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/30425001" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">30425001</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0302313&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0302313</a>]</span><br /> -
Osteonecrosis <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/397758007" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">397758007</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/M87.9" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">M87.9</a>, <a href="https://purl.bioontology.org/ontology/ICD10CM/M87" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">M87</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0029445&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0029445</a>, <a href="https://bioportal.bioontology.org/search?q=C0027543&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0027543</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0010885" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0010885</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0010885" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0010885</a>]</span><br /> -
Pathologic fractures <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/22640007" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">22640007</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/268029009" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">268029009</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/M84.4" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">M84.4</a>]</span> <span class="mim-feature-ids hidden">[ICD9CM: <a href="https://purl.bioontology.org/ontology/ICD9CM/733.10" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">733.10</a>, <a href="https://purl.bioontology.org/ontology/ICD9CM/V13.51" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">V13.51</a>, <a href="https://purl.bioontology.org/ontology/ICD9CM/733.1" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">733.1</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0016663&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0016663</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002756" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002756</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002756" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002756</a>]</span><br /> -
Bone crises <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856525&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856525</a>]</span><br /> -
Bone pain <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/12584003" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">12584003</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0151825&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0151825</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002653" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002653</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002653" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002653</a>]</span><br />
</span>
</div>
<div>
<div>
<span class="h5 mim-font">
<em> Spine </em>
</span>
</div>
<div style="margin-left: 2em;">
<span class="mim-font">
- Vertebral compression <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/42942008" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">42942008</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0262431&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0262431</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002953" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002953</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0002953" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0002953</a>]</span><br />
</span>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<em> Limbs </em>
</span>
</div>
<div style="margin-left: 2em;">
<span class="mim-font">
- Avascular necrosis of femoral head <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/203476003" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">203476003</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0410480&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0410480</a>]</span><br /> -
Erlenmeyer flask' deformity of the femurs <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1855895&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1855895</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0004975" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0004975</a>]</span><br />
</span>
</div>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> SKIN, NAILS, & HAIR </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<div>
<span class="h5 mim-font">
<em> Skin </em>
</span>
</div>
<div style="margin-left: 2em;">
<span class="mim-font">
- Hyperpigmentation <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/4830009" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">4830009</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/49765009" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">49765009</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0162834&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0162834</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0000953" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0000953</a>]</span><br />
</span>
</div>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> HEMATOLOGY </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<span class="mim-font">
- Gaucher cells in the bone marrow <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856530&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856530</a>]</span><br /> -
Hypersplenism <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/58381000" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">58381000</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/D73.1" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">D73.1</a>]</span> <span class="mim-feature-ids hidden">[ICD9CM: <a href="https://purl.bioontology.org/ontology/ICD9CM/289.4" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">289.4</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0020532&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0020532</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001971" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001971</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001971" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001971</a>]</span><br /> -
Thrombocytopenia <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/415116008" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">415116008</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/302215000" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">302215000</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/D69.6" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">D69.6</a>]</span> <span class="mim-feature-ids hidden">[ICD9CM: <a href="https://purl.bioontology.org/ontology/ICD9CM/287.5" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">287.5</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0392386&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0392386</a>, <a href="https://bioportal.bioontology.org/search?q=C0040034&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0040034</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001873" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001873</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001873" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001873</a>]</span><br /> -
Anemia <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/271737000" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">271737000</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/D64.9" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">D64.9</a>]</span> <span class="mim-feature-ids hidden">[ICD9CM: <a href="https://purl.bioontology.org/ontology/ICD9CM/285.9" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">285.9</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0002871&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0002871</a>, <a href="https://bioportal.bioontology.org/search?q=C1000483&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1000483</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001903" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001903</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001903" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001903</a>]</span><br /> -
Pancytopenia <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/127034005" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">127034005</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/D61.81" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">D61.81</a>]</span> <span class="mim-feature-ids hidden">[ICD9CM: <a href="https://purl.bioontology.org/ontology/ICD9CM/284.1" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD9CM\', \'domain\': \'bioontology.org\'})">284.1</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0030312&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0030312</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001876" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001876</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001876" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001876</a>]</span><br />
</span>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> NEOPLASIA </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<span class="mim-font">
- Increased risk for multiple myeloma <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856523&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856523</a>]</span><br /> -
Increased risk for monoclonal gammopathy <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856524&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856524</a>]</span><br />
</span>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> LABORATORY ABNORMALITIES </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<span class="mim-font">
- Acid beta-glucosidase deficiency <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/62201009" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">62201009</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/180485001" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">180485001</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/190794006" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">190794006</a>]</span> <span class="mim-feature-ids hidden">[ICD10CM: <a href="https://purl.bioontology.org/ontology/ICD10CM/E75.22" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'ICD10CM\', \'domain\': \'bioontology.org\'})">E75.22</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1961835&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1961835</a>, <a href="https://bioportal.bioontology.org/search?q=C0017205&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0017205</a>]</span><br /> -
Increased bone serum acid phosphatase <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1856529&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1856529</a>]</span><br />
</span>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> MISCELLANEOUS </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<span class="mim-font">
- Age at onset most often in childhood (first decade)<br /> -
Onset and diagnosis may occur later (after age 20 years)<br /> -
Highly variable phenotype, some adults may be asymptomatic<br /> -
Increased frequency in Ashkenazi Jews (carrier frequency 1 in 14)<br />
</span>
</div>
</div>
</div>
<div>
<div>
<span class="h5 mim-font">
<strong> MOLECULAR BASIS </strong>
</span>
</div>
<div style="margin-left: 2em;">
<div>
<span class="mim-font">
- Caused by mutation in the acid beta glucosidase gene (GBA, <a href="/entry/606463#0001">606463.0001</a>)<br />
</span>
</div>
</div>
</div>
<div class="text-right">
<a href="#mimClinicalSynopsisFold" data-toggle="collapse">&#9650;&nbsp;Close</a>
</div>
</div>
</div>
</div>
<div>
<br />
</div>
<div>
<a id="text" class="mim-anchor"></a>
<h4 href="#mimTextFold" id="mimTextToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimTextToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<span class="mim-tip-floating" qtip_title="<strong>Looking For More References?</strong>" qtip_text="Click the 'reference plus' icon &lt;span class='glyphicon glyphicon-plus-sign'&gt;&lt;/span&gt at the end of each OMIM text paragraph to see more references related to the content of the preceding paragraph.">
<strong>TEXT</strong>
</span>
</span>
</h4>
<div id="mimTextFold" class="collapse in ">
<span class="mim-text-font">
<p>A number sign (#) is used with this entry because Gaucher disease type I (GD1) is caused by homozygous or compound heterozygous mutation in the GBA gene (<a href="/entry/606463">606463</a>), which encodes acid beta-glucosidase, on chromosome 1q22.</p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="description" class="mim-anchor"></a>
<h4 href="#mimDescriptionFold" id="mimDescriptionToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimDescriptionToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Description</strong>
</span>
</h4>
</div>
<div id="mimDescriptionFold" class="collapse in ">
<span class="mim-text-font">
<p>Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder due to deficient activity of beta-glucocerebrosidase. As a result of this deficiency, there is intracellular accumulation of glucosylceramide (GlcCer, glucosylcerebroside) primarily within cells of mononuclear phagocyte origin, which are the characteristic 'Gaucher cells' identified in most tissues (<a href="#44" class="mim-tip-reference" title="Jmoudiak, M., Futerman, A. H. &lt;strong&gt;Gaucher disease: pathological mechanisms and modern management.&lt;/strong&gt; Brit. J. Haemat. 129: 178-188, 2005.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15813845/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;15813845&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1111/j.1365-2141.2004.05351.x&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="15813845">Jmoudiak and Futerman, 2005</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15813845" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Gaucher disease is classically categorized phenotypically into 3 main subtypes: nonneuronopathic type I (GD1), acute neuronopathic type II (GD2; <a href="/entry/230900">230900</a>), and subacute neuronopathic type III (GD3; <a href="/entry/231000">231000</a>). Type I is the most common form of Gaucher disease and lacks primary central nervous system involvement. Types II and III have central nervous system involvement and neurologic manifestations (<a href="#47" class="mim-tip-reference" title="Knudson, A. G., Jr., Kaplan, W. D. &lt;strong&gt;Genetics of the sphingolipidoses. In: Aaronson, S. M.; Volk, B. W.: Cerebral Sphingolipidoses. A Symposium on Tay-Sachs Disease.&lt;/strong&gt; New York: Academic Press (pub.) 1962. Pp. 395-411."None>Knudson and Kaplan, 1962</a>; <a href="#44" class="mim-tip-reference" title="Jmoudiak, M., Futerman, A. H. &lt;strong&gt;Gaucher disease: pathological mechanisms and modern management.&lt;/strong&gt; Brit. J. Haemat. 129: 178-188, 2005.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15813845/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;15813845&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1111/j.1365-2141.2004.05351.x&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="15813845">Jmoudiak and Futerman, 2005</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15813845" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>All 3 forms of Gaucher disease are caused by mutation in the GBA gene. There are 2 additional phenotypes that may be distinguished: perinatal lethal Gaucher disease (<a href="/entry/608013">608013</a>), which is a severe form of type II, and Gaucher disease type IIIC (<a href="/entry/231005">231005</a>), which also has cardiovascular calcifications.</p><p>See also <a href="/entry/610539">610539</a> for a form of atypical Gaucher disease caused by mutation in the gene encoding saposin C (PSAP; <a href="/entry/176801">176801</a>), which is an activator of beta-glucosidase.</p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="clinicalFeatures" class="mim-anchor"></a>
<h4 href="#mimClinicalFeaturesFold" id="mimClinicalFeaturesToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimClinicalFeaturesToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Clinical Features</strong>
</span>
</h4>
</div>
<div id="mimClinicalFeaturesFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p>Type I Gaucher disease usually presents in childhood with hepatosplenomegaly, pancytopenia, and manifestations of bone marrow infiltration by characteristic 'Gaucher cells.' Other features include ocular pingueculae, or nodules, and dermal hyperpigmentation. There is a wide spectrum of clinical severity, ranging from affected infants to asymptomatic adults. There is no neurologic involvement in type I Gaucher disease (<a href="#35" class="mim-tip-reference" title="Goldblatt, J. &lt;strong&gt;Type I Gaucher disease.&lt;/strong&gt; J. Med. Genet. 25: 415-418, 1988.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3294411/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3294411&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1136/jmg.25.6.415&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3294411">Goldblatt, 1988</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3294411" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#22" class="mim-tip-reference" title="Choy, F. Y. M. &lt;strong&gt;Intrafamilial clinical variability of type 1 Gaucher disease in a French-Canadian family.&lt;/strong&gt; J. Med. Genet. 25: 322-325, 1988.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3385740/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3385740&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1136/jmg.25.5.322&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3385740">Choy (1988)</a> reported a French Canadian family in which 5 sibs had type I Gaucher disease. Glucocerebrosidase activity in patients' fibroblasts was 7.5 to 15.5% of normal controls; obligate carriers had approximately 50% normal activity. The 5 affected sibs showed considerable phenotypic heterogeneity: age at diagnosis ranged from 16 to 41 years. The most severely affected patient was very anemic and thrombocytopenic, and had severe orthopedic complications, including vertebral compression, avascular necrosis of the femoral head, and pathologic fractures of long bones. The least affected male had no orthopedic complications at age 49 years and his hematologic complications had been reversed by splenectomy at age 25. There was no clear correlation between residual GBA enzyme activity in cultured fibroblasts and clinical severity. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3385740" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>In a retrospective study of 20 untreated Dutch patients with type I Gaucher disease, <a href="#51" class="mim-tip-reference" title="Maaswinkel-Mooij, P., Hollak, C., van Eysden-Plaisier, M., Prins, M., Aerts, H., Poll, R. &lt;strong&gt;The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations.&lt;/strong&gt; J. Inherit. Metab. Dis. 23: 77-82, 2000.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10682310/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;10682310&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1023/a:1005655031239&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="10682310">Maaswinkel-Mooij et al. (2000)</a> found that the clinical manifestations were progressive in most patients, children as well as adults. This appeared to be in contrast with studies among Jewish patients. The results emphasized the need for regular follow-up to enable timely initiation of enzyme therapy. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=10682310" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#58" class="mim-tip-reference" title="Park, J. K., Koprivica, V., Andrews, D. Q., Madike, V., Tayebi, N., Stone, D. L., Sidransky, E. &lt;strong&gt;Glucocerebrosidase mutations among African-American patients with type 1 Gaucher disease.&lt;/strong&gt; Am. J. Med. Genet. 99: 147-151, 2001.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11241475/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;11241475&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1002/1096-8628(2001)9999:9999&lt;::aid-ajmg1144&gt;3.0.co;2-1&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="11241475">Park et al. (2001)</a> reported the clinical features and genotypes of 7 African American patients with type I Gaucher disease. Common features included hepatosplenomegaly, epistaxis, bone pain, anemia, and thrombocytopenia. All patients had moderate to severe manifestations, 4 presented before age 3 years, and all developed symptoms by adolescence. No probands shared the same genotype. The authors concluded that significant genotypic heterogeneity exists among African American patients with type I Gaucher disease, and that recombinations in the GBA gene may be common in this patient group. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=11241475" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="biochemicalFeatures" class="mim-anchor"></a>
<h4 href="#mimBiochemicalFeaturesFold" id="mimBiochemicalFeaturesToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimBiochemicalFeaturesToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Biochemical Features</strong>
</span>
</h4>
</div>
<div id="mimBiochemicalFeaturesFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p><a href="#14" class="mim-tip-reference" title="Brady, R. O., Kanfer, J. N., Shapiro, D. &lt;strong&gt;Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher&#x27;s disease.&lt;/strong&gt; Biochem. Biophys. Res. Commun. 18: 221-225, 1965.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14282020/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;14282020&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/0006-291x(65)90743-6&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="14282020">Brady et al. (1965)</a> demonstrated deficiency of the glucocerebrosidase enzyme in the spleen of patients with Gaucher disease. <a href="#81" class="mim-tip-reference" title="Wiedemann, H.-R., Gerken, H., Graucob, E., Hansen, H.-G. &lt;strong&gt;Recognition of heterozygosity in sphingolipidoses. (Letter)&lt;/strong&gt; Lancet 285: 1283 only, 1965. Note: Originally Volume 1."None>Wiedemann et al. (1965)</a> found typical Gaucher cells in the bone marrow of unaffected obligate heterozygotes from 2 families with Gaucher disease. <a href="#24" class="mim-tip-reference" title="Danes, B. S., Bearn, A. G. &lt;strong&gt;Gaucher&#x27;s disease: a genetic disease detected in skin fibroblast cultures.&lt;/strong&gt; Science 161: 1347-1348, 1968.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/5673446/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;5673446&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1126/science.161.3848.1347&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="5673446">Danes and Bearn (1968)</a> found giant fibroblasts containing metachromatic material in both affected persons and heterozygotes for the chronic noncerebral form of Gaucher disease. <a href="#8" class="mim-tip-reference" title="Beutler, E., Kuhl, W., Trinidad, F., Teplitz, R. L., Nadler, H. &lt;strong&gt;Beta-glucosidase activity in fibroblasts from homozygotes and heterozygotes for Gaucher&#x27;s disease.&lt;/strong&gt; Am. J. Hum. Genet. 23: 62-66, 1971.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/5581982/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;5581982&lt;/a&gt;]" pmid="5581982">Beutler et al. (1971)</a> demonstrated decreased beta-glucosidase activity in fibroblasts from homozygotes with the adult form of Gaucher disease. Heterozygotes showed intermediate levels of enzyme activity. <a href="#19" class="mim-tip-reference" title="Chiao, Y.-B., Peters, S. P., Diven, W. F., Lee, R. E., Glew, R. H. &lt;strong&gt;Demonstration of beta-xylosidase activity in various forms of Gaucher&#x27;s disease.&lt;/strong&gt; Metabolism 28: 56-62, 1979.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/759826/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;759826&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/0026-0495(79)90168-9&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="759826">Chiao et al. (1979)</a> found deficiency of beta-xylosidase (see <a href="/entry/278900">278900</a>) in different forms of Gaucher disease and suggested that clinical features such as severity may be related to this epiphenomenon. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=759826+14282020+5581982+5673446" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#61" class="mim-tip-reference" title="Pentchev, P. G., Neumeyer, B., Svennerholm, L., Groth, C. G., Brady, R. O. &lt;strong&gt;Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease.&lt;/strong&gt; Am. J. Hum. Genet. 35: 621-628, 1983.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6881138/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;6881138&lt;/a&gt;]" pmid="6881138">Pentchev et al. (1983)</a> found the same glucocerebrosidase crossreacting material in the spleen in all 3 types of Gaucher disease. However, enzyme activity was about 15% of normal in the adult nonneurologic form (type I) and about 2.3% in the neurologic forms (types II and III). The authors concluded that all 3 forms of Gaucher disease result from a structurally mutated enzyme with altered catalytic efficiency. <a href="#38" class="mim-tip-reference" title="Gravel, R. A., Leung, A. &lt;strong&gt;Complementation analysis in Gaucher disease using single cell microassay techniques: evidence for a single &#x27;Gaucher gene&#x27;.&lt;/strong&gt; Hum. Genet. 65: 112-116, 1983.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6418635/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;6418635&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1007/BF00286645&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="6418635">Gravel and Leung (1983)</a> found no complementation from fusion of cultured fibroblasts from the infantile and adult forms of Gaucher disease, suggesting that the 2 forms are allelic. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=6881138+6418635" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Using various inhibitors, <a href="#36" class="mim-tip-reference" title="Grabowski, G. A., Dinur, T., Osiecki, K. M., Kruse, J. R., Legler, G., Gatt, S. &lt;strong&gt;Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.&lt;/strong&gt; Am. J. Hum. Genet. 37: 499-510, 1985.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4003396/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;4003396&lt;/a&gt;]" pmid="4003396">Grabowski et al. (1985)</a> found 3 distinct groups of residual enzyme activity in patients with Gaucher disease. The groups were designated A, B, and C, but did not correspond to the phenotypic groups I, II, and III. The authors concluded that Gaucher disease type I is biochemically heterogeneous; that the nonneuronopathic and neuronopathic subtypes cannot be distinguished by such inhibitor studies; and that the Ashkenazi Jewish form of Gaucher disease type I results from a unique mutation in a specific active site domain of acid beta-glucosidase that leads to a defective enzyme. With monoclonal antibodies as well as polyclonal sera, <a href="#7" class="mim-tip-reference" title="Beutler, E., Kuhl, W., Sorge, J. &lt;strong&gt;Glucocerebrosidase &#x27;processing&#x27; and gene expression in various forms of Gaucher disease.&lt;/strong&gt; Am. J. Hum. Genet. 37: 1062-1070, 1985.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4083278/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;4083278&lt;/a&gt;]" pmid="4083278">Beutler et al. (1985)</a> could demonstrate no differences of glucocerebrosidase in types I, II, and III Gaucher disease. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=4083278+4003396" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Based on enzymatic and phenotypic examination of 25 families with type I Gaucher disease, <a href="#83" class="mim-tip-reference" title="Zlotogora, J., Zaizov, R., Klibansky, C., Matoth, Y., Bach, G., Cohen, T. &lt;strong&gt;Genetic heterogeneity in Gaucher disease.&lt;/strong&gt; J. Med. Genet. 23: 319-322, 1986.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3746831/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3746831&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1136/jmg.23.4.319&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3746831">Zlotogora et al. (1986)</a> concluded that the clinical variability results from different mutations at the same locus. The authors noted that <a href="#46" class="mim-tip-reference" title="Klibansky, C., Hoffman, J., Zaizov, R., Matoth, Y., Pinchas, J., DeVries, A. &lt;strong&gt;Chronic Gaucher disease: heat resistance of leukocyte beta-glucocerebrosidase in relation to some clinical parameters.&lt;/strong&gt; Biomedicine 19: 345-348, 1973.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4774111/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;4774111&lt;/a&gt;]" pmid="4774111">Klibansky et al. (1973)</a> had observed differences in heat activation profiles of glucocerebrosidase in type I patients with varying phenotypic severity. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=3746831+4774111" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#39" class="mim-tip-reference" title="Graves, P. N., Grabowski, G. A., Ludman, M. D., Palese, P., Smith, F. I. &lt;strong&gt;Human acid beta-glucosidase: Northern blot and S1 nuclease analysis of mRNA from HeLa cells and normal and Gaucher disease fibroblasts.&lt;/strong&gt; Am. J. Hum. Genet. 39: 763-774, 1986.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3026174/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3026174&lt;/a&gt;]" pmid="3026174">Graves et al. (1986)</a> found normal amounts of GBA mRNA in fibroblast extracts from patients with several types of Gaucher disease, suggesting single-base gene alterations leading to the synthesis of defective enzyme. Using immunoblotting techniques, <a href="#27" class="mim-tip-reference" title="Fabbro, D., Desnick, R. J., Grabowski, G. A. &lt;strong&gt;Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.&lt;/strong&gt; Am. J. Hum. Genet. 40: 15-31, 1987.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3812484/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3812484&lt;/a&gt;]" pmid="3812484">Fabbro et al. (1987)</a> found extensive heterogeneity in the nature of the biochemical defects in the various forms of Gaucher disease. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=3026174+3812484" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#5" class="mim-tip-reference" title="Bergmann, J. E., Grabowski, G. A. &lt;strong&gt;Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts.&lt;/strong&gt; Am. J. Hum. Genet. 44: 741-750, 1989.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2495719/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;2495719&lt;/a&gt;]" pmid="2495719">Bergmann and Grabowski (1989)</a> found abnormalities in the posttranslational processing of GBA in patients with Gaucher disease, but the abnormalities could not be correlated firmly with phenotype. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=2495719" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Because glycosphingolipids may be involved in the induction of insulin resistance, and the primary genetic defect in Gaucher disease leads to increased levels of these molecules, Gaucher patients constitute a human model to study the relationship between glucose metabolism and glycosphingolipids. In a study of 6 patients with Gaucher disease and 6 controls, <a href="#49" class="mim-tip-reference" title="Langeveld, M., Ghauharali, K. J. M., Sauerwein, H. P., Ackermans, M. T., Groener, J. E. M., Hollak, C. E. M., Aerts, J. M., Serlie, M. J. &lt;strong&gt;Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.&lt;/strong&gt; J. Clin. Endocr. Metab. 93: 845-851, 2008.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18089699/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;18089699&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1210/jc.2007-1702&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="18089699">Langeveld et al. (2008)</a> found that noninsulin-mediated glucose uptake during both euglycemia and hyperglycemia did not differ between patients and controls, but insulin-mediated glucose uptake was lower in Gaucher patients. Suppression of lipolysis by insulin tended to be less effective in Gaucher disease patients. <a href="#49" class="mim-tip-reference" title="Langeveld, M., Ghauharali, K. J. M., Sauerwein, H. P., Ackermans, M. T., Groener, J. E. M., Hollak, C. E. M., Aerts, J. M., Serlie, M. J. &lt;strong&gt;Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.&lt;/strong&gt; J. Clin. Endocr. Metab. 93: 845-851, 2008.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18089699/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;18089699&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1210/jc.2007-1702&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="18089699">Langeveld et al. (2008)</a> concluded that Gaucher disease is associated with peripheral insulin resistance, possibly through the influence of glycosphingolipids on insulin receptor functioning. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18089699" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#64" class="mim-tip-reference" title="Ramaswami, L., Mengel, E., Berrah, A., AlSayed, M., Broomfield, A., Donald, A., Seif El Dein, H. M., Freisens, S., Hwu, W.-L., Peterschmitt, M. J., Yoo H.-W., Abdelwahab, M. &lt;strong&gt;Throwing a spotlight on under-recognized manifestations of Gaucher disease: pulmonary involvement, lymphadenopathy, and Gaucheroma.&lt;/strong&gt; Molec. Genet. Metab. 133: 335-344, 2021.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34229967/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;34229967&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.ymgme.2021.06.009&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="34229967">Ramaswami et al. (2021)</a> reviewed pulmonary involvement, lymphadenopathy, and Gaucheromas in Gaucher disease. Approximately 68% of patients in a prospective study of Gaucher disease type I had pulmonary function abnormalities, 17% had chest radiograph abnormalities, and 3% had pulmonary hypertension. Findings on high-resolution chest CT included a ground glass appearance in the early stages of disease, with evolution into a reticulonodular pattern at later stages. Lymphadenopathy had an incidence of approximately 5% in Gaucher disease, and commonly involved mediastinal/mesenteric lymph nodes. Lymphadenopathy has the potential to mimic malignancy and can progress to protein-losing enteropathy. Risk factors included severe Gaucher disease and asplenia. Approximately 20 to 25% of patients with Gaucher disease developed a Gaucheroma, which is a cluster of Gaucher cells that form a pseudotumor occurring most frequently in the liver, spleen, bone, and lymph nodes. Most cases of Gaucheromas occurred in adults, and splenectomy increased the risk. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=34229967" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="otherFeatures" class="mim-anchor"></a>
<h4 href="#mimOtherFeaturesFold" id="mimOtherFeaturesToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimOtherFeaturesToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Other Features</strong>
</span>
</h4>
</div>
<div id="mimOtherFeaturesFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p><a href="#32" class="mim-tip-reference" title="Garfinkel, D., Sidi, Y., Ben-Bassat, M., Salomon, F., Hazaz, B., Pinkhas, J. &lt;strong&gt;Coexistence of Gaucher&#x27;s disease and multiple myeloma.&lt;/strong&gt; Arch. Intern. Med. 142: 2229-2230, 1982.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7138174/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;7138174&lt;/a&gt;]" pmid="7138174">Garfinkel et al. (1982)</a> observed an association between Gaucher disease and monoclonal gammopathy or multiple myeloma and suggested that chronic glucocerebroside accumulation may provide a stimulus to the immune system. A possible experimental counterpart is myeloma in Balb/C mice, which develops several months after the intraperitoneal injection of mineral oil. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=7138174" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Calcific constrictive pericarditis was described by several authors in patients with type I Gaucher disease (<a href="#40" class="mim-tip-reference" title="Harvey, P. K. P., Jones, M. C., Anderson, E. G. &lt;strong&gt;Pericardial abnormalities in Gaucher&#x27;s disease.&lt;/strong&gt; Brit. Heart J. 31: 603-606, 1969.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/5351295/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;5351295&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1136/hrt.31.5.603&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="5351295">Harvey et al., 1969</a>; <a href="#74" class="mim-tip-reference" title="Tamari, I., Motro, M., Neufeld, H. N. &lt;strong&gt;Unusual pericardial calcification in Gaucher&#x27;s disease.&lt;/strong&gt; Arch. Intern. Med. 143: 2010-2011, 1983.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6625792/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;6625792&lt;/a&gt;]" pmid="6625792">Tamari et al., 1983</a>). The pericardial involvement in these cases was likely related to unrecognized hemorrhagic pericarditis (<a href="#17" class="mim-tip-reference" title="Chabas, A., Cormand, B., Grinberg, D., Burguera, J. M., Balcells, S., Merino, J. L., Mate, I., Sobrino, J. A., Gonzalez-Duarte, R., Vilageliu, L. &lt;strong&gt;Unusual expression of Gaucher&#x27;s disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation.&lt;/strong&gt; J. Med. Genet. 32: 740-742, 1995.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8544197/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8544197&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1136/jmg.32.9.740&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="8544197">Chabas et al., 1995</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?term=6625792+5351295+8544197" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#21" class="mim-tip-reference" title="Choy, F. Y. M. &lt;strong&gt;Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type 1 Gaucher tissues.&lt;/strong&gt; Am. J. Med. Genet. 21: 519-528, 1985.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4025386/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;4025386&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1002/ajmg.1320210315&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="4025386">Choy (1985)</a> found increased bone serum acid phosphatase only in patients with Gaucher disease who had bone involvement. Acid phosphatase was normal in lymphocytes and cultured fibroblasts from these patients, suggesting that it was a secondary feature of the disease in which there is bone involvement and is unreliable for diagnosis. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=4025386" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#67" class="mim-tip-reference" title="Ross, D. J., Spira, S., Buchbinder, N. A. &lt;strong&gt;Gaucher cells in pulmonary-capillary blood in association with pulmonary hypertension. (Letter)&lt;/strong&gt; New Eng. J. Med. 336: 379-381, 1997.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9011805/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;9011805&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1056/NEJM199701303360516&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="9011805">Ross et al. (1997)</a> noted that aggregations of Gaucher cells within pulmonary alveolar spaces and interstitium in association with bilateral diffuse pulmonary reticulonodular infiltrates had been described in patients with type I Gaucher disease. In addition, there have been rare instances of Gaucher cells occluding pulmonary capillaries, with resulting pulmonary hypertension. The hepatopulmonary syndrome, as manifested by intrapulmonary shunting and hypoxemia, may also complicate type I Gaucher disease. <a href="#67" class="mim-tip-reference" title="Ross, D. J., Spira, S., Buchbinder, N. A. &lt;strong&gt;Gaucher cells in pulmonary-capillary blood in association with pulmonary hypertension. (Letter)&lt;/strong&gt; New Eng. J. Med. 336: 379-381, 1997.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9011805/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;9011805&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1056/NEJM199701303360516&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="9011805">Ross et al. (1997)</a> described a patient with type I Gaucher disease and pulmonary hypertension in whom they identified Gaucher cells in pulmonary capillary blood drawn from a catheter in the wedged position. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=9011805" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#53" class="mim-tip-reference" title="Miller, A., Brown, L. K., Pastores, G. M., Desnick, R. J. &lt;strong&gt;Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease.&lt;/strong&gt; Clin. Genet. 63: 368-376, 2003.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12752568/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;12752568&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1034/j.1399-0004.2003.00060.x&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="12752568">Miller et al. (2003)</a> evaluated pulmonary involvement in 150 consecutive patients with type I Gaucher disease. Clinical evidence of pulmonary involvement was noted in 5 patients, each of whom had dyspnea, diffuse infiltrates, restrictive impairment and low single breath carbon monoxide diffusing capacity. Two of these patients underwent exercise testing and showed abnormalities consistent with lung disease. In 13 patients randomly selected from the remaining 145, physical examination, chest radiographs, and pulmonary function were normal. However, responses on exercise testing in 6 patients were consistent with a circulatory impairment. Thus, the study found that less than 5% of patients with type I Gaucher disease have clinical interstitial lung disease. In addition, <a href="#53" class="mim-tip-reference" title="Miller, A., Brown, L. K., Pastores, G. M., Desnick, R. J. &lt;strong&gt;Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease.&lt;/strong&gt; Clin. Genet. 63: 368-376, 2003.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12752568/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;12752568&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1034/j.1399-0004.2003.00060.x&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="12752568">Miller et al. (2003)</a> found that some patients, without evident lung involvement, experienced limitations in physical exertion and were easily fatigued; this was attributable to impaired pulmonary circulation. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12752568" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Ocular manifestations in type I Gaucher disease include white deposits in the corneal epithelium, anterior chamber angle, ciliary body, and pupil margin (<a href="#62" class="mim-tip-reference" title="Petrohelos, M., Tricoulis, D., Kotsiras, I., Vouzoukos, A. &lt;strong&gt;Ocular manifestations of Gaucher&#x27;s disease.&lt;/strong&gt; Am. J. Ophthal. 80: 1006-1010, 1975.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1200092/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;1200092&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/0002-9394(75)90329-3&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="1200092">Petrohelos et al., 1975</a>; <a href="#78" class="mim-tip-reference" title="Wang, T.-J., Chen, M.-S., Shih, Y.-F., Hwu, W.-L., Lai, M.-Y. &lt;strong&gt;Fundus abnormalities in a patient with type I Gaucher&#x27;s disease with 12-year follow-up.&lt;/strong&gt; Am. J. Ophthal. 139: 359-362, 2005.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15734007/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;15734007&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.ajo.2004.07.053&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="15734007">Wang et al., 2005</a>). Fundus abnormalities include perimacular grayness and scattered white spots (<a href="#23" class="mim-tip-reference" title="Cogan, D. G., Chu, F. C., Gittinger, J., Tychsen, L. &lt;strong&gt;Fundal abnormalities of Gaucher&#x27;s disease.&lt;/strong&gt; Arch. Ophthal. 98: 2202-2203, 1980.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7447774/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;7447774&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1001/archopht.1980.01020041054010&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="7447774">Cogan et al., 1980</a>). In a 12-year follow-up of a patient with type I GD, <a href="#78" class="mim-tip-reference" title="Wang, T.-J., Chen, M.-S., Shih, Y.-F., Hwu, W.-L., Lai, M.-Y. &lt;strong&gt;Fundus abnormalities in a patient with type I Gaucher&#x27;s disease with 12-year follow-up.&lt;/strong&gt; Am. J. Ophthal. 139: 359-362, 2005.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15734007/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;15734007&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.ajo.2004.07.053&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="15734007">Wang et al. (2005)</a> demonstrated the presence of macular atrophy and increased retinal vascular permeability. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=1200092+15734007+7447774" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="pathogenesis" class="mim-anchor"></a>
<h4 href="#mimPathogenesisFold" id="mimPathogenesisToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimPathogenesisToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Pathogenesis</strong>
</span>
</h4>
</div>
<div id="mimPathogenesisFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p><a href="#57" class="mim-tip-reference" title="Pandey, M. K., Burrow, T. A., Rani, R., Martin, L. J., Witte, D., Setchell, K. D., Mckay, M. A., Magnusen, A. F., Zhang, W., Liou, B., Kohl, J., Grabowski, G. A. &lt;strong&gt;Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.&lt;/strong&gt; Nature 543: 108-112, 2017.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28225753/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;28225753&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1038/nature21368&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="28225753">Pandey et al. (2017)</a> showed that activation of complement C5a (<a href="/entry/120900">120900</a>) and C5a receptor-1 (C5AR1; <a href="/entry/113995">113995</a>) controls glucosylceramide (GC) accumulation and the inflammatory response in experimental and clinical Gaucher disease. Marked local and systemic complement activation occurred in glucocerebrosidase (GCase)-deficient mice or after pharmacologic inhibition of GCase and was associated with GC storage, tissue inflammation, and proinflammatory cytokine production. Whereas all GCase-inhibited mice died within 4 to 5 weeks, mice deficient in both GCase and C5aR1, and wildtype mice in which GCase and C5aR were pharmacologically inhibited, were protected from these adverse effects and consequently survived. In mice and humans, GCase deficiency was associated with strong formation of complement-activating GC-specific IgG autoantibodies, leading to complement activation and C5a generation. Subsequent C5aR1 activation controlled UDP-glucose ceramide glucosyltransferase production, thereby tipping the balance between GC formation and degradation. Thus, extensive GC storage induces complement-activating IgG autoantibodies that drive a pathway of C5a generation and C5aR1 activation that fuels a cycle of cellular GC accumulation and innate and adaptive immune cell recruitment and activation in Gaucher disease. <a href="#57" class="mim-tip-reference" title="Pandey, M. K., Burrow, T. A., Rani, R., Martin, L. J., Witte, D., Setchell, K. D., Mckay, M. A., Magnusen, A. F., Zhang, W., Liou, B., Kohl, J., Grabowski, G. A. &lt;strong&gt;Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.&lt;/strong&gt; Nature 543: 108-112, 2017.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28225753/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;28225753&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1038/nature21368&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="28225753">Pandey et al. (2017)</a> suggested that targeting C5AR1 may serve as a treatment option for patients with Gaucher disease and possibly other lysosomal storage diseases. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=28225753" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="inheritance" class="mim-anchor"></a>
<h4 href="#mimInheritanceFold" id="mimInheritanceToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimInheritanceToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Inheritance</strong>
</span>
</h4>
</div>
<div id="mimInheritanceFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p>Based on population studies among Ashkenazi Jewish populations in Israel, <a href="#31" class="mim-tip-reference" title="Fried, K. &lt;strong&gt;Population study of chronic Gaucher&#x27;s disease.&lt;/strong&gt; Israel J. Med. Sci. 9: 1396-1398, 1973.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4775122/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;4775122&lt;/a&gt;]" pmid="4775122">Fried (1973)</a> concluded that Gaucher disease is an autosomal recessive disorder. Homozygotes were affected with the disease. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=4775122" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="diagnosis" class="mim-anchor"></a>
<h4 href="#mimDiagnosisFold" id="mimDiagnosisToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimDiagnosisToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Diagnosis</strong>
</span>
</h4>
</div>
<div id="mimDiagnosisFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p><a href="#25" class="mim-tip-reference" title="Desnick, R. J., Dawson, G., Desnick, S. J., Sweeley, C. C., Krivit, W. &lt;strong&gt;Diagnosis of glycosphingolipidoses by urinary-sediment analysis.&lt;/strong&gt; New Eng. J. Med. 284: 739-744, 1971.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/5548035/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;5548035&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1056/NEJM197104082841401&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="5548035">Desnick et al. (1971)</a> demonstrated that both homozygotes and heterozygotes for Gaucher disease could be identified by chemical analysis of the sediment from a 24-hour urine collection. Individual neutral glycosphingolipids were separated by thin-layer chromatography and quantitatively estimated by gas-liquid chromatography. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=5548035" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>By an assay of leukocyte beta-glucosidase, <a href="#63" class="mim-tip-reference" title="Raghavan, S. S., Topol, J., Kolodny, E. H. &lt;strong&gt;Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease.&lt;/strong&gt; Am. J. Hum. Genet. 32: 158-173, 1980.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6770675/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;6770675&lt;/a&gt;]" pmid="6770675">Raghavan et al. (1980)</a> devised a method for identifying both heterozygotes and homozygotes. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=6770675" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Magnetic resonance imaging is a sensitive method for detecting bone involvement in Gaucher disease, evaluating complications such as osteonecrosis (<a href="#50" class="mim-tip-reference" title="Lanir, A., Hadar, H., Cohen, I., Tal, Y., Benmair, J., Schreiber, R., Clouse, M. E. &lt;strong&gt;Gaucher disease: assessment with MR imaging.&lt;/strong&gt; Radiology 161: 239-244, 1986.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3763873/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3763873&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1148/radiology.161.1.3763873&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3763873">Lanir et al., 1986</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3763873" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#84" class="mim-tip-reference" title="Zuckerman, S., Lahad, A., Shmueli, A., Zimran, A., Peleg, L., Orr-Urtreger, A., Levy-Lahad, E., Sagi, M. &lt;strong&gt;Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases.&lt;/strong&gt; JAMA 298: 1281-1290, 2007.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17878420/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;17878420&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1001/jama.298.11.1281&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="17878420">Zuckerman et al. (2007)</a> reviewed the outcome of screening for Gaucher disease among Ashkenazi Jewish individuals in Israel between 1995 and 2003. The carrier frequency was 5.7% in testing for 4 or 6 main GBA mutations. N370S (<a href="/entry/606463#0003">606463.0003</a>) was by far the most common variant identified. Importantly, most individuals homozygous for the mild N370S mutation are mildly symptomatic or even asymptomatic (<a href="#10" class="mim-tip-reference" title="Beutler, E., Nguyen, N. J., Henneberger, M. W., Smolec, J. M., McPherson, R. A., West, C., Gelbart, T. &lt;strong&gt;Gaucher disease: gene frequencies in the Ashkenazi Jewish population.&lt;/strong&gt; Am. J. Hum. Genet. 52: 85-88, 1993.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8434610/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8434610&lt;/a&gt;]" pmid="8434610">Beutler et al., 1993</a>). Of 82 couples at risk for offspring with type I GD, 70 (85%) were at risk for asymptomatic or mildly affected offspring, and 12 (15%) were at risk for moderately affected offspring. Prenatal diagnosis performed in 68 pregnancies detected 16 fetuses with GD. Pregnancies were terminated in 2 (15%) of 13 fetuses predicted to be asymptomatic or mildly affected and in 2 (67%) of 3 fetuses with predicted moderate disease. There were significantly fewer pregnancy terminations (1 of 13) in couples who consulted with a GD expert in addition to genetic counseling compared to those who had not consulted with a GD expert (3 of 3). Two of the 3 terminations performed in the group without medical consult were homozygous for N370S. In an accompanying editorial, <a href="#13" class="mim-tip-reference" title="Beutler, E. &lt;strong&gt;Carrier screening for Gaucher disease: more harm than good?&lt;/strong&gt; JAMA 298: 1329-1331, 2007.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17878426/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;17878426&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1001/jama.298.11.1329&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="17878426">Beutler (2007)</a> commented that carrier screening for Gaucher disease may do more harm than good given the extreme phenotypic variability and the inability to predict disease severity, especially in those with the common N370S mutation who may remain asymptomatic. <a href="#13" class="mim-tip-reference" title="Beutler, E. &lt;strong&gt;Carrier screening for Gaucher disease: more harm than good?&lt;/strong&gt; JAMA 298: 1329-1331, 2007.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17878426/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;17878426&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1001/jama.298.11.1329&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="17878426">Beutler (2007)</a> recalled a 72-year-old patient with Gaucher disease who had low levels of enzyme activity but remained asymptomatic (<a href="#11" class="mim-tip-reference" title="Beutler, E. &lt;strong&gt;Gaucher&#x27;s disease in an asymptomatic 72-year-old.&lt;/strong&gt; JAMA 237: 2529, 1977.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/576973/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;576973&lt;/a&gt;]" pmid="576973">Beutler, 1977</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?term=8434610+576973+17878420+17878426" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>In a review of the molecular genetics of Gaucher disease, <a href="#42" class="mim-tip-reference" title="Hruska, K. S., LaMarca, M. E., Scott, C. R., Sidransky, E. &lt;strong&gt;Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).&lt;/strong&gt; Hum. Mutat. 29: 567-583, 2008.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18338393/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;18338393&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1002/humu.20676&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="18338393">Hruska et al. (2008)</a> noted that most GBA mutations can be found in patients with various forms of the disorder. The phenotype is mainly determined by the combination of mutations on both alleles; thus the prediction of phenotype from genotypic data has limited utility. In addition, it has become increasingly difficult to categorize patients into 1 of the 3 classic types of Gaucher disease, indicating that the phenotypes fall into a continuum, with the major distinction being the presence and degree of neurologic function. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18338393" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="clinicalManagement" class="mim-anchor"></a>
<h4 href="#mimClinicalManagementFold" id="mimClinicalManagementToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimClinicalManagementToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Clinical Management</strong>
</span>
</h4>
</div>
<div id="mimClinicalManagementFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p>Most patients with type I Gaucher disease require splenectomy for management of thrombocytopenia and anemia; however, splenectomy is often followed by an increase in bone involvement, with osteolytic lesions within a few months of surgery (<a href="#1" class="mim-tip-reference" title="Ashkenazi, A., Zaizov, R., Matoth, Y. &lt;strong&gt;Effect of splenectomy on destructive bone changes in children with chronic (type I) Gaucher disease.&lt;/strong&gt; Europ. J. Pediat. 145: 138-141, 1986.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3732318/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3732318&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1007/BF00441877&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3732318">Ashkenazi et al., 1986</a>). Partial splenectomy has been advocated with the dual goals of minimizing the deleterious effect on bone and avoiding postsplenectomy sepsis (<a href="#68" class="mim-tip-reference" title="Rubin, M., Yampolski, I., Lambrozo, R., Zaizov, R., Dintsman, M. &lt;strong&gt;Partial splenectomy in Gaucher&#x27;s disease.&lt;/strong&gt; J. Pediat. Surg. 21: 125-128, 1986.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3950849/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3950849&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/s0022-3468(86)80063-x&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3950849">Rubin et al., 1986</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?term=3732318+3950849" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#34" class="mim-tip-reference" title="Goldblatt, J., Sacks, S., Dall, D., Beighton, P. &lt;strong&gt;Total hip arthroplasty in Gaucher&#x27;s disease: long-term prognosis.&lt;/strong&gt; Clin. Orthop. Relat. Dis. 228: 94-98, 1988.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3342593/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3342593&lt;/a&gt;]" pmid="3342593">Goldblatt et al. (1988)</a> reported that of 8 patients with Gaucher disease treated with 15 total hip arthroplasties, 11 (73%) remained fully mobile and asymptomatic with a follow-up time of up to 14 years after surgery. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3342593" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#77" class="mim-tip-reference" title="Wang, R. Y., Bodamer, O. A., Watson, M. S., Wilcox, W. R. &lt;strong&gt;Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals.&lt;/strong&gt; Genet. Med. 13: 457-484, 2011.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21502868/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;21502868&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1097/GIM.0b013e318211a7e1&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="21502868">Wang et al. (2011)</a> described the ACMG standards and guidelines for the diagnostic confirmation and management of presymptomatic individuals with lysosomal storage diseases. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=21502868" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#18" class="mim-tip-reference" title="Charrow, J., Fraga, C., Gu, X., Ida, H., Longo, N., Lukina, E., Nonino, A., Gaemers, S. J. M., Jouvin, M.-H., Li, J., Wu, Y., Xue, Y., Peterschmitt, M. J. &lt;strong&gt;Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: the phase 3, randomized, double-blind EDGE trial.&lt;/strong&gt; Molec. Genet. Metab. 123: 347-356, 2018.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29358012/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;29358012&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.ymgme.2017.12.001&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="29358012">Charrow et al. (2018)</a> reported results from a phase 3, randomized, double-blind trial comparing the effectiveness of a once-daily versus the approved twice-daily regimen of eliglustat at the same total daily dose in 121 adult patients with type I Gaucher Disease. After 1 year, 80.4% of patients receiving once-daily dosing and 83.1% of patients receiving twice-daily dosing remained stable. Mean values for hematologic and visceral measures were within therapeutic goal thresholds in both groups. Because patients with twice-daily dosing also showed greater tolerance for the drug, the study confirmed the twice-daily dosing recommendation on the drug label. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=29358012" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#79" class="mim-tip-reference" title="Weinreb, N. J., Camelo, J. S., Jr., Charrow, J., McClain, M. R., Mistry, P., Belmatoug, N. &lt;strong&gt;Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain imiglucerase treatment.&lt;/strong&gt; Molec. Genet. Metab. 132: 100-111, 2021.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33485799/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;33485799&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.ymgme.2020.12.295&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="33485799">Weinreb et al. (2021)</a> reported long-term outcomes in 475 patients with type I Gaucher disease who were treated with imiglucerase for approximately 20 years. Outcome measures included spleen volume (in nonsplenectomized patients), liver volume, bone crises, bone pain, hemoglobin levels, and platelet count. For outcomes analyses, the patients were stratified into splenectomized and nonsplenectomized cohorts, and secondary analyses were based on pretreatment disease severity. Clinically significant improvements were seen within 2 to 5 years of starting treatment for almost all of the outcomes assessed, and were maintained through 20 years of treatment in both splenectomized and nonsplenectomized groups regardless of pretreatment disease severity. The only exception was bone pain, which was not significantly improved from baseline in nonsplenectomized patients at 20 years, but was significantly improved in splenectomized patients. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=33485799" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>In a review of pulmonary involvement, lymphadenopathy, and Gaucheroma in Gaucher disease, <a href="#64" class="mim-tip-reference" title="Ramaswami, L., Mengel, E., Berrah, A., AlSayed, M., Broomfield, A., Donald, A., Seif El Dein, H. M., Freisens, S., Hwu, W.-L., Peterschmitt, M. J., Yoo H.-W., Abdelwahab, M. &lt;strong&gt;Throwing a spotlight on under-recognized manifestations of Gaucher disease: pulmonary involvement, lymphadenopathy, and Gaucheroma.&lt;/strong&gt; Molec. Genet. Metab. 133: 335-344, 2021.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34229967/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;34229967&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.ymgme.2021.06.009&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="34229967">Ramaswami et al. (2021)</a> discussed management recommendations. Management of lung disease included consideration of a bronchodilator in the winter and monitoring with pulmonary function tests. Mucolytics may be considered in patients with decreased forced vital capacity or other risk factors. Enzyme replacement therapy was recommended for patients with compromised lung expansion or hepatopulmonary syndrome. Lung transplantation may be considered in end-stage lung disease. Lymphadenopathy may necessitate adjustment of dose and frequency of enzyme replacement therapy. Patients with protein-losing enteropathy should consume a diet rich in medium chain triglycerides and vitamin K supplements, as well as undergo treatment according to established guidelines. Avoidance of lymph node biopsies and surgical removal was advised. An evaluation for Gaucheromas was recommended at baseline with subsequent regular monitoring by MRI/CT and measurement of disease biomarkers. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=34229967" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>Gene Therapy</em></strong></p><p>
In vitro, <a href="#71" class="mim-tip-reference" title="Sorge, J., Kuhl, W., West, C., Beutler, E. &lt;strong&gt;Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer.&lt;/strong&gt; Proc. Nat. Acad. Sci. 84: 906-909, 1987.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3547401/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3547401&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1073/pnas.84.4.906&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3547401">Sorge et al. (1987)</a> reported complete correction of the enzyme defect in fibroblasts from patients with type I Gaucher disease after retroviral-mediated GBA gene transfer. <a href="#29" class="mim-tip-reference" title="Fink, J. K., Correll, P. H., Perry, L. K., Brady, R. O., Karlsson, S. &lt;strong&gt;Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease.&lt;/strong&gt; Proc. Nat. Acad. Sci. 87: 2334-2338, 1990.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2315324/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;2315324&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1073/pnas.87.6.2334&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="2315324">Fink et al. (1990)</a> demonstrated that retroviral gene transfer could be used to correct the GBA deficiency in primary hematopoietic cells from patients with Gaucher disease. Correction was achieved in the progeny of transduced hematopoietic progenitor cells. <a href="#56" class="mim-tip-reference" title="Nolta, J. A., Yu, X. J., Bahner, I., Kohn, D. B. &lt;strong&gt;Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.&lt;/strong&gt; J. Clin. Invest. 90: 342-348, 1992. Note: Erratum: J. Clin. Invest. 90: 1635 only, 1992.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1379609/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;1379609&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1172/JCI115868&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="1379609">Nolta et al. (1992)</a> demonstrated that retroviral vectors can efficiently transfer the GBA gene into long-lived hematopoietic progenitor cells from the bone marrow of patients with Gaucher disease and express physiologically relevant levels of enzyme activity. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=3547401+1379609+2315324" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#72" class="mim-tip-reference" title="Starzl, T. E., Demetris, A. J., Trucco, M., Ricordi, C., Ildstad, S., Terasaki, P. I., Murase, N., Kendall, R. S., Kocova, M., Rudert, W. A., Zeevi, A., Van Thiel, D. &lt;strong&gt;Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher&#x27;s disease.&lt;/strong&gt; New Eng. J. Med. 328: 745-749, 1993.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8437594/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8437594&lt;/a&gt;, &lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/?term=8437594[PMID]&amp;report=imagesdocsum&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed Image&#x27;, &#x27;domain&#x27;: &#x27;ncbi.nlm.nih.gov&#x27;})&quot;&gt;images&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1056/NEJM199303183281101&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="8437594">Starzl et al. (1993)</a> reported that liver transplantation in a patient with type I Gaucher disease resulted in dramatic reduction in the lymph node deposits of glucocerebroside. They concluded that microchimerism corrected the metabolic abnormality. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8437594" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>See also ANIMAL MODEL section below.</p><p><strong><em>Enzyme Replacement Therapy</em></strong></p><p>
<a href="#3" class="mim-tip-reference" title="Barton, N. W., Furbish, F. S., Murray, G. J., Garfield, M., Brady, R. O. &lt;strong&gt;Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.&lt;/strong&gt; Proc. Nat. Acad. Sci. 87: 1913-1916, 1990.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2308952/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;2308952&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1073/pnas.87.5.1913&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="2308952">Barton et al. (1990)</a> found that weekly intravenous infusions of macrophage-targeted human placental glucocerebrosidase resulted in clinical improvement in a patient with type I Gaucher disease. Sequential deglycosylation of the oligosaccharide chains of the native enzyme were used to yield a mannose-terminated preparation that is specifically bound by lectin on the membrane of macrophages. Twenty-week treatment resulted in increased hemoglobin, increased platelet count, and radiographic evidence of skeletal improvement. <a href="#2" class="mim-tip-reference" title="Barton, N. W., Brady, R. O., Dambrosia, J. M., Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J., Murray, G. J., Parker, R. I., Argoff, C. E., Grewal, R. P., Yu, K.-T. &lt;strong&gt;Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher&#x27;s disease.&lt;/strong&gt; New Eng. J. Med. 324: 1464-1470, 1991.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2023606/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;2023606&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1056/NEJM199105233242104&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="2023606">Barton et al. (1991)</a> reported clinical improvement with intravenous infusion of macrophage-targeted enzyme therapy in 12 patients with type I disease. Serum hemoglobin concentration increased in all 12 patients, platelet count increased in 7, serum acid phosphatase decreased in 10, and plasma glucocerebroside level decreased in 9. After 6 months of treatment, splenic volume decreased in all patients, and hepatic volume in 5. Early signs of skeletal improvement were seen in 3 patients. The enzyme infusions were well tolerated, and no antibody to the exogenous enzyme developed. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=2308952+2023606" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Economic and other societal aspects of the use of modified glucocerebrosidase, alglucerase ('Ceredase'), in the treatment of Gaucher disease were discussed by <a href="#6" class="mim-tip-reference" title="Beutler, E., Gelbart, T., Kuhl, W., Sorge, J., West, C. &lt;strong&gt;Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state.&lt;/strong&gt; Proc. Nat. Acad. Sci. 88: 10544-10547, 1991.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1961718/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;1961718&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1073/pnas.88.23.10544&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="1961718">Beutler et al. (1991)</a> and <a href="#82" class="mim-tip-reference" title="Zimran, A., Gelbart, T., Westwood, B., Grabowski, G. A., Beutler, E. &lt;strong&gt;High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.&lt;/strong&gt; Am. J. Hum. Genet. 49: 855-859, 1991.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1897529/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;1897529&lt;/a&gt;]" pmid="1897529">Zimran et al. (1991)</a>. Theoretical considerations suggested to <a href="#28" class="mim-tip-reference" title="Figueroa, M. L., Rosenbloom, B. E., Kay, A. C., Garver, P., Thurston, D. W., Koziol, J. A., Gelbart, T., Beutler, E. &lt;strong&gt;A less costly regimen of alglucerase to treat Gaucher&#x27;s disease.&lt;/strong&gt; New Eng. J. Med. 327: 1632-1636, 1992.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1435900/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;1435900&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1056/NEJM199212033272304&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="1435900">Figueroa et al. (1992)</a> that more frequent administration might be more efficient. A series of 7 letters beginning with one by <a href="#55" class="mim-tip-reference" title="Moscicki, R. A., Taunton-Rigby, A. &lt;strong&gt;Treatment of Gaucher&#x27;s disease. (Letter)&lt;/strong&gt; New Eng. J. Med. 328: 1564 only, 1993.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8373459/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8373459&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1056/NEJM199305273282112&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="8373459">Moscicki and Taunton-Rigby (1993)</a> discussed the economics and related aspects of alglucerase therapy. Ceredase, derived from human placental tissues and produced by Genzyme Corporation of Cambridge, Massachusetts, was approved by the Food and Drug Administration in 1991. In mid-1994, the FDA approved a recombinant alternative to Ceredase, Cerezyme, which is also produced by Genzyme (<a href="#30" class="mim-tip-reference" title="Fox, J. L. &lt;strong&gt;Tailored therapy can lower costly Gaucher treatments.&lt;/strong&gt; Nature Med. 1: 290, 1995."None>Fox, 1995</a>). From a retrospective analysis, <a href="#45" class="mim-tip-reference" title="Kaplan, P., Mazur, A., Manor, O., Charrow, J., Esplin, J., Gribble, T. J., Wappner, R. S., Wisch, J. S., Weinreb, N. J. &lt;strong&gt;Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.&lt;/strong&gt; J. Pediat. 129: 149-153, 1996.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8757576/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8757576&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/s0022-3476(96)70203-2&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="8757576">Kaplan et al. (1996)</a> noted that in most children with type I Gaucher disease with subnormal growth velocity, adequate alglucerase (Ceredase) treatment resulted in growth velocity improvement. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=1897529+8373459+8757576+1961718+1435900" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>In a review of 1,028 Gaucher patients treated with macrophage-targeted enzyme replacement therapy for 2 to 5 years, <a href="#80" class="mim-tip-reference" title="Weinreb, N. J., Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pastores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., Zimran, A. &lt;strong&gt;Effectiveness of enzyme replacement therapy in 1028 patients with type I Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.&lt;/strong&gt; Am. J. Med. 113: 112-119, 2002.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12133749/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;12133749&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/s0002-9343(02)01150-6&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="12133749">Weinreb et al. (2002)</a> found improvement in anemia, thrombocytopenia, organomegaly, bone pain, and bone crises. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12133749" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#41" class="mim-tip-reference" title="Hollak, C. E. M., van Weely, S., van Oers, M. H. J., Aerts, J. M. F. G. &lt;strong&gt;Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease.&lt;/strong&gt; J. Clin. Invest. 93: 1288-1292, 1994.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8132768/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8132768&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1172/JCI117084&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="8132768">Hollak et al. (1994)</a> observed a very marked increase (more than 600-fold) of chitotriosidase (CHIT1; <a href="/entry/600031">600031</a>) activity in the plasma of 30 of 32 symptomatic patients with type I Gaucher disease. Chitotriosidase activity declined dramatically during enzyme supplementation therapy, suggesting that it could be used as a biomarker of therapeutic efficacy. In contrast, 3 GBA-deficient individuals without clinical symptoms had only slight increases in chitotriosidase. The authors considered it unlikely that chitotriosidase itself contributes to the clinical presentation of Gaucher disease. <a href="#41" class="mim-tip-reference" title="Hollak, C. E. M., van Weely, S., van Oers, M. H. J., Aerts, J. M. F. G. &lt;strong&gt;Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease.&lt;/strong&gt; J. Clin. Invest. 93: 1288-1292, 1994.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8132768/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8132768&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1172/JCI117084&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="8132768">Hollak et al. (1994)</a> suggested that the macrophages loaded with glucosylceramide in Gaucher disease are the main source of the plasma CHIT1 enzyme activity. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8132768" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Approximately 6% of Caucasians have chitotriosidase deficiency (<a href="/entry/614122">614122</a>) without clinical symptoms. <a href="#37" class="mim-tip-reference" title="Grace, M. E., Balwani, M., Nazarenko, I., Prakash-Cheng, A., Desnick, R. J. &lt;strong&gt;Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations--implications for diagnosis and therapeutic monitoring.&lt;/strong&gt; Hum. Mutat. 28: 866-873, 2007.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17464953/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;17464953&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1002/humu.20524&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="17464953">Grace et al. (2007)</a> noted that the identification of CHIT1 gene mutations that alter plasma chitotriosidase activity is important for the use of this biomarker to monitor disease activity and therapeutic response in Gaucher disease. The authors thus genotyped the CHIT1 gene in 320 unrelated patients with Gaucher disease, including 272 of Ashkenazi Jewish descent. Among all patients, 4% and 37.2% were homozygous and heterozygous, respectively, for a common 24-bp duplication in the CHIT1 gene (<a href="/entry/600031#0001">600031.0001</a>) that results in decreased enzyme activity. In addition, <a href="#37" class="mim-tip-reference" title="Grace, M. E., Balwani, M., Nazarenko, I., Prakash-Cheng, A., Desnick, R. J. &lt;strong&gt;Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations--implications for diagnosis and therapeutic monitoring.&lt;/strong&gt; Hum. Mutat. 28: 866-873, 2007.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17464953/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;17464953&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1002/humu.20524&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="17464953">Grace et al. (2007)</a> identified 3 novel mutations in the CHIT1 gene (<a href="/entry/600031#0002">600031.0002</a>-<a href="/entry/600031#0005">600031.0005</a>) in individuals with Gaucher disease and chitotriosidase deficiency. The findings were important for use and interpretation of plasma chitotriosidase activity in patients with Gaucher disease. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17464953" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>Chemical Chaperone Therapy</em></strong></p><p>
Some lysosomal storage diseases appear to be caused by lysosomal enzyme variants that retain catalytic activity but are predisposed to misfolding or mistrafficking in the cell (<a href="#4" class="mim-tip-reference" title="Berg-Fussman, A., Grace, M. E., Ioannou, Y., Grabowski, G. A. &lt;strong&gt;Human acid beta-glucosidase: N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity.&lt;/strong&gt; J. Biol. Chem. 268: 14861-14866, 1993.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8325864/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8325864&lt;/a&gt;]" pmid="8325864">Berg-Fussman et al., 1993</a>). The use of chemical chaperones to template proper folding within the secretory pathway, prevent postsecretory misfolding, or stabilize proteins with a predilection to misfold is well documented (<a href="#54" class="mim-tip-reference" title="Morello, J.-P., Bouvier, M., Petaja-Repo, U. E., Bichet, D. G. &lt;strong&gt;Pharmacological chaperones: a new twist on receptor folding.&lt;/strong&gt; Trends Pharm. Sci. 21: 466-469, 2000.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11121835/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;11121835&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/s0165-6147(00)01575-3&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="11121835">Morello et al., 2000</a>). Pursuant to experience in Fabry disease (<a href="/entry/301500">301500</a>), <a href="#69" class="mim-tip-reference" title="Sawkar, A. R., Cheng, W.-C., Beutler, E., Wong, C.-H., Balch, W. E., Kelly, J. W. &lt;strong&gt;Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease.&lt;/strong&gt; Proc. Nat. Acad. Sci. 99: 15428-15433, 2002.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12434014/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;12434014&lt;/a&gt;, &lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/?term=12434014[PMID]&amp;report=imagesdocsum&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed Image&#x27;, &#x27;domain&#x27;: &#x27;ncbi.nlm.nih.gov&#x27;})&quot;&gt;images&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1073/pnas.192582899&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="12434014">Sawkar et al. (2002)</a> found that addition of subinhibitory concentrations of the GBA inhibitor deoxynojirimycin (NN-DNJ) to fibroblasts in vitro resulted in a 2-fold increase in the activity of the N370S mutant (<a href="/entry/606463#0003">606463.0003</a>) GBA enzyme. The increased activity persisted for at least 6 days after withdrawal of the putative chaperone. The same chaperone increased wildtype beta-glucosidase activity, but not that of the L444P mutation (<a href="/entry/606463#0001">606463.0001</a>). Beta-glucosidase was stabilized against heat denaturation in a dose-dependent fashion. <a href="#69" class="mim-tip-reference" title="Sawkar, A. R., Cheng, W.-C., Beutler, E., Wong, C.-H., Balch, W. E., Kelly, J. W. &lt;strong&gt;Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease.&lt;/strong&gt; Proc. Nat. Acad. Sci. 99: 15428-15433, 2002.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12434014/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;12434014&lt;/a&gt;, &lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/?term=12434014[PMID]&amp;report=imagesdocsum&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed Image&#x27;, &#x27;domain&#x27;: &#x27;ncbi.nlm.nih.gov&#x27;})&quot;&gt;images&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1073/pnas.192582899&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="12434014">Sawkar et al. (2002)</a> proposed that NN-DNJ chaperones beta-glucosidase folding at neutral pH, thus allowing the stabilized enzyme to transit from the endoplasmic reticulum to the Golgi, enabling proper trafficking to the lysosome. Importantly, a modest increase in beta-glucosidase activity seemed to be sufficient to achieve a therapeutic effect. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=12434014+11121835+8325864" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#73" class="mim-tip-reference" title="Steet, R. A., Chung, S., Wustman, B., Powe, A., Do, H., Kornfeld, S. A. &lt;strong&gt;The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.&lt;/strong&gt; Proc. Nat. Acad. Sci. 103: 13813-13818, 2006.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16945909/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;16945909&lt;/a&gt;, &lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/?term=16945909[PMID]&amp;report=imagesdocsum&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed Image&#x27;, &#x27;domain&#x27;: &#x27;ncbi.nlm.nih.gov&#x27;})&quot;&gt;images&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1073/pnas.0605928103&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="16945909">Steet et al. (2006)</a> found that the iminosugar isofagomine (IFG), an active-site inhibitor of beta-glucosidase, facilitated the folding and transport of newly synthesized mutant N370S GBA from the endoplasmic reticulum to lysosomes. IFG increased beta-glucosidase activity approximately 3-fold in N370S fibroblasts and the enzyme showed some altered kinetic properties. Although IFG inhibited the enzyme in situ, washout of the drug resulted in full recovery of enzyme activity by 24 hours. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=16945909" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>Substrate Reduction Therapy</em></strong></p><p>
<a href="#59" class="mim-tip-reference" title="Pastores, G. M., Barnett, N. L., Kolodny, E. H. &lt;strong&gt;An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.&lt;/strong&gt; Clin. Ther. 27: 1215-1227, 2005.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16199246/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;16199246&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.clinthera.2005.08.004&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="16199246">Pastores et al. (2005)</a> reported results from treatment with N-butyldeoxynojirimycin (NB-DNJ; Miglustat), an inhibitor of glucosylceramide synthase (UGCG; <a href="/entry/602874">602874</a>), in 10 adult patients with type I Gaucher disease. Treatment over 24 months resulted in decreased liver and spleen volumes and clinical improvement. Bone involvement and platelet and hemoglobin levels remained stable and the treatment was well tolerated. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=16199246" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>Bone Marrow Transplantation</em></strong></p><p>
<a href="#65" class="mim-tip-reference" title="Ringden, O., Groth, C. G., Erikson, A., Granqvist, E. S., Mansson, J.-E., Sparrelid, E. &lt;strong&gt;Ten years&#x27; experience of bone marrow transplantation for Gaucher disease.&lt;/strong&gt; Transplantation 59: 864-870, 1995.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7701581/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;7701581&lt;/a&gt;]" pmid="7701581">Ringden et al. (1995)</a> reported experience with allogenic bone marrow transplantation (BMT) in 6 patients, ranging from 2 to 9 years, with severe Gaucher disease in Sweden. The donors were HLA-identical sibs in 4 cases, the father with 1 incompatible HLA antigen in one case, and an HLA-A, -B, and -DR-identical unrelated donor in the sixth case. Among the donors, 3 were heterozygous for glucocerebrosidase and 3 were healthy homozygotes. Before transplantation, 4 patients underwent total splenectomy and 2 had partial splenectomy. In the former, 1 of the 4 patients developed pneumococcal meningitis. In the group with partial splenectomy, transfusion requirements were increased. The parental graft was rejected, but 4 of 5 other patients had donor enzyme levels from 2 to 11 years after BMT. Two patients became mixed chimeras with approximately 40% of donor erythrocyte markers for 1 and 80% for the other. One of these had low enzyme activity in his lymphocytes, but the clinical outcome was excellent. Gaucher cells disappeared from the bone marrow and liver size normalized or decreased within 2 to 3 years after BMT. All patients with engraftment had a growth spurt. <a href="#65" class="mim-tip-reference" title="Ringden, O., Groth, C. G., Erikson, A., Granqvist, E. S., Mansson, J.-E., Sparrelid, E. &lt;strong&gt;Ten years&#x27; experience of bone marrow transplantation for Gaucher disease.&lt;/strong&gt; Transplantation 59: 864-870, 1995.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7701581/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;7701581&lt;/a&gt;]" pmid="7701581">Ringden et al. (1995)</a> suggested that if an HLA-compatible donor is available, BMT is the treatment of choice in advanced Gaucher disease. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=7701581" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="molecularGenetics" class="mim-anchor"></a>
<h4 href="#mimMolecularGeneticsFold" id="mimMolecularGeneticsToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimMolecularGeneticsToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Molecular Genetics</strong>
</span>
</h4>
</div>
<div id="mimMolecularGeneticsFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p><a href="#75" class="mim-tip-reference" title="Tsuji, S., Choudary, P. V., Martin, B. M., Stubblefield, B. K., Mayor, J. A., Barranger, J. A., Ginns, E. I. &lt;strong&gt;A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher&#x27;s disease.&lt;/strong&gt; New Eng. J. Med. 316: 570-575, 1987.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2880291/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;2880291&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1056/NEJM198703053161002&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="2880291">Tsuji et al. (1987)</a> identified an L444P substitution in the GBA gene (<a href="/entry/606463#0001">606463.0001</a>) in patients with Gaucher disease types I, II, and III. All 4 patients with type I disease had the mutation as a single allele and were presumably compound heterozygous with another unidentified pathogenic GBA mutation. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=2880291" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>In 3 unrelated Ashkenazi Jewish patients with type I Gaucher disease, <a href="#76" class="mim-tip-reference" title="Tsuji, S., Martin, B. M., Barranger, J. A., Stubblefield, B. K., LaMarca, M. E., Ginns, E. I. &lt;strong&gt;Genetic heterogeneity in type I Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals.&lt;/strong&gt; Proc. Nat. Acad. Sci. 85: 2349-2352, 1988. Note: Erratum: Proc. Nat. Acad. Sci. 85: 5708 only, 1988.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3353383/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3353383&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1073/pnas.85.7.2349&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3353383">Tsuji et al. (1988)</a> identified a homozygous mutation in the GBA gene (N370S; <a href="/entry/606463#0003">606463.0003</a>). Further studies showed that 15 of 21 additional type I patients had 1 allele with this mutation. The N370S mutation was not identified in patients with the type II or type III phenotype. One patient with type I disease was compound heterozygous for N370S and L444P. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3353383" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Among 62 Ashkenazi Jewish patients with Gaucher disease, <a href="#82" class="mim-tip-reference" title="Zimran, A., Gelbart, T., Westwood, B., Grabowski, G. A., Beutler, E. &lt;strong&gt;High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.&lt;/strong&gt; Am. J. Hum. Genet. 49: 855-859, 1991.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1897529/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;1897529&lt;/a&gt;]" pmid="1897529">Zimran et al. (1991)</a> found that N370S represented 73% of the 124 mutant alleles, making N370S the most common mutant GBA allele among Ashkenazi Jewish patients with type I disease. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=1897529" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="populationGenetics" class="mim-anchor"></a>
<h4 href="#mimPopulationGeneticsFold" id="mimPopulationGeneticsToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimPopulationGeneticsToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Population Genetics</strong>
</span>
</h4>
</div>
<div id="mimPopulationGeneticsFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p><a href="#20" class="mim-tip-reference" title="Choy, F. Y. M., Bouillon, L., Laurin, C. A. &lt;strong&gt;Gaucher disease: accurate identification of asymptomatic French-Canadian carrier using nonlabeled authentic sphingolipid substrate N-palmitoyl dihydroglucocerebroside.&lt;/strong&gt; Am. J. Med. Genet. 27: 895-905, 1987.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3425599/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3425599&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1002/ajmg.1320270416&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3425599">Choy et al. (1987)</a> described a method for identification of the carrier state in French Canadians. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3425599" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>In 1982, approximately 20,000 cases of Gaucher disease were reported in the United States. Over two-thirds of these persons were of Ashkenazi extraction (<a href="#15" class="mim-tip-reference" title="Brady, R. O. &lt;strong&gt;Personal Communication.&lt;/strong&gt; Bethesda, Md. 3/30/1982."None>Brady, 1982</a>).</p><p>By examination of glucocerebrosidase activity in leukocytes of a series of blood donors, <a href="#52" class="mim-tip-reference" title="Matoth, Y., Chazan, S., Cnaan, A., Gelernter, I., Klibansky, C. &lt;strong&gt;Frequency of carriers of chronic (type I) Gaucher disease in Ashkenazi Jews.&lt;/strong&gt; Am. J. Med. Genet. 27: 561-565, 1987.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3631130/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3631130&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1002/ajmg.1320270309&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3631130">Matoth et al. (1987)</a> estimated the frequency of carriers among Ashkenazi Jews in Israel as 4.6%. This figure was in close agreement with the carrier rate of 4% estimated from the number of known cases of Gaucher disease in Israel. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3631130" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#82" class="mim-tip-reference" title="Zimran, A., Gelbart, T., Westwood, B., Grabowski, G. A., Beutler, E. &lt;strong&gt;High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.&lt;/strong&gt; Am. J. Hum. Genet. 49: 855-859, 1991.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1897529/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;1897529&lt;/a&gt;]" pmid="1897529">Zimran et al. (1991)</a> estimated the total gene frequency for Gaucher disease among Ashkenazi Jews to be 0.047, which is equivalent to a carrier frequency of 8.9% and a birth incidence of 1 in 450. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=1897529" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Among 593 unrelated normal Ashkenazi Jewish individuals, <a href="#82" class="mim-tip-reference" title="Zimran, A., Gelbart, T., Westwood, B., Grabowski, G. A., Beutler, E. &lt;strong&gt;High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.&lt;/strong&gt; Am. J. Hum. Genet. 49: 855-859, 1991.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1897529/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;1897529&lt;/a&gt;]" pmid="1897529">Zimran et al. (1991)</a> identified 37 heterozygotes and 2 homozygotes for the N370S mutation, yielding an allele frequency of 0.035. Among 1,528 Ashkenazi Jewish individuals, <a href="#10" class="mim-tip-reference" title="Beutler, E., Nguyen, N. J., Henneberger, M. W., Smolec, J. M., McPherson, R. A., West, C., Gelbart, T. &lt;strong&gt;Gaucher disease: gene frequencies in the Ashkenazi Jewish population.&lt;/strong&gt; Am. J. Hum. Genet. 52: 85-88, 1993.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8434610/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8434610&lt;/a&gt;]" pmid="8434610">Beutler et al. (1993)</a> identified 87 heterozygotes and 4 homozygotes for N370S, yielding a frequency of 0.0311; pooling with data reported by <a href="#82" class="mim-tip-reference" title="Zimran, A., Gelbart, T., Westwood, B., Grabowski, G. A., Beutler, E. &lt;strong&gt;High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.&lt;/strong&gt; Am. J. Hum. Genet. 49: 855-859, 1991.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1897529/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;1897529&lt;/a&gt;]" pmid="1897529">Zimran et al. (1991)</a> yielded a frequency of 0.032 for the N370S allele. <a href="#10" class="mim-tip-reference" title="Beutler, E., Nguyen, N. J., Henneberger, M. W., Smolec, J. M., McPherson, R. A., West, C., Gelbart, T. &lt;strong&gt;Gaucher disease: gene frequencies in the Ashkenazi Jewish population.&lt;/strong&gt; Am. J. Hum. Genet. 52: 85-88, 1993.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8434610/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;8434610&lt;/a&gt;]" pmid="8434610">Beutler et al. (1993)</a> found that 10 of 2,305 normal Ashkenazi Jewish individuals were heterozygous for the 84GG insertion mutation (<a href="/entry/606463#0014">606463.0014</a>), yielding an allele frequency of 0.00217. The authors found that the ratio of N370S to 84GG was higher in the general Jewish population than in the patient population, which was presumably due to the fact that N370S homozygotes may have late-onset disease or no significant clinical manifestations at all. To bring the gene frequency in the patient population into conformity with the gene frequency in the general population, nearly two-thirds of persons with a Gaucher disease genotype would be missing from the patient population, presumably because their clinical manifestations were very mild. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=8434610+1897529" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Both Tay-Sachs disease (TSD; <a href="/entry/272800">272800</a>) and Gaucher disease have a high frequency in the Ashkenazi Jewish population, reaching a frequency of about 1:29 for TSD carriers and 1:16 for Gaucher disease carriers. By comparing the frequencies of the common GBA N370S mutation among carriers of the common TSD mutation, 1277TATC (<a href="/entry/606869#0001">606869.0001</a>), and in the general Ashkenazi population, <a href="#60" class="mim-tip-reference" title="Peleg, L., Frisch, A., Goldman, B., Karpaty, M., Narinsky, R., Bronstein, S., Frydman, M. &lt;strong&gt;Lower frequency of Gaucher disease carriers among Tay-Sachs disease carriers.&lt;/strong&gt; Europ. J. Hum. Genet. 6: 185-186, 1998.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9781065/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;9781065&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1038/sj.ejhg.5200176&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="9781065">Peleg et al. (1998)</a> determined that carriers of both diseases do not possess additional evolutionary advantage over single mutation carriers. The frequency of GD carriers among 308 TSD heterozygotes was 1:28, which is about half that expected (p = 0.03). The authors concluded that one or both mutations arose relatively recently in different regions of Europe and had not yet reached genetic equilibrium. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=9781065" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#66" class="mim-tip-reference" title="Rockah, R., Narinsky, R., Frydman, M., Cohen, I. J., Zaizov, R., Weizman, A., Frisch, A. &lt;strong&gt;Linkage disequilibrium of common Gaucher disease mutations with a polymorphic site in the pyruvate kinase (PKLR) gene.&lt;/strong&gt; Am. J. Med. Genet. 78: 233-236, 1998.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9677056/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;9677056&lt;/a&gt;]" pmid="9677056">Rockah et al. (1998)</a> found linkage disequilibrium between the 2 common Ashkenazi Gaucher disease mutations N370S and 84GG and polymorphic sites in the PKLR gene (<a href="/entry/609712">609712</a>). One hundred of 104 (96%) alleles carrying N370S also carried the A1 allele of the PKLR gene, which was present in only 6.7% of the control population, yielding a calculated linkage disequilibrium of 0.957. The mutation 84GG was found to be associated uniquely with the PKLR A6 allele, with a linkage disequilibrium of 1.00. These results suggested that the N3670S and 84GG mutations each originated in a single founder in the Ashkenazi Jewish population. Thus, founder effect followed by genetic drift rather than an evolutionary advantage for heterozygotes best explains the high frequency of these mutations in Ashkenazi Jews. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=9677056" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Despite considerable uncertainty about the demographic history of Ashkenazi Jews and their ancestors, <a href="#70" class="mim-tip-reference" title="Slatkin, M. &lt;strong&gt;A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases.&lt;/strong&gt; Am. J. Hum. Genet. 75: 282-293, 2004.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15208782/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;15208782&lt;/a&gt;, &lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/?term=15208782[PMID]&amp;report=imagesdocsum&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed Image&#x27;, &#x27;domain&#x27;: &#x27;ncbi.nlm.nih.gov&#x27;})&quot;&gt;images&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1086/423146&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="15208782">Slatkin (2004)</a> considered available genetic data to be consistent with a founder effect resulting from a severe bottleneck in population size between 1100 A.D. and 1400 A.D. and an earlier bottleneck in 75 A.D., at the beginning of the Jewish Diaspora. <a href="#70" class="mim-tip-reference" title="Slatkin, M. &lt;strong&gt;A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases.&lt;/strong&gt; Am. J. Hum. Genet. 75: 282-293, 2004.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15208782/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;15208782&lt;/a&gt;, &lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/?term=15208782[PMID]&amp;report=imagesdocsum&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed Image&#x27;, &#x27;domain&#x27;: &#x27;ncbi.nlm.nih.gov&#x27;})&quot;&gt;images&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1086/423146&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="15208782">Slatkin (2004)</a> concluded that a founder effect could account for the relatively high frequency of alleles causing 4 different lysosomal storage disorders, including Tay-Sachs disease and Gaucher disease, if the disease-associated alleles are recessive in their effects on reproductive fitness. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15208782" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#18" class="mim-tip-reference" title="Charrow, J., Fraga, C., Gu, X., Ida, H., Longo, N., Lukina, E., Nonino, A., Gaemers, S. J. M., Jouvin, M.-H., Li, J., Wu, Y., Xue, Y., Peterschmitt, M. J. &lt;strong&gt;Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: the phase 3, randomized, double-blind EDGE trial.&lt;/strong&gt; Molec. Genet. Metab. 123: 347-356, 2018.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29358012/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;29358012&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.ymgme.2017.12.001&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="29358012">Charrow et al. (2018)</a> stated that GD I is estimated to affect 1 in 40,000 in the general population and 1 in 850 among those of Ashkenazi Jewish ancestry. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=29358012" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#48" class="mim-tip-reference" title="Koto, Y., Sakai, N., Lee, Y., Kakee, N., Matsuda, J., Tsuboi, K., Shimozawa, N., Okuyama, T., Nakamura, K., Narita, A., kobayashi, H., Uehara, R., Nakamura, Y., Kato, K., Eto, Y. &lt;strong&gt;Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan.&lt;/strong&gt; Molec. Genet. Metab. 133: 277-288, 2021.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34090759/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;34090759&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.ymgme.2021.05.004&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="34090759">Koto et al. (2021)</a> surveyed hospitals in Japan for information about patients with lysosomal storage diseases (LSDs) treated between 2013-2016 and 2018-2019. Sixty-nine individuals with Gaucher disease were identified, of whom 37.7% had GD type I, 23.2% had GD type II, 30.4% had GD type III, and 8.7% had an unknown type. <a href="#48" class="mim-tip-reference" title="Koto, Y., Sakai, N., Lee, Y., Kakee, N., Matsuda, J., Tsuboi, K., Shimozawa, N., Okuyama, T., Nakamura, K., Narita, A., kobayashi, H., Uehara, R., Nakamura, Y., Kato, K., Eto, Y. &lt;strong&gt;Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan.&lt;/strong&gt; Molec. Genet. Metab. 133: 277-288, 2021.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34090759/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;34090759&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1016/j.ymgme.2021.05.004&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="34090759">Koto et al. (2021)</a> calculated a birth prevalence of Gaucher disease in Japan of 0.19 per 100,000. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=34090759" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="history" class="mim-anchor"></a>
<h4 href="#mimHistoryFold" id="mimHistoryToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimHistoryToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>History</strong>
</span>
</h4>
</div>
<div id="mimHistoryFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p>Type I Gaucher disease was first described in a doctoral thesis by <a href="#33" class="mim-tip-reference" title="Gaucher, P. C. E. &lt;strong&gt;De l&#x27;epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie.&lt;/strong&gt; Thesis, Faculte-de Medicine: Paris 1882."None>Gaucher (1882)</a> as a nonleukemic splenic epithelioma (<a href="#35" class="mim-tip-reference" title="Goldblatt, J. &lt;strong&gt;Type I Gaucher disease.&lt;/strong&gt; J. Med. Genet. 25: 415-418, 1988.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3294411/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;3294411&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1136/jmg.25.6.415&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="3294411">Goldblatt, 1988</a>). <a href="#16" class="mim-tip-reference" title="Brill, N. E., Mandlebaum, F. S., Libman, E. &lt;strong&gt;Primary splenomegaly-Gaucher type: report on one of four cases occurring in a single generation of one family.&lt;/strong&gt; Am. J. Med. Sci. 129: 491-504, 1905."None>Brill et al. (1905)</a> first used the eponym 'Gaucher disease.' <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3294411" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Although Gaucher disease is clearly autosomal recessive, a dominant form was suggested by <a href="#43" class="mim-tip-reference" title="Hsia, D. Y.-Y., Naylor, J., Bigler, J. A. &lt;strong&gt;Gaucher&#x27;s disease: report of two cases in father and son and review of the literature.&lt;/strong&gt; New Eng. J. Med. 261: 164-169, 1959.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/13666999/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;13666999&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1056/NEJM195907232610402&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="13666999">Hsia et al. (1959)</a> on the basis of affected father and son. The father was German-Jewish and the mother Swedish-English. The mother may have been a carrier; this quasi-dominant mechanism is even more likely in reports of presumed dominant inheritance in Jewish groups where the frequency of the Gaucher disease is relatively high. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=13666999" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
<div>
<a id="animalModel" class="mim-anchor"></a>
<h4 href="#mimAnimalModelFold" id="mimAnimalModelToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span id="mimAnimalModelToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<span class="mim-font">
<strong>Animal Model</strong>
</span>
</h4>
</div>
<div id="mimAnimalModelFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<p><a href="#26" class="mim-tip-reference" title="Enquist, I. B., Nilsson, E., Ooka, A., Mansson, J.-E., Olsson, K., Ehinger, M., Brady, R. O., Richter, J., Karlsson, S. &lt;strong&gt;Effective cell and gene therapy in a murine model of Gaucher disease.&lt;/strong&gt; Proc. Nat. Acad. Sci. 103: 13819-13824, 2006.[PubMed: &lt;a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16954197/&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed&#x27;, &#x27;domain&#x27;: &#x27;pubmed.ncbi.nlm.nih.gov&#x27;})&quot;&gt;16954197&lt;/a&gt;, &lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pmc/?term=16954197[PMID]&amp;report=imagesdocsum&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;name&#x27;: &#x27;PubMed Image&#x27;, &#x27;domain&#x27;: &#x27;ncbi.nlm.nih.gov&#x27;})&quot;&gt;images&lt;/a&gt;] [&lt;a href=&quot;https://doi.org/10.1073/pnas.0606016103&quot; target=&quot;_blank&quot; onclick=&quot;gtag(&#x27;event&#x27;, &#x27;mim_outbound&#x27;, {&#x27;destination&#x27;: &#x27;Publisher&#x27;})&quot;&gt;Full Text&lt;/a&gt;]" pmid="16954197">Enquist et al. (2006)</a> used the Cre/loxP system to conditionally delete exons 9-11 of the Gba gene in mice after birth. The mice were viable, demonstrated deficiency of glucocerebrosidase, and developed splenomegaly and microcytic anemia similar to type I Gaucher disease, including infiltration of Gaucher cells in the bone marrow, spleen, and liver. Both bone marrow transplantation and gene therapy with a retroviral vector prevented the disease and corrected an already established Gaucher phenotype. Both therapies resulted in increased Gba activity and decreased numbers of Gaucher cells 5 to 6 months after treatment. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=16954197" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
</span>
<div>
<br />
</div>
</div>
</div>
<div>
<a id="seeAlso" class="mim-anchor"></a>
<h4 href="#mimSeeAlsoFold" id="mimSeeAlsoToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span class="mim-font">
<span id="mimSeeAlsoToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<strong>See Also:</strong>
</span>
</h4>
<div id="mimSeeAlsoFold" class="collapse in mimTextToggleFold">
<span class="mim-text-font">
<a href="#Beutler1970" class="mim-tip-reference" title="Beutler, E., Kuhl, W. &lt;strong&gt;The diagnosis of the adult type of Gaucher&#x27;s disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes.&lt;/strong&gt; J. Lab. Clin. Med. 76: 747-755, 1970.">Beutler and Kuhl (1970)</a>; <a href="#Beutler1992" class="mim-tip-reference" title="Beutler, E. &lt;strong&gt;Gaucher disease: new molecular approaches to diagnosis and treatment.&lt;/strong&gt; Science 256: 794-799, 1992.">Beutler (1992)</a>
</span>
<div>
<br />
</div>
</div>
</div>
<div>
<a id="references"class="mim-anchor"></a>
<h4 href="#mimReferencesFold" id="mimReferencesToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
<span class="mim-font">
<span id="mimReferencesToggleTriangle" class="small mimTextToggleTriangle">&#9660;</span>
<strong>REFERENCES</strong>
</span>
</h4>
<div>
<p />
</div>
<div id="mimReferencesFold" class="collapse in mimTextToggleFold">
<ol>
<li>
<a id="1" class="mim-anchor"></a>
<a id="Ashkenazi1986" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Ashkenazi, A., Zaizov, R., Matoth, Y.
<strong>Effect of splenectomy on destructive bone changes in children with chronic (type I) Gaucher disease.</strong>
Europ. J. Pediat. 145: 138-141, 1986.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3732318/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3732318</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3732318" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1007/BF00441877" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="2" class="mim-anchor"></a>
<a id="Barton1991" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Barton, N. W., Brady, R. O., Dambrosia, J. M., Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J., Murray, G. J., Parker, R. I., Argoff, C. E., Grewal, R. P., Yu, K.-T.
<strong>Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease.</strong>
New Eng. J. Med. 324: 1464-1470, 1991.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/2023606/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">2023606</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=2023606" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1056/NEJM199105233242104" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="3" class="mim-anchor"></a>
<a id="Barton1990" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Barton, N. W., Furbish, F. S., Murray, G. J., Garfield, M., Brady, R. O.
<strong>Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.</strong>
Proc. Nat. Acad. Sci. 87: 1913-1916, 1990.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/2308952/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">2308952</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=2308952" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1073/pnas.87.5.1913" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="4" class="mim-anchor"></a>
<a id="Berg-Fussman1993" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Berg-Fussman, A., Grace, M. E., Ioannou, Y., Grabowski, G. A.
<strong>Human acid beta-glucosidase: N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity.</strong>
J. Biol. Chem. 268: 14861-14866, 1993.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8325864/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8325864</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8325864" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="5" class="mim-anchor"></a>
<a id="Bergmann1989" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Bergmann, J. E., Grabowski, G. A.
<strong>Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts.</strong>
Am. J. Hum. Genet. 44: 741-750, 1989.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/2495719/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">2495719</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=2495719" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="6" class="mim-anchor"></a>
<a id="Beutler1991" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Beutler, E., Gelbart, T., Kuhl, W., Sorge, J., West, C.
<strong>Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state.</strong>
Proc. Nat. Acad. Sci. 88: 10544-10547, 1991.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/1961718/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">1961718</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=1961718" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1073/pnas.88.23.10544" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="7" class="mim-anchor"></a>
<a id="Beutler1985" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Beutler, E., Kuhl, W., Sorge, J.
<strong>Glucocerebrosidase 'processing' and gene expression in various forms of Gaucher disease.</strong>
Am. J. Hum. Genet. 37: 1062-1070, 1985.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/4083278/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">4083278</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=4083278" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="8" class="mim-anchor"></a>
<a id="Beutler1971" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Beutler, E., Kuhl, W., Trinidad, F., Teplitz, R. L., Nadler, H.
<strong>Beta-glucosidase activity in fibroblasts from homozygotes and heterozygotes for Gaucher's disease.</strong>
Am. J. Hum. Genet. 23: 62-66, 1971.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/5581982/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">5581982</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=5581982" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="9" class="mim-anchor"></a>
<a id="Beutler1970" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Beutler, E., Kuhl, W.
<strong>The diagnosis of the adult type of Gaucher's disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes.</strong>
J. Lab. Clin. Med. 76: 747-755, 1970.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/5477334/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">5477334</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=5477334" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="10" class="mim-anchor"></a>
<a id="Beutler1993" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Beutler, E., Nguyen, N. J., Henneberger, M. W., Smolec, J. M., McPherson, R. A., West, C., Gelbart, T.
<strong>Gaucher disease: gene frequencies in the Ashkenazi Jewish population.</strong>
Am. J. Hum. Genet. 52: 85-88, 1993.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8434610/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8434610</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8434610" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="11" class="mim-anchor"></a>
<a id="Beutler1977" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Beutler, E.
<strong>Gaucher's disease in an asymptomatic 72-year-old.</strong>
JAMA 237: 2529, 1977.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/576973/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">576973</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=576973" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="12" class="mim-anchor"></a>
<a id="Beutler1992" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Beutler, E.
<strong>Gaucher disease: new molecular approaches to diagnosis and treatment.</strong>
Science 256: 794-799, 1992.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/1589760/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">1589760</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=1589760" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1126/science.1589760" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="13" class="mim-anchor"></a>
<a id="Beutler2007" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Beutler, E.
<strong>Carrier screening for Gaucher disease: more harm than good?</strong>
JAMA 298: 1329-1331, 2007.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17878426/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17878426</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17878426" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1001/jama.298.11.1329" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="14" class="mim-anchor"></a>
<a id="Brady1965" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Brady, R. O., Kanfer, J. N., Shapiro, D.
<strong>Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease.</strong>
Biochem. Biophys. Res. Commun. 18: 221-225, 1965.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/14282020/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">14282020</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=14282020" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/0006-291x(65)90743-6" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="15" class="mim-anchor"></a>
<a id="Brady1982" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Brady, R. O.
<strong>Personal Communication.</strong>
Bethesda, Md. 3/30/1982.
</p>
</div>
</li>
<li>
<a id="16" class="mim-anchor"></a>
<a id="Brill1905" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Brill, N. E., Mandlebaum, F. S., Libman, E.
<strong>Primary splenomegaly-Gaucher type: report on one of four cases occurring in a single generation of one family.</strong>
Am. J. Med. Sci. 129: 491-504, 1905.
</p>
</div>
</li>
<li>
<a id="17" class="mim-anchor"></a>
<a id="Chabas1995" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Chabas, A., Cormand, B., Grinberg, D., Burguera, J. M., Balcells, S., Merino, J. L., Mate, I., Sobrino, J. A., Gonzalez-Duarte, R., Vilageliu, L.
<strong>Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation.</strong>
J. Med. Genet. 32: 740-742, 1995.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8544197/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8544197</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8544197" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1136/jmg.32.9.740" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="18" class="mim-anchor"></a>
<a id="Charrow2018" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Charrow, J., Fraga, C., Gu, X., Ida, H., Longo, N., Lukina, E., Nonino, A., Gaemers, S. J. M., Jouvin, M.-H., Li, J., Wu, Y., Xue, Y., Peterschmitt, M. J.
<strong>Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: the phase 3, randomized, double-blind EDGE trial.</strong>
Molec. Genet. Metab. 123: 347-356, 2018.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/29358012/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">29358012</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=29358012" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/j.ymgme.2017.12.001" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="19" class="mim-anchor"></a>
<a id="Chiao1979" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Chiao, Y.-B., Peters, S. P., Diven, W. F., Lee, R. E., Glew, R. H.
<strong>Demonstration of beta-xylosidase activity in various forms of Gaucher's disease.</strong>
Metabolism 28: 56-62, 1979.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/759826/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">759826</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=759826" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/0026-0495(79)90168-9" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="20" class="mim-anchor"></a>
<a id="Choy1987" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Choy, F. Y. M., Bouillon, L., Laurin, C. A.
<strong>Gaucher disease: accurate identification of asymptomatic French-Canadian carrier using nonlabeled authentic sphingolipid substrate N-palmitoyl dihydroglucocerebroside.</strong>
Am. J. Med. Genet. 27: 895-905, 1987.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3425599/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3425599</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3425599" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1002/ajmg.1320270416" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="21" class="mim-anchor"></a>
<a id="Choy1985" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Choy, F. Y. M.
<strong>Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type 1 Gaucher tissues.</strong>
Am. J. Med. Genet. 21: 519-528, 1985.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/4025386/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">4025386</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=4025386" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1002/ajmg.1320210315" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="22" class="mim-anchor"></a>
<a id="Choy1988" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Choy, F. Y. M.
<strong>Intrafamilial clinical variability of type 1 Gaucher disease in a French-Canadian family.</strong>
J. Med. Genet. 25: 322-325, 1988.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3385740/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3385740</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3385740" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1136/jmg.25.5.322" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="23" class="mim-anchor"></a>
<a id="Cogan1980" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Cogan, D. G., Chu, F. C., Gittinger, J., Tychsen, L.
<strong>Fundal abnormalities of Gaucher's disease.</strong>
Arch. Ophthal. 98: 2202-2203, 1980.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/7447774/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">7447774</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=7447774" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1001/archopht.1980.01020041054010" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="24" class="mim-anchor"></a>
<a id="Danes1968" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Danes, B. S., Bearn, A. G.
<strong>Gaucher's disease: a genetic disease detected in skin fibroblast cultures.</strong>
Science 161: 1347-1348, 1968.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/5673446/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">5673446</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=5673446" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1126/science.161.3848.1347" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="25" class="mim-anchor"></a>
<a id="Desnick1971" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Desnick, R. J., Dawson, G., Desnick, S. J., Sweeley, C. C., Krivit, W.
<strong>Diagnosis of glycosphingolipidoses by urinary-sediment analysis.</strong>
New Eng. J. Med. 284: 739-744, 1971.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/5548035/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">5548035</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=5548035" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1056/NEJM197104082841401" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="26" class="mim-anchor"></a>
<a id="Enquist2006" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Enquist, I. B., Nilsson, E., Ooka, A., Mansson, J.-E., Olsson, K., Ehinger, M., Brady, R. O., Richter, J., Karlsson, S.
<strong>Effective cell and gene therapy in a murine model of Gaucher disease.</strong>
Proc. Nat. Acad. Sci. 103: 13819-13824, 2006.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/16954197/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">16954197</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=16954197[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=16954197" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1073/pnas.0606016103" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="27" class="mim-anchor"></a>
<a id="Fabbro1987" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Fabbro, D., Desnick, R. J., Grabowski, G. A.
<strong>Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.</strong>
Am. J. Hum. Genet. 40: 15-31, 1987.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3812484/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3812484</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3812484" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="28" class="mim-anchor"></a>
<a id="Figueroa1992" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Figueroa, M. L., Rosenbloom, B. E., Kay, A. C., Garver, P., Thurston, D. W., Koziol, J. A., Gelbart, T., Beutler, E.
<strong>A less costly regimen of alglucerase to treat Gaucher's disease.</strong>
New Eng. J. Med. 327: 1632-1636, 1992.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/1435900/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">1435900</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=1435900" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1056/NEJM199212033272304" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="29" class="mim-anchor"></a>
<a id="Fink1990" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Fink, J. K., Correll, P. H., Perry, L. K., Brady, R. O., Karlsson, S.
<strong>Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease.</strong>
Proc. Nat. Acad. Sci. 87: 2334-2338, 1990.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/2315324/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">2315324</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=2315324" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1073/pnas.87.6.2334" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="30" class="mim-anchor"></a>
<a id="Fox1995" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Fox, J. L.
<strong>Tailored therapy can lower costly Gaucher treatments.</strong>
Nature Med. 1: 290, 1995.
</p>
</div>
</li>
<li>
<a id="31" class="mim-anchor"></a>
<a id="Fried1973" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Fried, K.
<strong>Population study of chronic Gaucher's disease.</strong>
Israel J. Med. Sci. 9: 1396-1398, 1973.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/4775122/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">4775122</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=4775122" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="32" class="mim-anchor"></a>
<a id="Garfinkel1982" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Garfinkel, D., Sidi, Y., Ben-Bassat, M., Salomon, F., Hazaz, B., Pinkhas, J.
<strong>Coexistence of Gaucher's disease and multiple myeloma.</strong>
Arch. Intern. Med. 142: 2229-2230, 1982.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/7138174/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">7138174</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=7138174" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="33" class="mim-anchor"></a>
<a id="Gaucher1882" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Gaucher, P. C. E.
<strong>De l'epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie.</strong>
Thesis, Faculte-de Medicine: Paris 1882.
</p>
</div>
</li>
<li>
<a id="34" class="mim-anchor"></a>
<a id="Goldblatt1988" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Goldblatt, J., Sacks, S., Dall, D., Beighton, P.
<strong>Total hip arthroplasty in Gaucher's disease: long-term prognosis.</strong>
Clin. Orthop. Relat. Dis. 228: 94-98, 1988.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3342593/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3342593</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3342593" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="35" class="mim-anchor"></a>
<a id="Goldblatt1988" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Goldblatt, J.
<strong>Type I Gaucher disease.</strong>
J. Med. Genet. 25: 415-418, 1988.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3294411/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3294411</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3294411" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1136/jmg.25.6.415" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="36" class="mim-anchor"></a>
<a id="Grabowski1985" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Grabowski, G. A., Dinur, T., Osiecki, K. M., Kruse, J. R., Legler, G., Gatt, S.
<strong>Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.</strong>
Am. J. Hum. Genet. 37: 499-510, 1985.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/4003396/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">4003396</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=4003396" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="37" class="mim-anchor"></a>
<a id="Grace2007" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Grace, M. E., Balwani, M., Nazarenko, I., Prakash-Cheng, A., Desnick, R. J.
<strong>Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations--implications for diagnosis and therapeutic monitoring.</strong>
Hum. Mutat. 28: 866-873, 2007.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17464953/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17464953</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17464953" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1002/humu.20524" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="38" class="mim-anchor"></a>
<a id="Gravel1983" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Gravel, R. A., Leung, A.
<strong>Complementation analysis in Gaucher disease using single cell microassay techniques: evidence for a single 'Gaucher gene'.</strong>
Hum. Genet. 65: 112-116, 1983.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/6418635/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">6418635</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=6418635" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1007/BF00286645" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="39" class="mim-anchor"></a>
<a id="Graves1986" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Graves, P. N., Grabowski, G. A., Ludman, M. D., Palese, P., Smith, F. I.
<strong>Human acid beta-glucosidase: Northern blot and S1 nuclease analysis of mRNA from HeLa cells and normal and Gaucher disease fibroblasts.</strong>
Am. J. Hum. Genet. 39: 763-774, 1986.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3026174/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3026174</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3026174" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="40" class="mim-anchor"></a>
<a id="Harvey1969" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Harvey, P. K. P., Jones, M. C., Anderson, E. G.
<strong>Pericardial abnormalities in Gaucher's disease.</strong>
Brit. Heart J. 31: 603-606, 1969.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/5351295/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">5351295</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=5351295" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1136/hrt.31.5.603" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="41" class="mim-anchor"></a>
<a id="Hollak1994" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Hollak, C. E. M., van Weely, S., van Oers, M. H. J., Aerts, J. M. F. G.
<strong>Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease.</strong>
J. Clin. Invest. 93: 1288-1292, 1994.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8132768/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8132768</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8132768" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1172/JCI117084" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="42" class="mim-anchor"></a>
<a id="Hruska2008" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Hruska, K. S., LaMarca, M. E., Scott, C. R., Sidransky, E.
<strong>Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).</strong>
Hum. Mutat. 29: 567-583, 2008.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18338393/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18338393</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18338393" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1002/humu.20676" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="43" class="mim-anchor"></a>
<a id="Hsia1959" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Hsia, D. Y.-Y., Naylor, J., Bigler, J. A.
<strong>Gaucher's disease: report of two cases in father and son and review of the literature.</strong>
New Eng. J. Med. 261: 164-169, 1959.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/13666999/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">13666999</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=13666999" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1056/NEJM195907232610402" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="44" class="mim-anchor"></a>
<a id="Jmoudiak2005" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Jmoudiak, M., Futerman, A. H.
<strong>Gaucher disease: pathological mechanisms and modern management.</strong>
Brit. J. Haemat. 129: 178-188, 2005.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15813845/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15813845</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15813845" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1111/j.1365-2141.2004.05351.x" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="45" class="mim-anchor"></a>
<a id="Kaplan1996" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Kaplan, P., Mazur, A., Manor, O., Charrow, J., Esplin, J., Gribble, T. J., Wappner, R. S., Wisch, J. S., Weinreb, N. J.
<strong>Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.</strong>
J. Pediat. 129: 149-153, 1996.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8757576/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8757576</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8757576" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/s0022-3476(96)70203-2" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="46" class="mim-anchor"></a>
<a id="Klibansky1973" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Klibansky, C., Hoffman, J., Zaizov, R., Matoth, Y., Pinchas, J., DeVries, A.
<strong>Chronic Gaucher disease: heat resistance of leukocyte beta-glucocerebrosidase in relation to some clinical parameters.</strong>
Biomedicine 19: 345-348, 1973.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/4774111/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">4774111</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=4774111" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="47" class="mim-anchor"></a>
<a id="Knudson1962" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Knudson, A. G., Jr., Kaplan, W. D.
<strong>Genetics of the sphingolipidoses. In: Aaronson, S. M.; Volk, B. W.: Cerebral Sphingolipidoses. A Symposium on Tay-Sachs Disease.</strong>
New York: Academic Press (pub.) 1962. Pp. 395-411.
</p>
</div>
</li>
<li>
<a id="48" class="mim-anchor"></a>
<a id="Koto2021" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Koto, Y., Sakai, N., Lee, Y., Kakee, N., Matsuda, J., Tsuboi, K., Shimozawa, N., Okuyama, T., Nakamura, K., Narita, A., kobayashi, H., Uehara, R., Nakamura, Y., Kato, K., Eto, Y.
<strong>Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan.</strong>
Molec. Genet. Metab. 133: 277-288, 2021.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/34090759/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">34090759</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=34090759" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/j.ymgme.2021.05.004" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="49" class="mim-anchor"></a>
<a id="Langeveld2008" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Langeveld, M., Ghauharali, K. J. M., Sauerwein, H. P., Ackermans, M. T., Groener, J. E. M., Hollak, C. E. M., Aerts, J. M., Serlie, M. J.
<strong>Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.</strong>
J. Clin. Endocr. Metab. 93: 845-851, 2008.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18089699/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18089699</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18089699" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1210/jc.2007-1702" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="50" class="mim-anchor"></a>
<a id="Lanir1986" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Lanir, A., Hadar, H., Cohen, I., Tal, Y., Benmair, J., Schreiber, R., Clouse, M. E.
<strong>Gaucher disease: assessment with MR imaging.</strong>
Radiology 161: 239-244, 1986.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3763873/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3763873</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3763873" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1148/radiology.161.1.3763873" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="51" class="mim-anchor"></a>
<a id="Maaswinkel-Mooij2000" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Maaswinkel-Mooij, P., Hollak, C., van Eysden-Plaisier, M., Prins, M., Aerts, H., Poll, R.
<strong>The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations.</strong>
J. Inherit. Metab. Dis. 23: 77-82, 2000.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/10682310/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">10682310</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=10682310" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1023/a:1005655031239" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="52" class="mim-anchor"></a>
<a id="Matoth1987" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Matoth, Y., Chazan, S., Cnaan, A., Gelernter, I., Klibansky, C.
<strong>Frequency of carriers of chronic (type I) Gaucher disease in Ashkenazi Jews.</strong>
Am. J. Med. Genet. 27: 561-565, 1987.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3631130/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3631130</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3631130" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1002/ajmg.1320270309" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="53" class="mim-anchor"></a>
<a id="Miller2003" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Miller, A., Brown, L. K., Pastores, G. M., Desnick, R. J.
<strong>Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease.</strong>
Clin. Genet. 63: 368-376, 2003.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12752568/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12752568</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12752568" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1034/j.1399-0004.2003.00060.x" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="54" class="mim-anchor"></a>
<a id="Morello2000" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Morello, J.-P., Bouvier, M., Petaja-Repo, U. E., Bichet, D. G.
<strong>Pharmacological chaperones: a new twist on receptor folding.</strong>
Trends Pharm. Sci. 21: 466-469, 2000.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/11121835/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">11121835</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=11121835" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/s0165-6147(00)01575-3" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="55" class="mim-anchor"></a>
<a id="Moscicki1993" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Moscicki, R. A., Taunton-Rigby, A.
<strong>Treatment of Gaucher's disease. (Letter)</strong>
New Eng. J. Med. 328: 1564 only, 1993.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8373459/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8373459</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8373459" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1056/NEJM199305273282112" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="56" class="mim-anchor"></a>
<a id="Nolta1992" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Nolta, J. A., Yu, X. J., Bahner, I., Kohn, D. B.
<strong>Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.</strong>
J. Clin. Invest. 90: 342-348, 1992. Note: Erratum: J. Clin. Invest. 90: 1635 only, 1992.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/1379609/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">1379609</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=1379609" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1172/JCI115868" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="57" class="mim-anchor"></a>
<a id="Pandey2017" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Pandey, M. K., Burrow, T. A., Rani, R., Martin, L. J., Witte, D., Setchell, K. D., Mckay, M. A., Magnusen, A. F., Zhang, W., Liou, B., Kohl, J., Grabowski, G. A.
<strong>Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.</strong>
Nature 543: 108-112, 2017.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/28225753/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">28225753</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=28225753" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1038/nature21368" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="58" class="mim-anchor"></a>
<a id="Park2001" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Park, J. K., Koprivica, V., Andrews, D. Q., Madike, V., Tayebi, N., Stone, D. L., Sidransky, E.
<strong>Glucocerebrosidase mutations among African-American patients with type 1 Gaucher disease.</strong>
Am. J. Med. Genet. 99: 147-151, 2001.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/11241475/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">11241475</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=11241475" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1002/1096-8628(2001)9999:9999&lt;::aid-ajmg1144&gt;3.0.co;2-1" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="59" class="mim-anchor"></a>
<a id="Pastores2005" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Pastores, G. M., Barnett, N. L., Kolodny, E. H.
<strong>An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.</strong>
Clin. Ther. 27: 1215-1227, 2005.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/16199246/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">16199246</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=16199246" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/j.clinthera.2005.08.004" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="60" class="mim-anchor"></a>
<a id="Peleg1998" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Peleg, L., Frisch, A., Goldman, B., Karpaty, M., Narinsky, R., Bronstein, S., Frydman, M.
<strong>Lower frequency of Gaucher disease carriers among Tay-Sachs disease carriers.</strong>
Europ. J. Hum. Genet. 6: 185-186, 1998.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/9781065/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">9781065</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=9781065" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1038/sj.ejhg.5200176" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="61" class="mim-anchor"></a>
<a id="Pentchev1983" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Pentchev, P. G., Neumeyer, B., Svennerholm, L., Groth, C. G., Brady, R. O.
<strong>Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease.</strong>
Am. J. Hum. Genet. 35: 621-628, 1983.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/6881138/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">6881138</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=6881138" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="62" class="mim-anchor"></a>
<a id="Petrohelos1975" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Petrohelos, M., Tricoulis, D., Kotsiras, I., Vouzoukos, A.
<strong>Ocular manifestations of Gaucher's disease.</strong>
Am. J. Ophthal. 80: 1006-1010, 1975.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/1200092/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">1200092</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=1200092" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/0002-9394(75)90329-3" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="63" class="mim-anchor"></a>
<a id="Raghavan1980" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Raghavan, S. S., Topol, J., Kolodny, E. H.
<strong>Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease.</strong>
Am. J. Hum. Genet. 32: 158-173, 1980.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/6770675/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">6770675</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=6770675" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="64" class="mim-anchor"></a>
<a id="Ramaswami2021" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Ramaswami, L., Mengel, E., Berrah, A., AlSayed, M., Broomfield, A., Donald, A., Seif El Dein, H. M., Freisens, S., Hwu, W.-L., Peterschmitt, M. J., Yoo H.-W., Abdelwahab, M.
<strong>Throwing a spotlight on under-recognized manifestations of Gaucher disease: pulmonary involvement, lymphadenopathy, and Gaucheroma.</strong>
Molec. Genet. Metab. 133: 335-344, 2021.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/34229967/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">34229967</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=34229967" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/j.ymgme.2021.06.009" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="65" class="mim-anchor"></a>
<a id="Ringden1995" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Ringden, O., Groth, C. G., Erikson, A., Granqvist, E. S., Mansson, J.-E., Sparrelid, E.
<strong>Ten years' experience of bone marrow transplantation for Gaucher disease.</strong>
Transplantation 59: 864-870, 1995.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/7701581/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">7701581</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=7701581" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="66" class="mim-anchor"></a>
<a id="Rockah1998" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Rockah, R., Narinsky, R., Frydman, M., Cohen, I. J., Zaizov, R., Weizman, A., Frisch, A.
<strong>Linkage disequilibrium of common Gaucher disease mutations with a polymorphic site in the pyruvate kinase (PKLR) gene.</strong>
Am. J. Med. Genet. 78: 233-236, 1998.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/9677056/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">9677056</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=9677056" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="67" class="mim-anchor"></a>
<a id="Ross1997" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Ross, D. J., Spira, S., Buchbinder, N. A.
<strong>Gaucher cells in pulmonary-capillary blood in association with pulmonary hypertension. (Letter)</strong>
New Eng. J. Med. 336: 379-381, 1997.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/9011805/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">9011805</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=9011805" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1056/NEJM199701303360516" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="68" class="mim-anchor"></a>
<a id="Rubin1986" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Rubin, M., Yampolski, I., Lambrozo, R., Zaizov, R., Dintsman, M.
<strong>Partial splenectomy in Gaucher's disease.</strong>
J. Pediat. Surg. 21: 125-128, 1986.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3950849/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3950849</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3950849" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/s0022-3468(86)80063-x" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="69" class="mim-anchor"></a>
<a id="Sawkar2002" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Sawkar, A. R., Cheng, W.-C., Beutler, E., Wong, C.-H., Balch, W. E., Kelly, J. W.
<strong>Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease.</strong>
Proc. Nat. Acad. Sci. 99: 15428-15433, 2002.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12434014/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12434014</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=12434014[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12434014" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1073/pnas.192582899" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="70" class="mim-anchor"></a>
<a id="Slatkin2004" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Slatkin, M.
<strong>A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases.</strong>
Am. J. Hum. Genet. 75: 282-293, 2004.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15208782/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15208782</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=15208782[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15208782" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1086/423146" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="71" class="mim-anchor"></a>
<a id="Sorge1987" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Sorge, J., Kuhl, W., West, C., Beutler, E.
<strong>Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer.</strong>
Proc. Nat. Acad. Sci. 84: 906-909, 1987.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3547401/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3547401</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3547401" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1073/pnas.84.4.906" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="72" class="mim-anchor"></a>
<a id="Starzl1993" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Starzl, T. E., Demetris, A. J., Trucco, M., Ricordi, C., Ildstad, S., Terasaki, P. I., Murase, N., Kendall, R. S., Kocova, M., Rudert, W. A., Zeevi, A., Van Thiel, D.
<strong>Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease.</strong>
New Eng. J. Med. 328: 745-749, 1993.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8437594/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8437594</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=8437594[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8437594" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1056/NEJM199303183281101" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="73" class="mim-anchor"></a>
<a id="Steet2006" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Steet, R. A., Chung, S., Wustman, B., Powe, A., Do, H., Kornfeld, S. A.
<strong>The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.</strong>
Proc. Nat. Acad. Sci. 103: 13813-13818, 2006.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/16945909/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">16945909</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=16945909[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=16945909" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1073/pnas.0605928103" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="74" class="mim-anchor"></a>
<a id="Tamari1983" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Tamari, I., Motro, M., Neufeld, H. N.
<strong>Unusual pericardial calcification in Gaucher's disease.</strong>
Arch. Intern. Med. 143: 2010-2011, 1983.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/6625792/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">6625792</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=6625792" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="75" class="mim-anchor"></a>
<a id="Tsuji1987" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Tsuji, S., Choudary, P. V., Martin, B. M., Stubblefield, B. K., Mayor, J. A., Barranger, J. A., Ginns, E. I.
<strong>A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease.</strong>
New Eng. J. Med. 316: 570-575, 1987.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/2880291/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">2880291</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=2880291" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1056/NEJM198703053161002" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="76" class="mim-anchor"></a>
<a id="Tsuji1988" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Tsuji, S., Martin, B. M., Barranger, J. A., Stubblefield, B. K., LaMarca, M. E., Ginns, E. I.
<strong>Genetic heterogeneity in type I Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals.</strong>
Proc. Nat. Acad. Sci. 85: 2349-2352, 1988. Note: Erratum: Proc. Nat. Acad. Sci. 85: 5708 only, 1988.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3353383/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3353383</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3353383" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1073/pnas.85.7.2349" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="77" class="mim-anchor"></a>
<a id="Wang2011" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Wang, R. Y., Bodamer, O. A., Watson, M. S., Wilcox, W. R.
<strong>Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals.</strong>
Genet. Med. 13: 457-484, 2011.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21502868/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21502868</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=21502868" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1097/GIM.0b013e318211a7e1" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="78" class="mim-anchor"></a>
<a id="Wang2005" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Wang, T.-J., Chen, M.-S., Shih, Y.-F., Hwu, W.-L., Lai, M.-Y.
<strong>Fundus abnormalities in a patient with type I Gaucher's disease with 12-year follow-up.</strong>
Am. J. Ophthal. 139: 359-362, 2005.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15734007/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15734007</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15734007" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/j.ajo.2004.07.053" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="79" class="mim-anchor"></a>
<a id="Weinreb2021" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Weinreb, N. J., Camelo, J. S., Jr., Charrow, J., McClain, M. R., Mistry, P., Belmatoug, N.
<strong>Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain imiglucerase treatment.</strong>
Molec. Genet. Metab. 132: 100-111, 2021.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/33485799/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">33485799</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=33485799" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/j.ymgme.2020.12.295" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="80" class="mim-anchor"></a>
<a id="Weinreb2002" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Weinreb, N. J., Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pastores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., Zimran, A.
<strong>Effectiveness of enzyme replacement therapy in 1028 patients with type I Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.</strong>
Am. J. Med. 113: 112-119, 2002.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12133749/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12133749</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12133749" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1016/s0002-9343(02)01150-6" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="81" class="mim-anchor"></a>
<a id="Wiedemann1965" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Wiedemann, H.-R., Gerken, H., Graucob, E., Hansen, H.-G.
<strong>Recognition of heterozygosity in sphingolipidoses. (Letter)</strong>
Lancet 285: 1283 only, 1965. Note: Originally Volume 1.
</p>
</div>
</li>
<li>
<a id="82" class="mim-anchor"></a>
<a id="Zimran1991" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Zimran, A., Gelbart, T., Westwood, B., Grabowski, G. A., Beutler, E.
<strong>High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.</strong>
Am. J. Hum. Genet. 49: 855-859, 1991.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/1897529/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">1897529</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=1897529" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
</p>
</div>
</li>
<li>
<a id="83" class="mim-anchor"></a>
<a id="Zlotogora1986" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Zlotogora, J., Zaizov, R., Klibansky, C., Matoth, Y., Bach, G., Cohen, T.
<strong>Genetic heterogeneity in Gaucher disease.</strong>
J. Med. Genet. 23: 319-322, 1986.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/3746831/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">3746831</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=3746831" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1136/jmg.23.4.319" target="_blank">Full Text</a>]
</p>
</div>
</li>
<li>
<a id="84" class="mim-anchor"></a>
<a id="Zuckerman2007" class="mim-anchor"></a>
<div class="">
<p class="mim-text-font">
Zuckerman, S., Lahad, A., Shmueli, A., Zimran, A., Peleg, L., Orr-Urtreger, A., Levy-Lahad, E., Sagi, M.
<strong>Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases.</strong>
JAMA 298: 1281-1290, 2007.
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17878420/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17878420</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17878420" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
[<a href="https://doi.org/10.1001/jama.298.11.1281" target="_blank">Full Text</a>]
</p>
</div>
</li>
</ol>
<div>
<br />
</div>
</div>
</div>
<div>
<a id="contributors" class="mim-anchor"></a>
<div class="row">
<div class="col-lg-2 col-md-2 col-sm-4 col-xs-4">
<span class="mim-text-font">
<a href="#mimCollapseContributors" role="button" data-toggle="collapse"> Contributors: </a>
</span>
</div>
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
<span class="mim-text-font">
Hilary J. Vernon - updated : 10/08/2021
</span>
</div>
</div>
<div class="row collapse" id="mimCollapseContributors">
<div class="col-lg-offset-2 col-md-offset-4 col-sm-offset-4 col-xs-offset-2 col-lg-6 col-md-6 col-sm-6 col-xs-6">
<span class="mim-text-font">
Hilary J. Vernon - updated : 09/13/2021<br>Hilary J. Vernon - updated : 05/18/2021<br>Hilary J. Vernon - updated : 05/22/2020<br>Ada Hamosh - updated : 08/08/2017<br>Ada Hamosh - updated : 10/3/2012<br>John A. Phillips, III - updated : 4/27/2009<br>Cassandra L. Kniffin - updated : 8/25/2008<br>Cassandra L. Kniffin - updated : 4/3/2008<br>Cassandra L. Kniffin - updated : 10/17/2007<br>Cassandra L. Kniffin - updated : 11/1/2006<br>Jane Kelly - updated : 9/26/2006<br>Victor A. McKusick - updated : 8/12/2004<br>Victor A. McKusick - updated : 6/4/2003<br>Victor A. McKusick - updated : 1/14/2003<br>Ada Hamosh - updated : 11/29/2001<br>Victor A. McKusick - updated : 8/2/2001<br>Ada Hamosh - updated : 4/23/2001<br>Sonja A. Rasmussen - updated : 4/4/2001<br>Kathryn R. Wagner - updated : 3/30/2001<br>Victor A. McKusick - updated : 7/25/2000<br>Paul Brennan - updated : 4/11/2000<br>Victor A. McKusick - updated : 2/23/2000<br>Victor A. McKusick - updated : 2/22/2000<br>Victor A. McKusick - updated : 8/30/1999<br>Ada Hamosh - updated : 7/15/1999<br>Victor A. McKusick - updated : 5/17/1999<br>Victor A. McKusick - updated : 4/16/1999<br>Victor A. McKusick - updated : 10/1/1998<br>Victor A. McKusick - updated : 9/11/1998<br>Victor A. McKusick - updated : 8/3/1998<br>Victor A. McKusick - updated : 7/28/1998<br>Victor A. McKusick - updated : 4/29/1998<br>Victor A. McKusick - updated : 12/1/1997<br>Victor A. McKusick - updated : 10/3/1997<br>Ethylin Wang Jabs - updated : 7/21/1997<br>Victor A. McKusick - updated : 6/23/1997<br>Victor A. McKusick - updated : 3/6/1997<br>Victor A. McKusick - updated : 3/4/1997<br>Cynthia K. Ewing - updated : 10/6/1996<br>Moyra Smith - updated : 9/16/1996<br>Stylianos E. Antonarakis - updated : 7/2/1996
</span>
</div>
</div>
</div>
<div>
<a id="creationDate" class="mim-anchor"></a>
<div class="row">
<div class="col-lg-2 col-md-2 col-sm-4 col-xs-4">
<span class="text-nowrap mim-text-font">
Creation Date:
</span>
</div>
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
<span class="mim-text-font">
Victor A. McKusick : 6/3/1986
</span>
</div>
</div>
</div>
<div>
<a id="editHistory" class="mim-anchor"></a>
<div class="row">
<div class="col-lg-2 col-md-2 col-sm-4 col-xs-4">
<span class="text-nowrap mim-text-font">
<a href="#mimCollapseEditHistory" role="button" data-toggle="collapse"> Edit History: </a>
</span>
</div>
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
<span class="mim-text-font">
carol : 06/13/2024
</span>
</div>
</div>
<div class="row collapse" id="mimCollapseEditHistory">
<div class="col-lg-offset-2 col-md-offset-2 col-sm-offset-4 col-xs-offset-4 col-lg-6 col-md-6 col-sm-6 col-xs-6">
<span class="mim-text-font">
carol : 10/08/2021<br>carol : 09/13/2021<br>carol : 05/19/2021<br>carol : 05/18/2021<br>carol : 05/13/2021<br>carol : 09/04/2020<br>carol : 05/22/2020<br>alopez : 08/08/2017<br>alopez : 02/15/2017<br>carol : 10/14/2016<br>terry : 03/28/2013<br>alopez : 11/26/2012<br>alopez : 10/3/2012<br>carol : 5/1/2012<br>terry : 3/20/2012<br>carol : 7/26/2011<br>terry : 6/3/2009<br>terry : 5/4/2009<br>alopez : 4/27/2009<br>wwang : 9/18/2008<br>ckniffin : 8/25/2008<br>wwang : 4/15/2008<br>ckniffin : 4/3/2008<br>carol : 10/24/2007<br>ckniffin : 10/17/2007<br>carol : 9/13/2007<br>ckniffin : 11/3/2006<br>carol : 11/2/2006<br>ckniffin : 11/1/2006<br>carol : 10/3/2006<br>carol : 9/26/2006<br>terry : 11/3/2004<br>tkritzer : 8/17/2004<br>terry : 8/12/2004<br>mgross : 9/18/2003<br>tkritzer : 6/10/2003<br>terry : 6/4/2003<br>tkritzer : 5/8/2003<br>carol : 1/23/2003<br>tkritzer : 1/21/2003<br>terry : 1/14/2003<br>ckniffin : 5/7/2002<br>terry : 11/29/2001<br>terry : 11/28/2001<br>terry : 11/19/2001<br>terry : 11/19/2001<br>carol : 11/16/2001<br>terry : 8/2/2001<br>cwells : 5/9/2001<br>cwells : 5/8/2001<br>terry : 4/23/2001<br>mcapotos : 4/5/2001<br>mcapotos : 4/4/2001<br>carol : 3/30/2001<br>terry : 3/30/2001<br>carol : 8/2/2000<br>terry : 7/25/2000<br>alopez : 4/11/2000<br>carol : 2/23/2000<br>terry : 2/22/2000<br>jlewis : 9/8/1999<br>terry : 8/30/1999<br>alopez : 7/26/1999<br>terry : 7/15/1999<br>carol : 6/25/1999<br>mgross : 5/21/1999<br>terry : 5/17/1999<br>carol : 4/19/1999<br>terry : 4/16/1999<br>carol : 10/5/1998<br>terry : 10/1/1998<br>terry : 9/11/1998<br>carol : 8/4/1998<br>terry : 8/3/1998<br>carol : 7/29/1998<br>terry : 7/28/1998<br>joanna : 5/13/1998<br>carol : 5/8/1998<br>terry : 4/29/1998<br>carol : 4/7/1998<br>terry : 3/28/1998<br>mark : 12/8/1997<br>terry : 12/1/1997<br>jenny : 10/7/1997<br>terry : 10/3/1997<br>mark : 8/1/1997<br>mark : 8/1/1997<br>jenny : 8/1/1997<br>mark : 7/31/1997<br>mark : 6/25/1997<br>jenny : 6/23/1997<br>mark : 6/22/1997<br>mark : 6/22/1997<br>jenny : 6/17/1997<br>mark : 5/28/1997<br>mark : 5/24/1997<br>terry : 3/6/1997<br>jamie : 3/5/1997<br>terry : 3/5/1997<br>mark : 3/4/1997<br>terry : 3/3/1997<br>mark : 1/20/1997<br>mark : 1/18/1997<br>terry : 10/31/1996<br>mark : 10/6/1996<br>mark : 9/16/1996<br>mark : 7/22/1996<br>terry : 7/2/1996<br>terry : 6/27/1996<br>terry : 6/21/1996<br>mark : 6/7/1996<br>terry : 6/6/1996<br>terry : 5/16/1996<br>mark : 5/16/1996<br>terry : 5/13/1996<br>mark : 12/13/1995<br>mark : 10/24/1995<br>davew : 8/19/1994<br>terry : 5/2/1994<br>mimadm : 4/29/1994<br>warfield : 4/15/1994<br>carol : 1/27/1994
</span>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="container visible-print-block">
<div class="row">
<div class="col-md-8 col-md-offset-1">
<div>
<div>
<h3>
<span class="mim-font">
<strong>#</strong> 230800
</span>
</h3>
</div>
<div>
<h3>
<span class="mim-font">
GAUCHER DISEASE, TYPE I; GD1
</span>
</h3>
</div>
<div>
<br />
</div>
<div>
<div >
<p>
<span class="mim-font">
<em>Alternative titles; symbols</em>
</span>
</p>
</div>
<div>
<h4>
<span class="mim-font">
GD I<br />
GAUCHER DISEASE, NONCEREBRAL JUVENILE<br />
GLUCOCEREBROSIDASE DEFICIENCY<br />
ACID BETA-GLUCOSIDASE DEFICIENCY<br />
GBA DEFICIENCY
</span>
</h4>
</div>
</div>
<div>
<br />
</div>
</div>
<div>
<p>
<span class="mim-text-font">
<strong>SNOMEDCT:</strong> 62201009; &nbsp;
<strong>ORPHA:</strong> 355, 77259; &nbsp;
<strong>DO:</strong> 0110957; &nbsp;
</span>
</p>
</div>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Phenotype-Gene Relationships</strong>
</span>
</h4>
<div>
<table class="table table-bordered table-condensed small mim-table-padding">
<thead>
<tr class="active">
<th>
Location
</th>
<th>
Phenotype
</th>
<th>
Phenotype <br /> MIM number
</th>
<th>
Inheritance
</th>
<th>
Phenotype <br /> mapping key
</th>
<th>
Gene/Locus
</th>
<th>
Gene/Locus <br /> MIM number
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<span class="mim-font">
1q22
</span>
</td>
<td>
<span class="mim-font">
Gaucher disease, type I
</span>
</td>
<td>
<span class="mim-font">
230800
</span>
</td>
<td>
<span class="mim-font">
Autosomal recessive
</span>
</td>
<td>
<span class="mim-font">
3
</span>
</td>
<td>
<span class="mim-font">
GBA1
</span>
</td>
<td>
<span class="mim-font">
606463
</span>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>TEXT</strong>
</span>
</h4>
<span class="mim-text-font">
<p>A number sign (#) is used with this entry because Gaucher disease type I (GD1) is caused by homozygous or compound heterozygous mutation in the GBA gene (606463), which encodes acid beta-glucosidase, on chromosome 1q22.</p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Description</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder due to deficient activity of beta-glucocerebrosidase. As a result of this deficiency, there is intracellular accumulation of glucosylceramide (GlcCer, glucosylcerebroside) primarily within cells of mononuclear phagocyte origin, which are the characteristic 'Gaucher cells' identified in most tissues (Jmoudiak and Futerman, 2005). </p><p>Gaucher disease is classically categorized phenotypically into 3 main subtypes: nonneuronopathic type I (GD1), acute neuronopathic type II (GD2; 230900), and subacute neuronopathic type III (GD3; 231000). Type I is the most common form of Gaucher disease and lacks primary central nervous system involvement. Types II and III have central nervous system involvement and neurologic manifestations (Knudson and Kaplan, 1962; Jmoudiak and Futerman, 2005). </p><p>All 3 forms of Gaucher disease are caused by mutation in the GBA gene. There are 2 additional phenotypes that may be distinguished: perinatal lethal Gaucher disease (608013), which is a severe form of type II, and Gaucher disease type IIIC (231005), which also has cardiovascular calcifications.</p><p>See also 610539 for a form of atypical Gaucher disease caused by mutation in the gene encoding saposin C (PSAP; 176801), which is an activator of beta-glucosidase.</p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Clinical Features</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Type I Gaucher disease usually presents in childhood with hepatosplenomegaly, pancytopenia, and manifestations of bone marrow infiltration by characteristic 'Gaucher cells.' Other features include ocular pingueculae, or nodules, and dermal hyperpigmentation. There is a wide spectrum of clinical severity, ranging from affected infants to asymptomatic adults. There is no neurologic involvement in type I Gaucher disease (Goldblatt, 1988). </p><p>Choy (1988) reported a French Canadian family in which 5 sibs had type I Gaucher disease. Glucocerebrosidase activity in patients' fibroblasts was 7.5 to 15.5% of normal controls; obligate carriers had approximately 50% normal activity. The 5 affected sibs showed considerable phenotypic heterogeneity: age at diagnosis ranged from 16 to 41 years. The most severely affected patient was very anemic and thrombocytopenic, and had severe orthopedic complications, including vertebral compression, avascular necrosis of the femoral head, and pathologic fractures of long bones. The least affected male had no orthopedic complications at age 49 years and his hematologic complications had been reversed by splenectomy at age 25. There was no clear correlation between residual GBA enzyme activity in cultured fibroblasts and clinical severity. </p><p>In a retrospective study of 20 untreated Dutch patients with type I Gaucher disease, Maaswinkel-Mooij et al. (2000) found that the clinical manifestations were progressive in most patients, children as well as adults. This appeared to be in contrast with studies among Jewish patients. The results emphasized the need for regular follow-up to enable timely initiation of enzyme therapy. </p><p>Park et al. (2001) reported the clinical features and genotypes of 7 African American patients with type I Gaucher disease. Common features included hepatosplenomegaly, epistaxis, bone pain, anemia, and thrombocytopenia. All patients had moderate to severe manifestations, 4 presented before age 3 years, and all developed symptoms by adolescence. No probands shared the same genotype. The authors concluded that significant genotypic heterogeneity exists among African American patients with type I Gaucher disease, and that recombinations in the GBA gene may be common in this patient group. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Biochemical Features</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Brady et al. (1965) demonstrated deficiency of the glucocerebrosidase enzyme in the spleen of patients with Gaucher disease. Wiedemann et al. (1965) found typical Gaucher cells in the bone marrow of unaffected obligate heterozygotes from 2 families with Gaucher disease. Danes and Bearn (1968) found giant fibroblasts containing metachromatic material in both affected persons and heterozygotes for the chronic noncerebral form of Gaucher disease. Beutler et al. (1971) demonstrated decreased beta-glucosidase activity in fibroblasts from homozygotes with the adult form of Gaucher disease. Heterozygotes showed intermediate levels of enzyme activity. Chiao et al. (1979) found deficiency of beta-xylosidase (see 278900) in different forms of Gaucher disease and suggested that clinical features such as severity may be related to this epiphenomenon. </p><p>Pentchev et al. (1983) found the same glucocerebrosidase crossreacting material in the spleen in all 3 types of Gaucher disease. However, enzyme activity was about 15% of normal in the adult nonneurologic form (type I) and about 2.3% in the neurologic forms (types II and III). The authors concluded that all 3 forms of Gaucher disease result from a structurally mutated enzyme with altered catalytic efficiency. Gravel and Leung (1983) found no complementation from fusion of cultured fibroblasts from the infantile and adult forms of Gaucher disease, suggesting that the 2 forms are allelic. </p><p>Using various inhibitors, Grabowski et al. (1985) found 3 distinct groups of residual enzyme activity in patients with Gaucher disease. The groups were designated A, B, and C, but did not correspond to the phenotypic groups I, II, and III. The authors concluded that Gaucher disease type I is biochemically heterogeneous; that the nonneuronopathic and neuronopathic subtypes cannot be distinguished by such inhibitor studies; and that the Ashkenazi Jewish form of Gaucher disease type I results from a unique mutation in a specific active site domain of acid beta-glucosidase that leads to a defective enzyme. With monoclonal antibodies as well as polyclonal sera, Beutler et al. (1985) could demonstrate no differences of glucocerebrosidase in types I, II, and III Gaucher disease. </p><p>Based on enzymatic and phenotypic examination of 25 families with type I Gaucher disease, Zlotogora et al. (1986) concluded that the clinical variability results from different mutations at the same locus. The authors noted that Klibansky et al. (1973) had observed differences in heat activation profiles of glucocerebrosidase in type I patients with varying phenotypic severity. </p><p>Graves et al. (1986) found normal amounts of GBA mRNA in fibroblast extracts from patients with several types of Gaucher disease, suggesting single-base gene alterations leading to the synthesis of defective enzyme. Using immunoblotting techniques, Fabbro et al. (1987) found extensive heterogeneity in the nature of the biochemical defects in the various forms of Gaucher disease. </p><p>Bergmann and Grabowski (1989) found abnormalities in the posttranslational processing of GBA in patients with Gaucher disease, but the abnormalities could not be correlated firmly with phenotype. </p><p>Because glycosphingolipids may be involved in the induction of insulin resistance, and the primary genetic defect in Gaucher disease leads to increased levels of these molecules, Gaucher patients constitute a human model to study the relationship between glucose metabolism and glycosphingolipids. In a study of 6 patients with Gaucher disease and 6 controls, Langeveld et al. (2008) found that noninsulin-mediated glucose uptake during both euglycemia and hyperglycemia did not differ between patients and controls, but insulin-mediated glucose uptake was lower in Gaucher patients. Suppression of lipolysis by insulin tended to be less effective in Gaucher disease patients. Langeveld et al. (2008) concluded that Gaucher disease is associated with peripheral insulin resistance, possibly through the influence of glycosphingolipids on insulin receptor functioning. </p><p>Ramaswami et al. (2021) reviewed pulmonary involvement, lymphadenopathy, and Gaucheromas in Gaucher disease. Approximately 68% of patients in a prospective study of Gaucher disease type I had pulmonary function abnormalities, 17% had chest radiograph abnormalities, and 3% had pulmonary hypertension. Findings on high-resolution chest CT included a ground glass appearance in the early stages of disease, with evolution into a reticulonodular pattern at later stages. Lymphadenopathy had an incidence of approximately 5% in Gaucher disease, and commonly involved mediastinal/mesenteric lymph nodes. Lymphadenopathy has the potential to mimic malignancy and can progress to protein-losing enteropathy. Risk factors included severe Gaucher disease and asplenia. Approximately 20 to 25% of patients with Gaucher disease developed a Gaucheroma, which is a cluster of Gaucher cells that form a pseudotumor occurring most frequently in the liver, spleen, bone, and lymph nodes. Most cases of Gaucheromas occurred in adults, and splenectomy increased the risk. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Other Features</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Garfinkel et al. (1982) observed an association between Gaucher disease and monoclonal gammopathy or multiple myeloma and suggested that chronic glucocerebroside accumulation may provide a stimulus to the immune system. A possible experimental counterpart is myeloma in Balb/C mice, which develops several months after the intraperitoneal injection of mineral oil. </p><p>Calcific constrictive pericarditis was described by several authors in patients with type I Gaucher disease (Harvey et al., 1969; Tamari et al., 1983). The pericardial involvement in these cases was likely related to unrecognized hemorrhagic pericarditis (Chabas et al., 1995). </p><p>Choy (1985) found increased bone serum acid phosphatase only in patients with Gaucher disease who had bone involvement. Acid phosphatase was normal in lymphocytes and cultured fibroblasts from these patients, suggesting that it was a secondary feature of the disease in which there is bone involvement and is unreliable for diagnosis. </p><p>Ross et al. (1997) noted that aggregations of Gaucher cells within pulmonary alveolar spaces and interstitium in association with bilateral diffuse pulmonary reticulonodular infiltrates had been described in patients with type I Gaucher disease. In addition, there have been rare instances of Gaucher cells occluding pulmonary capillaries, with resulting pulmonary hypertension. The hepatopulmonary syndrome, as manifested by intrapulmonary shunting and hypoxemia, may also complicate type I Gaucher disease. Ross et al. (1997) described a patient with type I Gaucher disease and pulmonary hypertension in whom they identified Gaucher cells in pulmonary capillary blood drawn from a catheter in the wedged position. </p><p>Miller et al. (2003) evaluated pulmonary involvement in 150 consecutive patients with type I Gaucher disease. Clinical evidence of pulmonary involvement was noted in 5 patients, each of whom had dyspnea, diffuse infiltrates, restrictive impairment and low single breath carbon monoxide diffusing capacity. Two of these patients underwent exercise testing and showed abnormalities consistent with lung disease. In 13 patients randomly selected from the remaining 145, physical examination, chest radiographs, and pulmonary function were normal. However, responses on exercise testing in 6 patients were consistent with a circulatory impairment. Thus, the study found that less than 5% of patients with type I Gaucher disease have clinical interstitial lung disease. In addition, Miller et al. (2003) found that some patients, without evident lung involvement, experienced limitations in physical exertion and were easily fatigued; this was attributable to impaired pulmonary circulation. </p><p>Ocular manifestations in type I Gaucher disease include white deposits in the corneal epithelium, anterior chamber angle, ciliary body, and pupil margin (Petrohelos et al., 1975; Wang et al., 2005). Fundus abnormalities include perimacular grayness and scattered white spots (Cogan et al., 1980). In a 12-year follow-up of a patient with type I GD, Wang et al. (2005) demonstrated the presence of macular atrophy and increased retinal vascular permeability. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Pathogenesis</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Pandey et al. (2017) showed that activation of complement C5a (120900) and C5a receptor-1 (C5AR1; 113995) controls glucosylceramide (GC) accumulation and the inflammatory response in experimental and clinical Gaucher disease. Marked local and systemic complement activation occurred in glucocerebrosidase (GCase)-deficient mice or after pharmacologic inhibition of GCase and was associated with GC storage, tissue inflammation, and proinflammatory cytokine production. Whereas all GCase-inhibited mice died within 4 to 5 weeks, mice deficient in both GCase and C5aR1, and wildtype mice in which GCase and C5aR were pharmacologically inhibited, were protected from these adverse effects and consequently survived. In mice and humans, GCase deficiency was associated with strong formation of complement-activating GC-specific IgG autoantibodies, leading to complement activation and C5a generation. Subsequent C5aR1 activation controlled UDP-glucose ceramide glucosyltransferase production, thereby tipping the balance between GC formation and degradation. Thus, extensive GC storage induces complement-activating IgG autoantibodies that drive a pathway of C5a generation and C5aR1 activation that fuels a cycle of cellular GC accumulation and innate and adaptive immune cell recruitment and activation in Gaucher disease. Pandey et al. (2017) suggested that targeting C5AR1 may serve as a treatment option for patients with Gaucher disease and possibly other lysosomal storage diseases. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Inheritance</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Based on population studies among Ashkenazi Jewish populations in Israel, Fried (1973) concluded that Gaucher disease is an autosomal recessive disorder. Homozygotes were affected with the disease. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Diagnosis</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Desnick et al. (1971) demonstrated that both homozygotes and heterozygotes for Gaucher disease could be identified by chemical analysis of the sediment from a 24-hour urine collection. Individual neutral glycosphingolipids were separated by thin-layer chromatography and quantitatively estimated by gas-liquid chromatography. </p><p>By an assay of leukocyte beta-glucosidase, Raghavan et al. (1980) devised a method for identifying both heterozygotes and homozygotes. </p><p>Magnetic resonance imaging is a sensitive method for detecting bone involvement in Gaucher disease, evaluating complications such as osteonecrosis (Lanir et al., 1986). </p><p>Zuckerman et al. (2007) reviewed the outcome of screening for Gaucher disease among Ashkenazi Jewish individuals in Israel between 1995 and 2003. The carrier frequency was 5.7% in testing for 4 or 6 main GBA mutations. N370S (606463.0003) was by far the most common variant identified. Importantly, most individuals homozygous for the mild N370S mutation are mildly symptomatic or even asymptomatic (Beutler et al., 1993). Of 82 couples at risk for offspring with type I GD, 70 (85%) were at risk for asymptomatic or mildly affected offspring, and 12 (15%) were at risk for moderately affected offspring. Prenatal diagnosis performed in 68 pregnancies detected 16 fetuses with GD. Pregnancies were terminated in 2 (15%) of 13 fetuses predicted to be asymptomatic or mildly affected and in 2 (67%) of 3 fetuses with predicted moderate disease. There were significantly fewer pregnancy terminations (1 of 13) in couples who consulted with a GD expert in addition to genetic counseling compared to those who had not consulted with a GD expert (3 of 3). Two of the 3 terminations performed in the group without medical consult were homozygous for N370S. In an accompanying editorial, Beutler (2007) commented that carrier screening for Gaucher disease may do more harm than good given the extreme phenotypic variability and the inability to predict disease severity, especially in those with the common N370S mutation who may remain asymptomatic. Beutler (2007) recalled a 72-year-old patient with Gaucher disease who had low levels of enzyme activity but remained asymptomatic (Beutler, 1977). </p><p>In a review of the molecular genetics of Gaucher disease, Hruska et al. (2008) noted that most GBA mutations can be found in patients with various forms of the disorder. The phenotype is mainly determined by the combination of mutations on both alleles; thus the prediction of phenotype from genotypic data has limited utility. In addition, it has become increasingly difficult to categorize patients into 1 of the 3 classic types of Gaucher disease, indicating that the phenotypes fall into a continuum, with the major distinction being the presence and degree of neurologic function. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Clinical Management</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Most patients with type I Gaucher disease require splenectomy for management of thrombocytopenia and anemia; however, splenectomy is often followed by an increase in bone involvement, with osteolytic lesions within a few months of surgery (Ashkenazi et al., 1986). Partial splenectomy has been advocated with the dual goals of minimizing the deleterious effect on bone and avoiding postsplenectomy sepsis (Rubin et al., 1986). </p><p>Goldblatt et al. (1988) reported that of 8 patients with Gaucher disease treated with 15 total hip arthroplasties, 11 (73%) remained fully mobile and asymptomatic with a follow-up time of up to 14 years after surgery. </p><p>Wang et al. (2011) described the ACMG standards and guidelines for the diagnostic confirmation and management of presymptomatic individuals with lysosomal storage diseases. </p><p>Charrow et al. (2018) reported results from a phase 3, randomized, double-blind trial comparing the effectiveness of a once-daily versus the approved twice-daily regimen of eliglustat at the same total daily dose in 121 adult patients with type I Gaucher Disease. After 1 year, 80.4% of patients receiving once-daily dosing and 83.1% of patients receiving twice-daily dosing remained stable. Mean values for hematologic and visceral measures were within therapeutic goal thresholds in both groups. Because patients with twice-daily dosing also showed greater tolerance for the drug, the study confirmed the twice-daily dosing recommendation on the drug label. </p><p>Weinreb et al. (2021) reported long-term outcomes in 475 patients with type I Gaucher disease who were treated with imiglucerase for approximately 20 years. Outcome measures included spleen volume (in nonsplenectomized patients), liver volume, bone crises, bone pain, hemoglobin levels, and platelet count. For outcomes analyses, the patients were stratified into splenectomized and nonsplenectomized cohorts, and secondary analyses were based on pretreatment disease severity. Clinically significant improvements were seen within 2 to 5 years of starting treatment for almost all of the outcomes assessed, and were maintained through 20 years of treatment in both splenectomized and nonsplenectomized groups regardless of pretreatment disease severity. The only exception was bone pain, which was not significantly improved from baseline in nonsplenectomized patients at 20 years, but was significantly improved in splenectomized patients. </p><p>In a review of pulmonary involvement, lymphadenopathy, and Gaucheroma in Gaucher disease, Ramaswami et al. (2021) discussed management recommendations. Management of lung disease included consideration of a bronchodilator in the winter and monitoring with pulmonary function tests. Mucolytics may be considered in patients with decreased forced vital capacity or other risk factors. Enzyme replacement therapy was recommended for patients with compromised lung expansion or hepatopulmonary syndrome. Lung transplantation may be considered in end-stage lung disease. Lymphadenopathy may necessitate adjustment of dose and frequency of enzyme replacement therapy. Patients with protein-losing enteropathy should consume a diet rich in medium chain triglycerides and vitamin K supplements, as well as undergo treatment according to established guidelines. Avoidance of lymph node biopsies and surgical removal was advised. An evaluation for Gaucheromas was recommended at baseline with subsequent regular monitoring by MRI/CT and measurement of disease biomarkers. </p><p><strong><em>Gene Therapy</em></strong></p><p>
In vitro, Sorge et al. (1987) reported complete correction of the enzyme defect in fibroblasts from patients with type I Gaucher disease after retroviral-mediated GBA gene transfer. Fink et al. (1990) demonstrated that retroviral gene transfer could be used to correct the GBA deficiency in primary hematopoietic cells from patients with Gaucher disease. Correction was achieved in the progeny of transduced hematopoietic progenitor cells. Nolta et al. (1992) demonstrated that retroviral vectors can efficiently transfer the GBA gene into long-lived hematopoietic progenitor cells from the bone marrow of patients with Gaucher disease and express physiologically relevant levels of enzyme activity. </p><p>Starzl et al. (1993) reported that liver transplantation in a patient with type I Gaucher disease resulted in dramatic reduction in the lymph node deposits of glucocerebroside. They concluded that microchimerism corrected the metabolic abnormality. </p><p>See also ANIMAL MODEL section below.</p><p><strong><em>Enzyme Replacement Therapy</em></strong></p><p>
Barton et al. (1990) found that weekly intravenous infusions of macrophage-targeted human placental glucocerebrosidase resulted in clinical improvement in a patient with type I Gaucher disease. Sequential deglycosylation of the oligosaccharide chains of the native enzyme were used to yield a mannose-terminated preparation that is specifically bound by lectin on the membrane of macrophages. Twenty-week treatment resulted in increased hemoglobin, increased platelet count, and radiographic evidence of skeletal improvement. Barton et al. (1991) reported clinical improvement with intravenous infusion of macrophage-targeted enzyme therapy in 12 patients with type I disease. Serum hemoglobin concentration increased in all 12 patients, platelet count increased in 7, serum acid phosphatase decreased in 10, and plasma glucocerebroside level decreased in 9. After 6 months of treatment, splenic volume decreased in all patients, and hepatic volume in 5. Early signs of skeletal improvement were seen in 3 patients. The enzyme infusions were well tolerated, and no antibody to the exogenous enzyme developed. </p><p>Economic and other societal aspects of the use of modified glucocerebrosidase, alglucerase ('Ceredase'), in the treatment of Gaucher disease were discussed by Beutler et al. (1991) and Zimran et al. (1991). Theoretical considerations suggested to Figueroa et al. (1992) that more frequent administration might be more efficient. A series of 7 letters beginning with one by Moscicki and Taunton-Rigby (1993) discussed the economics and related aspects of alglucerase therapy. Ceredase, derived from human placental tissues and produced by Genzyme Corporation of Cambridge, Massachusetts, was approved by the Food and Drug Administration in 1991. In mid-1994, the FDA approved a recombinant alternative to Ceredase, Cerezyme, which is also produced by Genzyme (Fox, 1995). From a retrospective analysis, Kaplan et al. (1996) noted that in most children with type I Gaucher disease with subnormal growth velocity, adequate alglucerase (Ceredase) treatment resulted in growth velocity improvement. </p><p>In a review of 1,028 Gaucher patients treated with macrophage-targeted enzyme replacement therapy for 2 to 5 years, Weinreb et al. (2002) found improvement in anemia, thrombocytopenia, organomegaly, bone pain, and bone crises. </p><p>Hollak et al. (1994) observed a very marked increase (more than 600-fold) of chitotriosidase (CHIT1; 600031) activity in the plasma of 30 of 32 symptomatic patients with type I Gaucher disease. Chitotriosidase activity declined dramatically during enzyme supplementation therapy, suggesting that it could be used as a biomarker of therapeutic efficacy. In contrast, 3 GBA-deficient individuals without clinical symptoms had only slight increases in chitotriosidase. The authors considered it unlikely that chitotriosidase itself contributes to the clinical presentation of Gaucher disease. Hollak et al. (1994) suggested that the macrophages loaded with glucosylceramide in Gaucher disease are the main source of the plasma CHIT1 enzyme activity. </p><p>Approximately 6% of Caucasians have chitotriosidase deficiency (614122) without clinical symptoms. Grace et al. (2007) noted that the identification of CHIT1 gene mutations that alter plasma chitotriosidase activity is important for the use of this biomarker to monitor disease activity and therapeutic response in Gaucher disease. The authors thus genotyped the CHIT1 gene in 320 unrelated patients with Gaucher disease, including 272 of Ashkenazi Jewish descent. Among all patients, 4% and 37.2% were homozygous and heterozygous, respectively, for a common 24-bp duplication in the CHIT1 gene (600031.0001) that results in decreased enzyme activity. In addition, Grace et al. (2007) identified 3 novel mutations in the CHIT1 gene (600031.0002-600031.0005) in individuals with Gaucher disease and chitotriosidase deficiency. The findings were important for use and interpretation of plasma chitotriosidase activity in patients with Gaucher disease. </p><p><strong><em>Chemical Chaperone Therapy</em></strong></p><p>
Some lysosomal storage diseases appear to be caused by lysosomal enzyme variants that retain catalytic activity but are predisposed to misfolding or mistrafficking in the cell (Berg-Fussman et al., 1993). The use of chemical chaperones to template proper folding within the secretory pathway, prevent postsecretory misfolding, or stabilize proteins with a predilection to misfold is well documented (Morello et al., 2000). Pursuant to experience in Fabry disease (301500), Sawkar et al. (2002) found that addition of subinhibitory concentrations of the GBA inhibitor deoxynojirimycin (NN-DNJ) to fibroblasts in vitro resulted in a 2-fold increase in the activity of the N370S mutant (606463.0003) GBA enzyme. The increased activity persisted for at least 6 days after withdrawal of the putative chaperone. The same chaperone increased wildtype beta-glucosidase activity, but not that of the L444P mutation (606463.0001). Beta-glucosidase was stabilized against heat denaturation in a dose-dependent fashion. Sawkar et al. (2002) proposed that NN-DNJ chaperones beta-glucosidase folding at neutral pH, thus allowing the stabilized enzyme to transit from the endoplasmic reticulum to the Golgi, enabling proper trafficking to the lysosome. Importantly, a modest increase in beta-glucosidase activity seemed to be sufficient to achieve a therapeutic effect. </p><p>Steet et al. (2006) found that the iminosugar isofagomine (IFG), an active-site inhibitor of beta-glucosidase, facilitated the folding and transport of newly synthesized mutant N370S GBA from the endoplasmic reticulum to lysosomes. IFG increased beta-glucosidase activity approximately 3-fold in N370S fibroblasts and the enzyme showed some altered kinetic properties. Although IFG inhibited the enzyme in situ, washout of the drug resulted in full recovery of enzyme activity by 24 hours. </p><p><strong><em>Substrate Reduction Therapy</em></strong></p><p>
Pastores et al. (2005) reported results from treatment with N-butyldeoxynojirimycin (NB-DNJ; Miglustat), an inhibitor of glucosylceramide synthase (UGCG; 602874), in 10 adult patients with type I Gaucher disease. Treatment over 24 months resulted in decreased liver and spleen volumes and clinical improvement. Bone involvement and platelet and hemoglobin levels remained stable and the treatment was well tolerated. </p><p><strong><em>Bone Marrow Transplantation</em></strong></p><p>
Ringden et al. (1995) reported experience with allogenic bone marrow transplantation (BMT) in 6 patients, ranging from 2 to 9 years, with severe Gaucher disease in Sweden. The donors were HLA-identical sibs in 4 cases, the father with 1 incompatible HLA antigen in one case, and an HLA-A, -B, and -DR-identical unrelated donor in the sixth case. Among the donors, 3 were heterozygous for glucocerebrosidase and 3 were healthy homozygotes. Before transplantation, 4 patients underwent total splenectomy and 2 had partial splenectomy. In the former, 1 of the 4 patients developed pneumococcal meningitis. In the group with partial splenectomy, transfusion requirements were increased. The parental graft was rejected, but 4 of 5 other patients had donor enzyme levels from 2 to 11 years after BMT. Two patients became mixed chimeras with approximately 40% of donor erythrocyte markers for 1 and 80% for the other. One of these had low enzyme activity in his lymphocytes, but the clinical outcome was excellent. Gaucher cells disappeared from the bone marrow and liver size normalized or decreased within 2 to 3 years after BMT. All patients with engraftment had a growth spurt. Ringden et al. (1995) suggested that if an HLA-compatible donor is available, BMT is the treatment of choice in advanced Gaucher disease. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Molecular Genetics</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Tsuji et al. (1987) identified an L444P substitution in the GBA gene (606463.0001) in patients with Gaucher disease types I, II, and III. All 4 patients with type I disease had the mutation as a single allele and were presumably compound heterozygous with another unidentified pathogenic GBA mutation. </p><p>In 3 unrelated Ashkenazi Jewish patients with type I Gaucher disease, Tsuji et al. (1988) identified a homozygous mutation in the GBA gene (N370S; 606463.0003). Further studies showed that 15 of 21 additional type I patients had 1 allele with this mutation. The N370S mutation was not identified in patients with the type II or type III phenotype. One patient with type I disease was compound heterozygous for N370S and L444P. </p><p>Among 62 Ashkenazi Jewish patients with Gaucher disease, Zimran et al. (1991) found that N370S represented 73% of the 124 mutant alleles, making N370S the most common mutant GBA allele among Ashkenazi Jewish patients with type I disease. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Population Genetics</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Choy et al. (1987) described a method for identification of the carrier state in French Canadians. </p><p>In 1982, approximately 20,000 cases of Gaucher disease were reported in the United States. Over two-thirds of these persons were of Ashkenazi extraction (Brady, 1982).</p><p>By examination of glucocerebrosidase activity in leukocytes of a series of blood donors, Matoth et al. (1987) estimated the frequency of carriers among Ashkenazi Jews in Israel as 4.6%. This figure was in close agreement with the carrier rate of 4% estimated from the number of known cases of Gaucher disease in Israel. </p><p>Zimran et al. (1991) estimated the total gene frequency for Gaucher disease among Ashkenazi Jews to be 0.047, which is equivalent to a carrier frequency of 8.9% and a birth incidence of 1 in 450. </p><p>Among 593 unrelated normal Ashkenazi Jewish individuals, Zimran et al. (1991) identified 37 heterozygotes and 2 homozygotes for the N370S mutation, yielding an allele frequency of 0.035. Among 1,528 Ashkenazi Jewish individuals, Beutler et al. (1993) identified 87 heterozygotes and 4 homozygotes for N370S, yielding a frequency of 0.0311; pooling with data reported by Zimran et al. (1991) yielded a frequency of 0.032 for the N370S allele. Beutler et al. (1993) found that 10 of 2,305 normal Ashkenazi Jewish individuals were heterozygous for the 84GG insertion mutation (606463.0014), yielding an allele frequency of 0.00217. The authors found that the ratio of N370S to 84GG was higher in the general Jewish population than in the patient population, which was presumably due to the fact that N370S homozygotes may have late-onset disease or no significant clinical manifestations at all. To bring the gene frequency in the patient population into conformity with the gene frequency in the general population, nearly two-thirds of persons with a Gaucher disease genotype would be missing from the patient population, presumably because their clinical manifestations were very mild. </p><p>Both Tay-Sachs disease (TSD; 272800) and Gaucher disease have a high frequency in the Ashkenazi Jewish population, reaching a frequency of about 1:29 for TSD carriers and 1:16 for Gaucher disease carriers. By comparing the frequencies of the common GBA N370S mutation among carriers of the common TSD mutation, 1277TATC (606869.0001), and in the general Ashkenazi population, Peleg et al. (1998) determined that carriers of both diseases do not possess additional evolutionary advantage over single mutation carriers. The frequency of GD carriers among 308 TSD heterozygotes was 1:28, which is about half that expected (p = 0.03). The authors concluded that one or both mutations arose relatively recently in different regions of Europe and had not yet reached genetic equilibrium. </p><p>Rockah et al. (1998) found linkage disequilibrium between the 2 common Ashkenazi Gaucher disease mutations N370S and 84GG and polymorphic sites in the PKLR gene (609712). One hundred of 104 (96%) alleles carrying N370S also carried the A1 allele of the PKLR gene, which was present in only 6.7% of the control population, yielding a calculated linkage disequilibrium of 0.957. The mutation 84GG was found to be associated uniquely with the PKLR A6 allele, with a linkage disequilibrium of 1.00. These results suggested that the N3670S and 84GG mutations each originated in a single founder in the Ashkenazi Jewish population. Thus, founder effect followed by genetic drift rather than an evolutionary advantage for heterozygotes best explains the high frequency of these mutations in Ashkenazi Jews. </p><p>Despite considerable uncertainty about the demographic history of Ashkenazi Jews and their ancestors, Slatkin (2004) considered available genetic data to be consistent with a founder effect resulting from a severe bottleneck in population size between 1100 A.D. and 1400 A.D. and an earlier bottleneck in 75 A.D., at the beginning of the Jewish Diaspora. Slatkin (2004) concluded that a founder effect could account for the relatively high frequency of alleles causing 4 different lysosomal storage disorders, including Tay-Sachs disease and Gaucher disease, if the disease-associated alleles are recessive in their effects on reproductive fitness. </p><p>Charrow et al. (2018) stated that GD I is estimated to affect 1 in 40,000 in the general population and 1 in 850 among those of Ashkenazi Jewish ancestry. </p><p>Koto et al. (2021) surveyed hospitals in Japan for information about patients with lysosomal storage diseases (LSDs) treated between 2013-2016 and 2018-2019. Sixty-nine individuals with Gaucher disease were identified, of whom 37.7% had GD type I, 23.2% had GD type II, 30.4% had GD type III, and 8.7% had an unknown type. Koto et al. (2021) calculated a birth prevalence of Gaucher disease in Japan of 0.19 per 100,000. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>History</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Type I Gaucher disease was first described in a doctoral thesis by Gaucher (1882) as a nonleukemic splenic epithelioma (Goldblatt, 1988). Brill et al. (1905) first used the eponym 'Gaucher disease.' </p><p>Although Gaucher disease is clearly autosomal recessive, a dominant form was suggested by Hsia et al. (1959) on the basis of affected father and son. The father was German-Jewish and the mother Swedish-English. The mother may have been a carrier; this quasi-dominant mechanism is even more likely in reports of presumed dominant inheritance in Jewish groups where the frequency of the Gaucher disease is relatively high. </p>
</span>
<div>
<br />
</div>
<div>
<h4>
<span class="mim-font">
<strong>Animal Model</strong>
</span>
</h4>
</div>
<span class="mim-text-font">
<p>Enquist et al. (2006) used the Cre/loxP system to conditionally delete exons 9-11 of the Gba gene in mice after birth. The mice were viable, demonstrated deficiency of glucocerebrosidase, and developed splenomegaly and microcytic anemia similar to type I Gaucher disease, including infiltration of Gaucher cells in the bone marrow, spleen, and liver. Both bone marrow transplantation and gene therapy with a retroviral vector prevented the disease and corrected an already established Gaucher phenotype. Both therapies resulted in increased Gba activity and decreased numbers of Gaucher cells 5 to 6 months after treatment. </p>
</span>
<div>
<br />
</div>
</div>
<div>
<h4>
<span class="mim-font">
<strong>See Also:</strong>
</span>
</h4>
<span class="mim-text-font">
Beutler and Kuhl (1970); Beutler (1992)
</span>
<div>
<br />
</div>
</div>
<div>
<h4>
<span class="mim-font">
<strong>REFERENCES</strong>
</span>
</h4>
<div>
<p />
</div>
<div>
<ol>
<li>
<p class="mim-text-font">
Ashkenazi, A., Zaizov, R., Matoth, Y.
<strong>Effect of splenectomy on destructive bone changes in children with chronic (type I) Gaucher disease.</strong>
Europ. J. Pediat. 145: 138-141, 1986.
[PubMed: 3732318]
[Full Text: https://doi.org/10.1007/BF00441877]
</p>
</li>
<li>
<p class="mim-text-font">
Barton, N. W., Brady, R. O., Dambrosia, J. M., Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J., Murray, G. J., Parker, R. I., Argoff, C. E., Grewal, R. P., Yu, K.-T.
<strong>Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher&#x27;s disease.</strong>
New Eng. J. Med. 324: 1464-1470, 1991.
[PubMed: 2023606]
[Full Text: https://doi.org/10.1056/NEJM199105233242104]
</p>
</li>
<li>
<p class="mim-text-font">
Barton, N. W., Furbish, F. S., Murray, G. J., Garfield, M., Brady, R. O.
<strong>Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.</strong>
Proc. Nat. Acad. Sci. 87: 1913-1916, 1990.
[PubMed: 2308952]
[Full Text: https://doi.org/10.1073/pnas.87.5.1913]
</p>
</li>
<li>
<p class="mim-text-font">
Berg-Fussman, A., Grace, M. E., Ioannou, Y., Grabowski, G. A.
<strong>Human acid beta-glucosidase: N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity.</strong>
J. Biol. Chem. 268: 14861-14866, 1993.
[PubMed: 8325864]
</p>
</li>
<li>
<p class="mim-text-font">
Bergmann, J. E., Grabowski, G. A.
<strong>Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts.</strong>
Am. J. Hum. Genet. 44: 741-750, 1989.
[PubMed: 2495719]
</p>
</li>
<li>
<p class="mim-text-font">
Beutler, E., Gelbart, T., Kuhl, W., Sorge, J., West, C.
<strong>Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state.</strong>
Proc. Nat. Acad. Sci. 88: 10544-10547, 1991.
[PubMed: 1961718]
[Full Text: https://doi.org/10.1073/pnas.88.23.10544]
</p>
</li>
<li>
<p class="mim-text-font">
Beutler, E., Kuhl, W., Sorge, J.
<strong>Glucocerebrosidase &#x27;processing&#x27; and gene expression in various forms of Gaucher disease.</strong>
Am. J. Hum. Genet. 37: 1062-1070, 1985.
[PubMed: 4083278]
</p>
</li>
<li>
<p class="mim-text-font">
Beutler, E., Kuhl, W., Trinidad, F., Teplitz, R. L., Nadler, H.
<strong>Beta-glucosidase activity in fibroblasts from homozygotes and heterozygotes for Gaucher&#x27;s disease.</strong>
Am. J. Hum. Genet. 23: 62-66, 1971.
[PubMed: 5581982]
</p>
</li>
<li>
<p class="mim-text-font">
Beutler, E., Kuhl, W.
<strong>The diagnosis of the adult type of Gaucher&#x27;s disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes.</strong>
J. Lab. Clin. Med. 76: 747-755, 1970.
[PubMed: 5477334]
</p>
</li>
<li>
<p class="mim-text-font">
Beutler, E., Nguyen, N. J., Henneberger, M. W., Smolec, J. M., McPherson, R. A., West, C., Gelbart, T.
<strong>Gaucher disease: gene frequencies in the Ashkenazi Jewish population.</strong>
Am. J. Hum. Genet. 52: 85-88, 1993.
[PubMed: 8434610]
</p>
</li>
<li>
<p class="mim-text-font">
Beutler, E.
<strong>Gaucher&#x27;s disease in an asymptomatic 72-year-old.</strong>
JAMA 237: 2529, 1977.
[PubMed: 576973]
</p>
</li>
<li>
<p class="mim-text-font">
Beutler, E.
<strong>Gaucher disease: new molecular approaches to diagnosis and treatment.</strong>
Science 256: 794-799, 1992.
[PubMed: 1589760]
[Full Text: https://doi.org/10.1126/science.1589760]
</p>
</li>
<li>
<p class="mim-text-font">
Beutler, E.
<strong>Carrier screening for Gaucher disease: more harm than good?</strong>
JAMA 298: 1329-1331, 2007.
[PubMed: 17878426]
[Full Text: https://doi.org/10.1001/jama.298.11.1329]
</p>
</li>
<li>
<p class="mim-text-font">
Brady, R. O., Kanfer, J. N., Shapiro, D.
<strong>Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher&#x27;s disease.</strong>
Biochem. Biophys. Res. Commun. 18: 221-225, 1965.
[PubMed: 14282020]
[Full Text: https://doi.org/10.1016/0006-291x(65)90743-6]
</p>
</li>
<li>
<p class="mim-text-font">
Brady, R. O.
<strong>Personal Communication.</strong>
Bethesda, Md. 3/30/1982.
</p>
</li>
<li>
<p class="mim-text-font">
Brill, N. E., Mandlebaum, F. S., Libman, E.
<strong>Primary splenomegaly-Gaucher type: report on one of four cases occurring in a single generation of one family.</strong>
Am. J. Med. Sci. 129: 491-504, 1905.
</p>
</li>
<li>
<p class="mim-text-font">
Chabas, A., Cormand, B., Grinberg, D., Burguera, J. M., Balcells, S., Merino, J. L., Mate, I., Sobrino, J. A., Gonzalez-Duarte, R., Vilageliu, L.
<strong>Unusual expression of Gaucher&#x27;s disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation.</strong>
J. Med. Genet. 32: 740-742, 1995.
[PubMed: 8544197]
[Full Text: https://doi.org/10.1136/jmg.32.9.740]
</p>
</li>
<li>
<p class="mim-text-font">
Charrow, J., Fraga, C., Gu, X., Ida, H., Longo, N., Lukina, E., Nonino, A., Gaemers, S. J. M., Jouvin, M.-H., Li, J., Wu, Y., Xue, Y., Peterschmitt, M. J.
<strong>Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: the phase 3, randomized, double-blind EDGE trial.</strong>
Molec. Genet. Metab. 123: 347-356, 2018.
[PubMed: 29358012]
[Full Text: https://doi.org/10.1016/j.ymgme.2017.12.001]
</p>
</li>
<li>
<p class="mim-text-font">
Chiao, Y.-B., Peters, S. P., Diven, W. F., Lee, R. E., Glew, R. H.
<strong>Demonstration of beta-xylosidase activity in various forms of Gaucher&#x27;s disease.</strong>
Metabolism 28: 56-62, 1979.
[PubMed: 759826]
[Full Text: https://doi.org/10.1016/0026-0495(79)90168-9]
</p>
</li>
<li>
<p class="mim-text-font">
Choy, F. Y. M., Bouillon, L., Laurin, C. A.
<strong>Gaucher disease: accurate identification of asymptomatic French-Canadian carrier using nonlabeled authentic sphingolipid substrate N-palmitoyl dihydroglucocerebroside.</strong>
Am. J. Med. Genet. 27: 895-905, 1987.
[PubMed: 3425599]
[Full Text: https://doi.org/10.1002/ajmg.1320270416]
</p>
</li>
<li>
<p class="mim-text-font">
Choy, F. Y. M.
<strong>Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type 1 Gaucher tissues.</strong>
Am. J. Med. Genet. 21: 519-528, 1985.
[PubMed: 4025386]
[Full Text: https://doi.org/10.1002/ajmg.1320210315]
</p>
</li>
<li>
<p class="mim-text-font">
Choy, F. Y. M.
<strong>Intrafamilial clinical variability of type 1 Gaucher disease in a French-Canadian family.</strong>
J. Med. Genet. 25: 322-325, 1988.
[PubMed: 3385740]
[Full Text: https://doi.org/10.1136/jmg.25.5.322]
</p>
</li>
<li>
<p class="mim-text-font">
Cogan, D. G., Chu, F. C., Gittinger, J., Tychsen, L.
<strong>Fundal abnormalities of Gaucher&#x27;s disease.</strong>
Arch. Ophthal. 98: 2202-2203, 1980.
[PubMed: 7447774]
[Full Text: https://doi.org/10.1001/archopht.1980.01020041054010]
</p>
</li>
<li>
<p class="mim-text-font">
Danes, B. S., Bearn, A. G.
<strong>Gaucher&#x27;s disease: a genetic disease detected in skin fibroblast cultures.</strong>
Science 161: 1347-1348, 1968.
[PubMed: 5673446]
[Full Text: https://doi.org/10.1126/science.161.3848.1347]
</p>
</li>
<li>
<p class="mim-text-font">
Desnick, R. J., Dawson, G., Desnick, S. J., Sweeley, C. C., Krivit, W.
<strong>Diagnosis of glycosphingolipidoses by urinary-sediment analysis.</strong>
New Eng. J. Med. 284: 739-744, 1971.
[PubMed: 5548035]
[Full Text: https://doi.org/10.1056/NEJM197104082841401]
</p>
</li>
<li>
<p class="mim-text-font">
Enquist, I. B., Nilsson, E., Ooka, A., Mansson, J.-E., Olsson, K., Ehinger, M., Brady, R. O., Richter, J., Karlsson, S.
<strong>Effective cell and gene therapy in a murine model of Gaucher disease.</strong>
Proc. Nat. Acad. Sci. 103: 13819-13824, 2006.
[PubMed: 16954197]
[Full Text: https://doi.org/10.1073/pnas.0606016103]
</p>
</li>
<li>
<p class="mim-text-font">
Fabbro, D., Desnick, R. J., Grabowski, G. A.
<strong>Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.</strong>
Am. J. Hum. Genet. 40: 15-31, 1987.
[PubMed: 3812484]
</p>
</li>
<li>
<p class="mim-text-font">
Figueroa, M. L., Rosenbloom, B. E., Kay, A. C., Garver, P., Thurston, D. W., Koziol, J. A., Gelbart, T., Beutler, E.
<strong>A less costly regimen of alglucerase to treat Gaucher&#x27;s disease.</strong>
New Eng. J. Med. 327: 1632-1636, 1992.
[PubMed: 1435900]
[Full Text: https://doi.org/10.1056/NEJM199212033272304]
</p>
</li>
<li>
<p class="mim-text-font">
Fink, J. K., Correll, P. H., Perry, L. K., Brady, R. O., Karlsson, S.
<strong>Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease.</strong>
Proc. Nat. Acad. Sci. 87: 2334-2338, 1990.
[PubMed: 2315324]
[Full Text: https://doi.org/10.1073/pnas.87.6.2334]
</p>
</li>
<li>
<p class="mim-text-font">
Fox, J. L.
<strong>Tailored therapy can lower costly Gaucher treatments.</strong>
Nature Med. 1: 290, 1995.
</p>
</li>
<li>
<p class="mim-text-font">
Fried, K.
<strong>Population study of chronic Gaucher&#x27;s disease.</strong>
Israel J. Med. Sci. 9: 1396-1398, 1973.
[PubMed: 4775122]
</p>
</li>
<li>
<p class="mim-text-font">
Garfinkel, D., Sidi, Y., Ben-Bassat, M., Salomon, F., Hazaz, B., Pinkhas, J.
<strong>Coexistence of Gaucher&#x27;s disease and multiple myeloma.</strong>
Arch. Intern. Med. 142: 2229-2230, 1982.
[PubMed: 7138174]
</p>
</li>
<li>
<p class="mim-text-font">
Gaucher, P. C. E.
<strong>De l&#x27;epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie.</strong>
Thesis, Faculte-de Medicine: Paris 1882.
</p>
</li>
<li>
<p class="mim-text-font">
Goldblatt, J., Sacks, S., Dall, D., Beighton, P.
<strong>Total hip arthroplasty in Gaucher&#x27;s disease: long-term prognosis.</strong>
Clin. Orthop. Relat. Dis. 228: 94-98, 1988.
[PubMed: 3342593]
</p>
</li>
<li>
<p class="mim-text-font">
Goldblatt, J.
<strong>Type I Gaucher disease.</strong>
J. Med. Genet. 25: 415-418, 1988.
[PubMed: 3294411]
[Full Text: https://doi.org/10.1136/jmg.25.6.415]
</p>
</li>
<li>
<p class="mim-text-font">
Grabowski, G. A., Dinur, T., Osiecki, K. M., Kruse, J. R., Legler, G., Gatt, S.
<strong>Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.</strong>
Am. J. Hum. Genet. 37: 499-510, 1985.
[PubMed: 4003396]
</p>
</li>
<li>
<p class="mim-text-font">
Grace, M. E., Balwani, M., Nazarenko, I., Prakash-Cheng, A., Desnick, R. J.
<strong>Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations--implications for diagnosis and therapeutic monitoring.</strong>
Hum. Mutat. 28: 866-873, 2007.
[PubMed: 17464953]
[Full Text: https://doi.org/10.1002/humu.20524]
</p>
</li>
<li>
<p class="mim-text-font">
Gravel, R. A., Leung, A.
<strong>Complementation analysis in Gaucher disease using single cell microassay techniques: evidence for a single &#x27;Gaucher gene&#x27;.</strong>
Hum. Genet. 65: 112-116, 1983.
[PubMed: 6418635]
[Full Text: https://doi.org/10.1007/BF00286645]
</p>
</li>
<li>
<p class="mim-text-font">
Graves, P. N., Grabowski, G. A., Ludman, M. D., Palese, P., Smith, F. I.
<strong>Human acid beta-glucosidase: Northern blot and S1 nuclease analysis of mRNA from HeLa cells and normal and Gaucher disease fibroblasts.</strong>
Am. J. Hum. Genet. 39: 763-774, 1986.
[PubMed: 3026174]
</p>
</li>
<li>
<p class="mim-text-font">
Harvey, P. K. P., Jones, M. C., Anderson, E. G.
<strong>Pericardial abnormalities in Gaucher&#x27;s disease.</strong>
Brit. Heart J. 31: 603-606, 1969.
[PubMed: 5351295]
[Full Text: https://doi.org/10.1136/hrt.31.5.603]
</p>
</li>
<li>
<p class="mim-text-font">
Hollak, C. E. M., van Weely, S., van Oers, M. H. J., Aerts, J. M. F. G.
<strong>Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease.</strong>
J. Clin. Invest. 93: 1288-1292, 1994.
[PubMed: 8132768]
[Full Text: https://doi.org/10.1172/JCI117084]
</p>
</li>
<li>
<p class="mim-text-font">
Hruska, K. S., LaMarca, M. E., Scott, C. R., Sidransky, E.
<strong>Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).</strong>
Hum. Mutat. 29: 567-583, 2008.
[PubMed: 18338393]
[Full Text: https://doi.org/10.1002/humu.20676]
</p>
</li>
<li>
<p class="mim-text-font">
Hsia, D. Y.-Y., Naylor, J., Bigler, J. A.
<strong>Gaucher&#x27;s disease: report of two cases in father and son and review of the literature.</strong>
New Eng. J. Med. 261: 164-169, 1959.
[PubMed: 13666999]
[Full Text: https://doi.org/10.1056/NEJM195907232610402]
</p>
</li>
<li>
<p class="mim-text-font">
Jmoudiak, M., Futerman, A. H.
<strong>Gaucher disease: pathological mechanisms and modern management.</strong>
Brit. J. Haemat. 129: 178-188, 2005.
[PubMed: 15813845]
[Full Text: https://doi.org/10.1111/j.1365-2141.2004.05351.x]
</p>
</li>
<li>
<p class="mim-text-font">
Kaplan, P., Mazur, A., Manor, O., Charrow, J., Esplin, J., Gribble, T. J., Wappner, R. S., Wisch, J. S., Weinreb, N. J.
<strong>Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.</strong>
J. Pediat. 129: 149-153, 1996.
[PubMed: 8757576]
[Full Text: https://doi.org/10.1016/s0022-3476(96)70203-2]
</p>
</li>
<li>
<p class="mim-text-font">
Klibansky, C., Hoffman, J., Zaizov, R., Matoth, Y., Pinchas, J., DeVries, A.
<strong>Chronic Gaucher disease: heat resistance of leukocyte beta-glucocerebrosidase in relation to some clinical parameters.</strong>
Biomedicine 19: 345-348, 1973.
[PubMed: 4774111]
</p>
</li>
<li>
<p class="mim-text-font">
Knudson, A. G., Jr., Kaplan, W. D.
<strong>Genetics of the sphingolipidoses. In: Aaronson, S. M.; Volk, B. W.: Cerebral Sphingolipidoses. A Symposium on Tay-Sachs Disease.</strong>
New York: Academic Press (pub.) 1962. Pp. 395-411.
</p>
</li>
<li>
<p class="mim-text-font">
Koto, Y., Sakai, N., Lee, Y., Kakee, N., Matsuda, J., Tsuboi, K., Shimozawa, N., Okuyama, T., Nakamura, K., Narita, A., kobayashi, H., Uehara, R., Nakamura, Y., Kato, K., Eto, Y.
<strong>Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan.</strong>
Molec. Genet. Metab. 133: 277-288, 2021.
[PubMed: 34090759]
[Full Text: https://doi.org/10.1016/j.ymgme.2021.05.004]
</p>
</li>
<li>
<p class="mim-text-font">
Langeveld, M., Ghauharali, K. J. M., Sauerwein, H. P., Ackermans, M. T., Groener, J. E. M., Hollak, C. E. M., Aerts, J. M., Serlie, M. J.
<strong>Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.</strong>
J. Clin. Endocr. Metab. 93: 845-851, 2008.
[PubMed: 18089699]
[Full Text: https://doi.org/10.1210/jc.2007-1702]
</p>
</li>
<li>
<p class="mim-text-font">
Lanir, A., Hadar, H., Cohen, I., Tal, Y., Benmair, J., Schreiber, R., Clouse, M. E.
<strong>Gaucher disease: assessment with MR imaging.</strong>
Radiology 161: 239-244, 1986.
[PubMed: 3763873]
[Full Text: https://doi.org/10.1148/radiology.161.1.3763873]
</p>
</li>
<li>
<p class="mim-text-font">
Maaswinkel-Mooij, P., Hollak, C., van Eysden-Plaisier, M., Prins, M., Aerts, H., Poll, R.
<strong>The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations.</strong>
J. Inherit. Metab. Dis. 23: 77-82, 2000.
[PubMed: 10682310]
[Full Text: https://doi.org/10.1023/a:1005655031239]
</p>
</li>
<li>
<p class="mim-text-font">
Matoth, Y., Chazan, S., Cnaan, A., Gelernter, I., Klibansky, C.
<strong>Frequency of carriers of chronic (type I) Gaucher disease in Ashkenazi Jews.</strong>
Am. J. Med. Genet. 27: 561-565, 1987.
[PubMed: 3631130]
[Full Text: https://doi.org/10.1002/ajmg.1320270309]
</p>
</li>
<li>
<p class="mim-text-font">
Miller, A., Brown, L. K., Pastores, G. M., Desnick, R. J.
<strong>Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease.</strong>
Clin. Genet. 63: 368-376, 2003.
[PubMed: 12752568]
[Full Text: https://doi.org/10.1034/j.1399-0004.2003.00060.x]
</p>
</li>
<li>
<p class="mim-text-font">
Morello, J.-P., Bouvier, M., Petaja-Repo, U. E., Bichet, D. G.
<strong>Pharmacological chaperones: a new twist on receptor folding.</strong>
Trends Pharm. Sci. 21: 466-469, 2000.
[PubMed: 11121835]
[Full Text: https://doi.org/10.1016/s0165-6147(00)01575-3]
</p>
</li>
<li>
<p class="mim-text-font">
Moscicki, R. A., Taunton-Rigby, A.
<strong>Treatment of Gaucher&#x27;s disease. (Letter)</strong>
New Eng. J. Med. 328: 1564 only, 1993.
[PubMed: 8373459]
[Full Text: https://doi.org/10.1056/NEJM199305273282112]
</p>
</li>
<li>
<p class="mim-text-font">
Nolta, J. A., Yu, X. J., Bahner, I., Kohn, D. B.
<strong>Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.</strong>
J. Clin. Invest. 90: 342-348, 1992. Note: Erratum: J. Clin. Invest. 90: 1635 only, 1992.
[PubMed: 1379609]
[Full Text: https://doi.org/10.1172/JCI115868]
</p>
</li>
<li>
<p class="mim-text-font">
Pandey, M. K., Burrow, T. A., Rani, R., Martin, L. J., Witte, D., Setchell, K. D., Mckay, M. A., Magnusen, A. F., Zhang, W., Liou, B., Kohl, J., Grabowski, G. A.
<strong>Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.</strong>
Nature 543: 108-112, 2017.
[PubMed: 28225753]
[Full Text: https://doi.org/10.1038/nature21368]
</p>
</li>
<li>
<p class="mim-text-font">
Park, J. K., Koprivica, V., Andrews, D. Q., Madike, V., Tayebi, N., Stone, D. L., Sidransky, E.
<strong>Glucocerebrosidase mutations among African-American patients with type 1 Gaucher disease.</strong>
Am. J. Med. Genet. 99: 147-151, 2001.
[PubMed: 11241475]
[Full Text: https://doi.org/10.1002/1096-8628(2001)9999:9999&lt;::aid-ajmg1144&gt;3.0.co;2-1]
</p>
</li>
<li>
<p class="mim-text-font">
Pastores, G. M., Barnett, N. L., Kolodny, E. H.
<strong>An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.</strong>
Clin. Ther. 27: 1215-1227, 2005.
[PubMed: 16199246]
[Full Text: https://doi.org/10.1016/j.clinthera.2005.08.004]
</p>
</li>
<li>
<p class="mim-text-font">
Peleg, L., Frisch, A., Goldman, B., Karpaty, M., Narinsky, R., Bronstein, S., Frydman, M.
<strong>Lower frequency of Gaucher disease carriers among Tay-Sachs disease carriers.</strong>
Europ. J. Hum. Genet. 6: 185-186, 1998.
[PubMed: 9781065]
[Full Text: https://doi.org/10.1038/sj.ejhg.5200176]
</p>
</li>
<li>
<p class="mim-text-font">
Pentchev, P. G., Neumeyer, B., Svennerholm, L., Groth, C. G., Brady, R. O.
<strong>Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease.</strong>
Am. J. Hum. Genet. 35: 621-628, 1983.
[PubMed: 6881138]
</p>
</li>
<li>
<p class="mim-text-font">
Petrohelos, M., Tricoulis, D., Kotsiras, I., Vouzoukos, A.
<strong>Ocular manifestations of Gaucher&#x27;s disease.</strong>
Am. J. Ophthal. 80: 1006-1010, 1975.
[PubMed: 1200092]
[Full Text: https://doi.org/10.1016/0002-9394(75)90329-3]
</p>
</li>
<li>
<p class="mim-text-font">
Raghavan, S. S., Topol, J., Kolodny, E. H.
<strong>Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease.</strong>
Am. J. Hum. Genet. 32: 158-173, 1980.
[PubMed: 6770675]
</p>
</li>
<li>
<p class="mim-text-font">
Ramaswami, L., Mengel, E., Berrah, A., AlSayed, M., Broomfield, A., Donald, A., Seif El Dein, H. M., Freisens, S., Hwu, W.-L., Peterschmitt, M. J., Yoo H.-W., Abdelwahab, M.
<strong>Throwing a spotlight on under-recognized manifestations of Gaucher disease: pulmonary involvement, lymphadenopathy, and Gaucheroma.</strong>
Molec. Genet. Metab. 133: 335-344, 2021.
[PubMed: 34229967]
[Full Text: https://doi.org/10.1016/j.ymgme.2021.06.009]
</p>
</li>
<li>
<p class="mim-text-font">
Ringden, O., Groth, C. G., Erikson, A., Granqvist, E. S., Mansson, J.-E., Sparrelid, E.
<strong>Ten years&#x27; experience of bone marrow transplantation for Gaucher disease.</strong>
Transplantation 59: 864-870, 1995.
[PubMed: 7701581]
</p>
</li>
<li>
<p class="mim-text-font">
Rockah, R., Narinsky, R., Frydman, M., Cohen, I. J., Zaizov, R., Weizman, A., Frisch, A.
<strong>Linkage disequilibrium of common Gaucher disease mutations with a polymorphic site in the pyruvate kinase (PKLR) gene.</strong>
Am. J. Med. Genet. 78: 233-236, 1998.
[PubMed: 9677056]
</p>
</li>
<li>
<p class="mim-text-font">
Ross, D. J., Spira, S., Buchbinder, N. A.
<strong>Gaucher cells in pulmonary-capillary blood in association with pulmonary hypertension. (Letter)</strong>
New Eng. J. Med. 336: 379-381, 1997.
[PubMed: 9011805]
[Full Text: https://doi.org/10.1056/NEJM199701303360516]
</p>
</li>
<li>
<p class="mim-text-font">
Rubin, M., Yampolski, I., Lambrozo, R., Zaizov, R., Dintsman, M.
<strong>Partial splenectomy in Gaucher&#x27;s disease.</strong>
J. Pediat. Surg. 21: 125-128, 1986.
[PubMed: 3950849]
[Full Text: https://doi.org/10.1016/s0022-3468(86)80063-x]
</p>
</li>
<li>
<p class="mim-text-font">
Sawkar, A. R., Cheng, W.-C., Beutler, E., Wong, C.-H., Balch, W. E., Kelly, J. W.
<strong>Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease.</strong>
Proc. Nat. Acad. Sci. 99: 15428-15433, 2002.
[PubMed: 12434014]
[Full Text: https://doi.org/10.1073/pnas.192582899]
</p>
</li>
<li>
<p class="mim-text-font">
Slatkin, M.
<strong>A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases.</strong>
Am. J. Hum. Genet. 75: 282-293, 2004.
[PubMed: 15208782]
[Full Text: https://doi.org/10.1086/423146]
</p>
</li>
<li>
<p class="mim-text-font">
Sorge, J., Kuhl, W., West, C., Beutler, E.
<strong>Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer.</strong>
Proc. Nat. Acad. Sci. 84: 906-909, 1987.
[PubMed: 3547401]
[Full Text: https://doi.org/10.1073/pnas.84.4.906]
</p>
</li>
<li>
<p class="mim-text-font">
Starzl, T. E., Demetris, A. J., Trucco, M., Ricordi, C., Ildstad, S., Terasaki, P. I., Murase, N., Kendall, R. S., Kocova, M., Rudert, W. A., Zeevi, A., Van Thiel, D.
<strong>Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher&#x27;s disease.</strong>
New Eng. J. Med. 328: 745-749, 1993.
[PubMed: 8437594]
[Full Text: https://doi.org/10.1056/NEJM199303183281101]
</p>
</li>
<li>
<p class="mim-text-font">
Steet, R. A., Chung, S., Wustman, B., Powe, A., Do, H., Kornfeld, S. A.
<strong>The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.</strong>
Proc. Nat. Acad. Sci. 103: 13813-13818, 2006.
[PubMed: 16945909]
[Full Text: https://doi.org/10.1073/pnas.0605928103]
</p>
</li>
<li>
<p class="mim-text-font">
Tamari, I., Motro, M., Neufeld, H. N.
<strong>Unusual pericardial calcification in Gaucher&#x27;s disease.</strong>
Arch. Intern. Med. 143: 2010-2011, 1983.
[PubMed: 6625792]
</p>
</li>
<li>
<p class="mim-text-font">
Tsuji, S., Choudary, P. V., Martin, B. M., Stubblefield, B. K., Mayor, J. A., Barranger, J. A., Ginns, E. I.
<strong>A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher&#x27;s disease.</strong>
New Eng. J. Med. 316: 570-575, 1987.
[PubMed: 2880291]
[Full Text: https://doi.org/10.1056/NEJM198703053161002]
</p>
</li>
<li>
<p class="mim-text-font">
Tsuji, S., Martin, B. M., Barranger, J. A., Stubblefield, B. K., LaMarca, M. E., Ginns, E. I.
<strong>Genetic heterogeneity in type I Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals.</strong>
Proc. Nat. Acad. Sci. 85: 2349-2352, 1988. Note: Erratum: Proc. Nat. Acad. Sci. 85: 5708 only, 1988.
[PubMed: 3353383]
[Full Text: https://doi.org/10.1073/pnas.85.7.2349]
</p>
</li>
<li>
<p class="mim-text-font">
Wang, R. Y., Bodamer, O. A., Watson, M. S., Wilcox, W. R.
<strong>Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals.</strong>
Genet. Med. 13: 457-484, 2011.
[PubMed: 21502868]
[Full Text: https://doi.org/10.1097/GIM.0b013e318211a7e1]
</p>
</li>
<li>
<p class="mim-text-font">
Wang, T.-J., Chen, M.-S., Shih, Y.-F., Hwu, W.-L., Lai, M.-Y.
<strong>Fundus abnormalities in a patient with type I Gaucher&#x27;s disease with 12-year follow-up.</strong>
Am. J. Ophthal. 139: 359-362, 2005.
[PubMed: 15734007]
[Full Text: https://doi.org/10.1016/j.ajo.2004.07.053]
</p>
</li>
<li>
<p class="mim-text-font">
Weinreb, N. J., Camelo, J. S., Jr., Charrow, J., McClain, M. R., Mistry, P., Belmatoug, N.
<strong>Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain imiglucerase treatment.</strong>
Molec. Genet. Metab. 132: 100-111, 2021.
[PubMed: 33485799]
[Full Text: https://doi.org/10.1016/j.ymgme.2020.12.295]
</p>
</li>
<li>
<p class="mim-text-font">
Weinreb, N. J., Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pastores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., Zimran, A.
<strong>Effectiveness of enzyme replacement therapy in 1028 patients with type I Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.</strong>
Am. J. Med. 113: 112-119, 2002.
[PubMed: 12133749]
[Full Text: https://doi.org/10.1016/s0002-9343(02)01150-6]
</p>
</li>
<li>
<p class="mim-text-font">
Wiedemann, H.-R., Gerken, H., Graucob, E., Hansen, H.-G.
<strong>Recognition of heterozygosity in sphingolipidoses. (Letter)</strong>
Lancet 285: 1283 only, 1965. Note: Originally Volume 1.
</p>
</li>
<li>
<p class="mim-text-font">
Zimran, A., Gelbart, T., Westwood, B., Grabowski, G. A., Beutler, E.
<strong>High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.</strong>
Am. J. Hum. Genet. 49: 855-859, 1991.
[PubMed: 1897529]
</p>
</li>
<li>
<p class="mim-text-font">
Zlotogora, J., Zaizov, R., Klibansky, C., Matoth, Y., Bach, G., Cohen, T.
<strong>Genetic heterogeneity in Gaucher disease.</strong>
J. Med. Genet. 23: 319-322, 1986.
[PubMed: 3746831]
[Full Text: https://doi.org/10.1136/jmg.23.4.319]
</p>
</li>
<li>
<p class="mim-text-font">
Zuckerman, S., Lahad, A., Shmueli, A., Zimran, A., Peleg, L., Orr-Urtreger, A., Levy-Lahad, E., Sagi, M.
<strong>Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases.</strong>
JAMA 298: 1281-1290, 2007.
[PubMed: 17878420]
[Full Text: https://doi.org/10.1001/jama.298.11.1281]
</p>
</li>
</ol>
<div>
<br />
</div>
</div>
</div>
<div>
<div class="row">
<div class="col-lg-1 col-md-1 col-sm-2 col-xs-2">
<span class="text-nowrap mim-text-font">
Contributors:
</span>
</div>
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
<span class="mim-text-font">
Hilary J. Vernon - updated : 10/08/2021<br>Hilary J. Vernon - updated : 09/13/2021<br>Hilary J. Vernon - updated : 05/18/2021<br>Hilary J. Vernon - updated : 05/22/2020<br>Ada Hamosh - updated : 08/08/2017<br>Ada Hamosh - updated : 10/3/2012<br>John A. Phillips, III - updated : 4/27/2009<br>Cassandra L. Kniffin - updated : 8/25/2008<br>Cassandra L. Kniffin - updated : 4/3/2008<br>Cassandra L. Kniffin - updated : 10/17/2007<br>Cassandra L. Kniffin - updated : 11/1/2006<br>Jane Kelly - updated : 9/26/2006<br>Victor A. McKusick - updated : 8/12/2004<br>Victor A. McKusick - updated : 6/4/2003<br>Victor A. McKusick - updated : 1/14/2003<br>Ada Hamosh - updated : 11/29/2001<br>Victor A. McKusick - updated : 8/2/2001<br>Ada Hamosh - updated : 4/23/2001<br>Sonja A. Rasmussen - updated : 4/4/2001<br>Kathryn R. Wagner - updated : 3/30/2001<br>Victor A. McKusick - updated : 7/25/2000<br>Paul Brennan - updated : 4/11/2000<br>Victor A. McKusick - updated : 2/23/2000<br>Victor A. McKusick - updated : 2/22/2000<br>Victor A. McKusick - updated : 8/30/1999<br>Ada Hamosh - updated : 7/15/1999<br>Victor A. McKusick - updated : 5/17/1999<br>Victor A. McKusick - updated : 4/16/1999<br>Victor A. McKusick - updated : 10/1/1998<br>Victor A. McKusick - updated : 9/11/1998<br>Victor A. McKusick - updated : 8/3/1998<br>Victor A. McKusick - updated : 7/28/1998<br>Victor A. McKusick - updated : 4/29/1998<br>Victor A. McKusick - updated : 12/1/1997<br>Victor A. McKusick - updated : 10/3/1997<br>Ethylin Wang Jabs - updated : 7/21/1997<br>Victor A. McKusick - updated : 6/23/1997<br>Victor A. McKusick - updated : 3/6/1997<br>Victor A. McKusick - updated : 3/4/1997<br>Cynthia K. Ewing - updated : 10/6/1996<br>Moyra Smith - updated : 9/16/1996<br>Stylianos E. Antonarakis - updated : 7/2/1996
</span>
</div>
</div>
</div>
<div>
<br />
</div>
<div>
<div class="row">
<div class="col-lg-1 col-md-1 col-sm-2 col-xs-2">
<span class="text-nowrap mim-text-font">
Creation Date:
</span>
</div>
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
<span class="mim-text-font">
Victor A. McKusick : 6/3/1986
</span>
</div>
</div>
</div>
<div>
<br />
</div>
<div>
<div class="row">
<div class="col-lg-1 col-md-1 col-sm-2 col-xs-2">
<span class="text-nowrap mim-text-font">
Edit History:
</span>
</div>
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
<span class="mim-text-font">
carol : 06/13/2024<br>carol : 10/08/2021<br>carol : 09/13/2021<br>carol : 05/19/2021<br>carol : 05/18/2021<br>carol : 05/13/2021<br>carol : 09/04/2020<br>carol : 05/22/2020<br>alopez : 08/08/2017<br>alopez : 02/15/2017<br>carol : 10/14/2016<br>terry : 03/28/2013<br>alopez : 11/26/2012<br>alopez : 10/3/2012<br>carol : 5/1/2012<br>terry : 3/20/2012<br>carol : 7/26/2011<br>terry : 6/3/2009<br>terry : 5/4/2009<br>alopez : 4/27/2009<br>wwang : 9/18/2008<br>ckniffin : 8/25/2008<br>wwang : 4/15/2008<br>ckniffin : 4/3/2008<br>carol : 10/24/2007<br>ckniffin : 10/17/2007<br>carol : 9/13/2007<br>ckniffin : 11/3/2006<br>carol : 11/2/2006<br>ckniffin : 11/1/2006<br>carol : 10/3/2006<br>carol : 9/26/2006<br>terry : 11/3/2004<br>tkritzer : 8/17/2004<br>terry : 8/12/2004<br>mgross : 9/18/2003<br>tkritzer : 6/10/2003<br>terry : 6/4/2003<br>tkritzer : 5/8/2003<br>carol : 1/23/2003<br>tkritzer : 1/21/2003<br>terry : 1/14/2003<br>ckniffin : 5/7/2002<br>terry : 11/29/2001<br>terry : 11/28/2001<br>terry : 11/19/2001<br>terry : 11/19/2001<br>carol : 11/16/2001<br>terry : 8/2/2001<br>cwells : 5/9/2001<br>cwells : 5/8/2001<br>terry : 4/23/2001<br>mcapotos : 4/5/2001<br>mcapotos : 4/4/2001<br>carol : 3/30/2001<br>terry : 3/30/2001<br>carol : 8/2/2000<br>terry : 7/25/2000<br>alopez : 4/11/2000<br>carol : 2/23/2000<br>terry : 2/22/2000<br>jlewis : 9/8/1999<br>terry : 8/30/1999<br>alopez : 7/26/1999<br>terry : 7/15/1999<br>carol : 6/25/1999<br>mgross : 5/21/1999<br>terry : 5/17/1999<br>carol : 4/19/1999<br>terry : 4/16/1999<br>carol : 10/5/1998<br>terry : 10/1/1998<br>terry : 9/11/1998<br>carol : 8/4/1998<br>terry : 8/3/1998<br>carol : 7/29/1998<br>terry : 7/28/1998<br>joanna : 5/13/1998<br>carol : 5/8/1998<br>terry : 4/29/1998<br>carol : 4/7/1998<br>terry : 3/28/1998<br>mark : 12/8/1997<br>terry : 12/1/1997<br>jenny : 10/7/1997<br>terry : 10/3/1997<br>mark : 8/1/1997<br>mark : 8/1/1997<br>jenny : 8/1/1997<br>mark : 7/31/1997<br>mark : 6/25/1997<br>jenny : 6/23/1997<br>mark : 6/22/1997<br>mark : 6/22/1997<br>jenny : 6/17/1997<br>mark : 5/28/1997<br>mark : 5/24/1997<br>terry : 3/6/1997<br>jamie : 3/5/1997<br>terry : 3/5/1997<br>mark : 3/4/1997<br>terry : 3/3/1997<br>mark : 1/20/1997<br>mark : 1/18/1997<br>terry : 10/31/1996<br>mark : 10/6/1996<br>mark : 9/16/1996<br>mark : 7/22/1996<br>terry : 7/2/1996<br>terry : 6/27/1996<br>terry : 6/21/1996<br>mark : 6/7/1996<br>terry : 6/6/1996<br>terry : 5/16/1996<br>mark : 5/16/1996<br>terry : 5/13/1996<br>mark : 12/13/1995<br>mark : 10/24/1995<br>davew : 8/19/1994<br>terry : 5/2/1994<br>mimadm : 4/29/1994<br>warfield : 4/15/1994<br>carol : 1/27/1994
</span>
</div>
</div>
</div>
<div>
<br />
</div>
</div>
</div>
</div>
</div>
<div id="mimFooter">
<div class="container ">
<div class="row">
<br />
<br />
</div>
</div>
<div class="hidden-print mim-footer">
<div class="container">
<div class="row">
<p />
</div>
<div class="row text-center small">
NOTE: OMIM is intended for use primarily by physicians and other professionals concerned with genetic disorders, by genetics researchers,
and by advanced students in science and medicine. While the OMIM database is open to the public, users seeking information about a personal
medical or genetic condition are urged to consult with a qualified physician for diagnosis and for answers to personal questions.
<br />
OMIM<sup>&reg;</sup> and Online Mendelian Inheritance in Man<sup>&reg;</sup> are registered trademarks of the Johns Hopkins University.
<br />
Copyright<sup>&reg;</sup> 1966-2025 Johns Hopkins University.
</div>
</div>
</div>
<div class="visible-print-block mim-footer" style="position: relative;">
<div class="container">
<div class="row">
<p />
</div>
<div class="row text-center small">
NOTE: OMIM is intended for use primarily by physicians and other professionals concerned with genetic disorders, by genetics researchers,
and by advanced students in science and medicine. While the OMIM database is open to the public, users seeking information about a personal
medical or genetic condition are urged to consult with a qualified physician for diagnosis and for answers to personal questions.
<br />
OMIM<sup>&reg;</sup> and Online Mendelian Inheritance in Man<sup>&reg;</sup> are registered trademarks of the Johns Hopkins University.
<br />
Copyright<sup>&reg;</sup> 1966-2025 Johns Hopkins University.
<br />
Printed: March 5, 2025
</div>
</div>
</div>
</div>
<div class="modal fade" id="mimDonationPopupModal" tabindex="-1" role="dialog" aria-labelledby="mimDonationPopupModalTitle">
<div class="modal-dialog" role="document">
<div class="modal-content">
<div class="modal-header">
<button type="button" id="mimDonationPopupCancel" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">&times;</span></button>
<h4 class="modal-title" id="mimDonationPopupModalTitle">
OMIM Donation:
</h4>
</div>
<div class="modal-body">
<div class="row">
<div class="col-lg-offset-1 col-md-offset-1 col-sm-offset-1 col-xs-offset-1 col-lg-10 col-md-10 col-sm-10 col-xs-10">
<p>
Dear OMIM User,
</p>
</div>
</div>
<div class="row">
<div class="col-lg-offset-1 col-md-offset-1 col-sm-offset-1 col-xs-offset-1 col-lg-10 col-md-10 col-sm-10 col-xs-10">
<p>
To ensure long-term funding for the OMIM project, we have diversified
our revenue stream. We are determined to keep this website freely
accessible. Unfortunately, it is not free to produce. Expert curators
review the literature and organize it to facilitate your work. Over 90%
of the OMIM's operating expenses go to salary support for MD and PhD
science writers and biocurators. Please join your colleagues by making a
donation now and again in the future. Donations are an important
component of our efforts to ensure long-term funding to provide you the
information that you need at your fingertips.
</p>
</div>
</div>
<div class="row">
<div class="col-lg-offset-1 col-md-offset-1 col-sm-offset-1 col-xs-offset-1 col-lg-10 col-md-10 col-sm-10 col-xs-10">
<p>
Thank you in advance for your generous support, <br />
Ada Hamosh, MD, MPH <br />
Scientific Director, OMIM <br />
</p>
</div>
</div>
</div>
<div class="modal-footer">
<button type="button" id="mimDonationPopupDonate" class="btn btn-success btn-block" data-dismiss="modal"> Donate To OMIM! </button>
</div>
</div>
</div>
</div>
</div>
</body>
</html>